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Abstract
Glucocorticoids regulate a myriad of metabolic and homeostatic processes
including lipid and glucose metabolism within the liver and electrolyte balance
within the kidney. Circulating levels of active glucocorticoid are regulated tightly by
a balance of hypothalamic-pituitary-adrenal (HPA) forward drive, glucocorticoid
negative feedback and rates of inactivation. Isoforms of ll|3-hydroxysteroid
dehydrogenase (llp-HSDl and 2) interconvert active and inactive glucocorticoids
thereby regulating access of glucocorticoids to the corticosteroid receptor (GR). The
A-ring reductases (5a- and 5(l-reductase) and 3a-hydroxysteroid dehydrogenase
(3a-HSD) are involved in both peripheral glucocorticoid metabolism and bile acid
biosynthesis. Bile acids are known to regulate their own biosynthesis by feed¬
forward induction of genes involved in bile acid detoxification and/or excretion and
suppression of those involved in biosynthesis. Alterations in hepatic bile acid
concentration may therefore influence glucocorticoid metabolism and thus HPA axis
activation.
The work in this thesis demonstrates that bile acids and their conjugates are
competitive inhibitors of glucocorticoid metabolism by both lip-HSDl and 5(1-
reductase in liver. In vivo, in male Wistar rats, manipulation of hepatic bile acid
concentrations by dietary supplementation with chenodeoxycholic acid (CDCA; 1%
w/w) suppressed activities of hepatic 5(3-reductase and lipHSDl activity and caused
a reduction in total urinary (mainly 5P-reduced) glucocorticoid metabolites. In
response to acute restraint stress bile acid treated animals showed a delay in return to
basal corticosterone levels indicative of altered clearance. In addition, adrenal weight
and lipid accumulation within the adrenal gland was reduced in bile acid treated
animals. Stimulation of bile acid synthesis by cholestyramine (5% w/w) reduced
hepatic 5P-reductase activity with animals excreting fewer urinary total (mainly 5P-
reduced) glucocorticoid metabolites. Conversely, a reduction in hepatic bile acid
content via administration of a fat-free diet induced hepatic 5p-reductase activity
accompanied by an increase in total, principally 5p-reduced, urinary metabolites.
Animals fed the fat-free diet had larger adrenal glands, and suppressed circulating
corticosterone, again suggesting altered HPA axis regulation.
I
These findings were pursued in rats with bile duct ligation, a pathological
model of elevated bile acids. In these animals, reduced activities of 5(3-reductase and
llp-HSDl were also identified. Lastly investigations were made of the impact of bile
acids on the renin-angiotensin-aldosterone system (RAAS). Manipulations which
increased bile acids concentrations were predicted to reduce the rate of aldosterone
inactivation, since it too is a substrate for 5P-reductase. Treatments increasing bile




I would like to thank my supervisors Dr Ruth Andrew and Professor Brian
Walker and Dr Chris Kenyon for their guidance, encouragement and support
throughout my PhD. I am indebted to everyone in the Department of Endocrinology
for their unrelenting patience, advice, scientific input and continuous support, in
particular Annick de Vries, Dawn Livingstone, Peter Raubenheimer and Rachel
McDonnell. I would like to acknowledge Dr Eleanor Davies and Dr Scott Mackenzie
from the Department of Cardiovascular Sciences, Glasgow University for their
assistance with real-time PCR, and all the staff at the BRF for their help and advice.
I am indebted to the Wellcome Trust and the CVRI for funding and supporting me
for the last four years.
Finally I must thank my family and friends, especially my Mother and Father
for their continual support and belief in my ability, my twin sister Jane for providing










Chapter 1 Introduction 1
1.1 The Endocrine System 2
1.2 Steroid hormones
1.2.1 Chemistry and nomenclature 3
1.3 Steroid biosynthesis 4
1.4 Steroid hormone 6
1.4.1 Zona glomerulosa 7
1.4.2 Zona fasciculata 7
1.4.3 Zona reticularis 7
1.5 Steroid metabolism 8
1.5.1 lip-hydroxysteroid dehydrogenase type 1 (lip-HSDl) 9
1.5.2 lip-hydroxysteroid dehydrogenase type 2 (llp-HSD2) 10
1.5.3 A-ring reduction 11
1.5.3.1 5a-Reductases 12
1.5.3.2 5(1-Reductase 13
1.5.3.3 3a-Hydroxysteroid Dehydrogenases (3aHSD) 13
1.5.4 Polar Steroid Metabolism 14
1.6 Regulation of glucocorticoid secretion
1.6.1 The pituitary gland 15
1.6.2 Hypothalamic-pituitary-adrenal (HPA) axis 16
1.6.3 HPA axis regulation and metabolism
IV
1.7 Glucocorticoid action
1.7.1 Nuclear hormone receptors 18
1.7.2 Orphan nuclear receptors 21
1.8 Roles of glucocorticoids in health and disease 22
1.8.1 Regulation of glucocorticoid metabolism 22
1.8.2 Dysregulation of glucocorticoid metabolism 24
1.8.3 Transgenic models of glucocorticoid metabolism 24
1.8.4 Obesity 25
1.9 Cholesterol homeostasis and bile acids 27
1.9.1 Enterohepatic circulation 27
1.10 Pathways of bile acid synthesis 28
1.10.1 Classical (neutral) pathway 29
1.10.2 Alternative (acidic) pathway 31
1.10.3 Conjugation 32
1.11 Regulation of bile acid biosynthesis 33
1.11.1 Competitive inhibition of synthetic enzymes 33
1.11.2 Bile acids as transcriptional regulators 33
1.12 Bile acids and glucocorticoids 36
1.13 Hypothesis and aims 38
Chapter 2 Materials and Methods
2.1 Materials 40
2.2 Commonly used buffers and solutions 40
2.3 Animal care and maintenance
2.3.1 Animal maintenance 44
2.3.2 Animal sacrifice and tissue collection 44
2.4 Plasma assays
2.4.1 Corticosterone radioimmunoassay 45
2.4.2 ACTH radioimmunoassay 45
2.4.3 Renin radioimmunoassay 47
2.4.4 Aldosterone ELISA 47
V
2.4.5 Insulin ELISA 48
2.5 Quantitative analysis of bile acid
2.5.1 Serum bile acids 49
2.5.2 Hepatic bile acids 50
2.5.3 Fecal bile acids 51
2.6 Spectrophotometric assays
2.6.1 Hepatic triglycerides 51
2.6.2 Hepatic glycogen 53
2.6.3 Plasma glucose 53
2.7 Analysis of glucocorticoid metabolites
2.7.1 Extraction of steroids from urine 54
2.7.2 Hydrolysis of steroids 54
2.7.3 Extraction of steroids from hydrolysate 55
2.7.4 Derivatisation of steroids 55
2.7.5 Extraction of derivatised steroids 55
2.8 Measurements of enzyme activity
2.8.1 Subcellular fractionation 56
2.8.2 Determination of concentration of protein 56
2.8.3 5(3-Reductase activity 57
2.8.4 lip-HSDl dehydrogenase activity 58
2.8.5 lip-HSD2 dehydrogense activity 58
2.8.6 3a-HSD activity 59
2.9 Analysis of steroid metabolites
2.9.1 High pressure liquid chromatography 59
2.9.2 Gas chromatography / mass spectrometry 60
2.10 Culture of Rat Hepatoma Cells (H4IIE) 61
2.11 Qualititative analysis of gene transcription
2.11.1 Isolation of total cellular RNA 62
2.11.2 Preparation of complementary DNA (cDNA) 63
2.11.3 Amplification of cDNA by polymerase 63
chain reaction (PCR)
VI
2.11.4 DNA purification 65
2.12 Quantification ofmessenger RNA (mRNA) by Northern blot analysis
2.12.1 Separation of RNA 65
2.12.2 Blotting 66
2.12.3 Hybridisation to 32P-labelled probe 67
2.13 Quantification ofmessenger RNA (mRNA) by real-time PCR
2.13.1 Taqman® real-time PCR 68
2.13.2 LightCycler® real-time PCR 69
2.14 Histology
2.14.1 Adrenal histology 71
2.14.2 Hematoxylin and Eosin stain 72
2.14.3 Oil red O stain 72
2.14.4 Liver histology 72
2.15 Statistical analysis 73
Chapter 3 Inhibitory effects of bile acids on glucocorticoid metabolism in
vitro
3.1 Introduction 75
3.2 Research Aims 77
3.3 Methods and method development
3.3.1 lip-HSDl activity in tissue homogenates
3.3.1.1 Establishing assay conditions of llp-HSDl 78
3.3.1.2 Impact of bile acids and bile salts on activity of 11(3-HSD1 78
3.3.1.3 Enzyme kinetics of lip-HSDl 78
3.3.1.4 Impact of bile acids on lip-HSDl reductase activity 79
3.3.2 5P-Reductase activity in tissue homogenates
3.3.2.1 Establishing assay conditions of 5(1-reductase 79
3.3.2.2 Impact of competing substrate (7a-hydroxycholestenone)
on 5|3-reductase activity 80
3.3.2.3 Impact of bile acids and bile salts on 5|3-reductase activity 80
3.3.2.4 Enzyme kinetics of 5p-reductase 80
VII
3.3.3 3a-HSD activity in tissue homogenates
3.3.3.1 Establishing assay conditions of 3a-HSD 80
3.3.3.2 Impact of bile acids and bile salts on 3cx-HSD activity 81
3.3.4 5a-Reductase 1 activity in cultured rat hepatoma cells
3.3.4.1 Screening of hepatoma cell lines for genes of interest 81
3.3.4.2 Establishing assay conditions of 5a-reductase 1 82
3.3.4.3 Impact of bile acids on 5a-reductase 1 activity 82
3.3.4.4 3a-HSD activity in cultured cells 82
3.3.4.5 Impact of bile acids 3a-HSD activity in cultured cells 83
3.3.5 Impact of bile acids on gene transcription 83
3.3.6 Data analysis 84
3.3.7 Statistical analysis 85
3.4 Results
3.4.1 llp-HSDl
3.4.1.1 Chromatography of lip-HSDl 86
3.4.1.2 Time course of lip-HSDl dehydrogenase activity 87
3.4.1.3 Impact of bile acids on lip-HSDl dehydrogenase activity 87
3.4.1.4 Impact of bile salts on lip-HSDl dehydrogenase activity 89
3.4.1.5 Enzyme kinetics of lip-HSDl dehydrogenase activity 90
3.4.1.6 Impact of bile salts on lip-HSDl reductase activity 91
3.4.2 5P-Reductase
3.4.2.1 Chromatography of 5P-reductase 93
3.4.2.2 Time course of 5p-reductase activity 94
3.4.2.3 Impact of bile acids on 5p-reductase activity 94
3.4.2.4 Impact of bile salts on 5p-reductase activity 96
3.4.2.5 Enzyme kinetics of 5p-reductase 97
3.4.2.6 Impact of 7a-hydroxycholestenone on 5p-reductase 98
activity
3.4.3 3a-HSD
3.4.3.1 Mass chromatography of 3a-HSD 99
VIII
3.4.3.2'Time course of 3a-HSD activity 100
3.4.3.3 Impact of bile acids and bile salts on 3a-HSD activity 100
3.4.4 5a-Reductase 1
3.4.4.1 PCR screening of hepatoma cell lines 101
3.4.4.2 Time course of 5a-reductase 1 activity 102
3.4.4.3 Impact of bile acids on 5a-reductasel activity in cultured 103
cells
3.4.5 Impact of bile acids on gene transcription 104
3.5 Discussion 106
Chapter 4 Effect of increased concentrations of hepatic bile acids on
glucocorticoid metabolism and HPA axis activation in vivo
4.1 Introduction 113
4.2 Research Aims 114
4.3 Methods and method development
4.3.1 Animals 115
4.3.2 Administration of diet 115
4.3.3 Restraint stress 115
4.3.4 Metabolic cages 116
4.3.5 Animal sacrifice and tissue collection 116
4.3.6 Analysis of hepatic enzyme activity 116
4.3.7 Abundance of transcripts 117
4.3.8 Analysis of plasma hormones and intermediate metabolites 117
4.3.9 Analysis of liver fat intermediates 117
4.3.10 Analysis of urinary steroids 117
4.3.11 Bile acid analysis 118
4.3.12 Histology 118
4.3.13 Statistical analysis 118
4.4 Results
4.4.1 Effect of CDCA and cholestyramine on physiological parameters
4.4.1.1 Body weight 119
IX
4.4.1.2 Organ weight 120
4.4.1.3 Bile acids 123
4.4.1.4 Blood and serum parameters 123
4.4.2 Impact of CDCA and cholestyramine on hepatic glucocorticoid
metabolizing enzymes
4.4.2.1 Hepatic enzyme activity 124
4.4.2.2 Urinary metabolites 127
4.4.2.3 Glucocorticoid-sensitive genes 127
4.4.3 Effect of CDCA or cholestyramine feeding on HPA axis 129
activation
4.5 Discussion 131
Chapter 5 Impact of decreased bile acids by a fat-free diet on glucocorticoid
metabolism and HPA axis activation
5.1 Introduction 138
5.2 Research aims 139
5.3 Materials and methods
5.3.1 Animals and animal maintenance 140
5.3.2 Preparation of diet 140
5.3.3 Metabolic cages 140
5.3.4 Animal sacrifice and tissue collection 140
5.3.5 Analysis of biochemical parameters 141
5.3.6 Abundance of transcripts 142
5.3.7 Statistical analyses 142
5.4 Results
5.4.1 Effect of fat-free diet on physiological parameters
5.4.1.1 Body weight 143
5.4.1.2 Organ weight 144
5.4.1.3 Blood and serum parameters 146
5.4.1.4 Bile acids 146
5.4.2 Impact on hepatic glucocorticoid metabolising enzymes
X
5.4.2.1 Hepatic enzyme activity 147
5.4.2.2 Urinary metabolites 150
5.4.2.3 Glucocorticoid sensitive genes 150
5.5 Discussion 151
Chapter 6 Impact of bile acids on the renin-angiotensin-aldosterone-system
6.1 Introduction 156
6.2 Research aims 157
6.3 Materials and methods
6.3.1 Animals and animal maintenance 158
6.3.2 Dietary manipulation 158
6.3.3 Metabolic cages 158
6.3.4 Animal sacrifice and tissue collection 158
6.3.5 Analysis of enzyme activity 158
6.3.6 Analysis of plasma hormones and intermediate metabolites 159
6.3.7 Analysis of urinary electrolytes 159
6.3.8 Quantification of target gene abundance 159
6.3.9 Adrenal gland preparation 159
6.3.10 Adrenal gland histology 159
6.3.11 Statistical analysis 160
6.4 Results
6.4.1 Impact of bile acids on fluid and electrolyte balance 161
6.4.2 Impact of bile acids on the renin-aldosterone system 162
6.4.3 Transcript abundance of adrenal target genes 163
6.4.4 Impact of bile acids on 11|3-HSD2 activity 164
6.4.5 Impact of bile acids on adrenal gland morphology 165




7.1 Discussion and future work 176
References 184




1.1 Basic steroid ring structure 3
1.2 Adrenocortical steroid biosynthetic pathway in man 5
1.3 Adrenal gland 6
1.4 Metabolic pathway of glucocorticoid hormones 8
1.5 Interconversion of active and inactive glucocorticoids by isoforms of 11(3-
HSD 9
1.6 Glucocorticoid hydrocarbon skeleton 11
1.7 Regulation of glucocorticoid synthesis in the rat via the HPA axis 16
1.8 Transactivation of the glucocorticoid receptor 20
1.9 Enterohepatic circulation of bile acids 28
1.10 Pathways of bile acid biosynthesis 30
1.11 A-ring reduction of bile acid intermediates 31
1.12 Conjugation of chenodeoxycholic acid 32
1.13 The role of FXR and LXR in cholesterol and bile acid biosynthesis 35
Chapter 2




3.2 Time course of production of [3H]4A with time in tissue homogenates 87
3.3 A Impact of bile acids on 11(3-HSD1 dehydrogenase activity 88
3.3 B Impact of bile salts on 11(3-HSD1 dehydrogenase activity 89
3.4 A Michaelis Menten plot demonstrating inhibition of llp-HSDl activity 90
by CDCA
3.4B Lineweaver burke plot demonstrating inhibition of llp-HSDl by CDCA 90
3.5 Impact of CDCA on lip-HSDl reductase activity 92
3.6 Radiochromatograms 93
3.7 Representative time course of production of [3H]45|3-THB with time 94
XIII
3.8 A Impact of bile acids on enzyme 5 (3-reductase velocity 95
3.8 B Impact of bile acids and bile salts on 5(3-reductase enzyme activity 96
3.9 A Michaelis Menten plot demonstrating inhibition of 5(3-reductase 97
by CDCA
3.9 B Lineweaver Burke plot demonstrating inhibition of 5(3-reductase 97
by CDCA
3.10 Impact of 7aHCOH on activity of steroid 5|3-reductase 98
3.11 Mass chromatogram of MO-TMS derivatives (m/z 564) 5a- and 99
5(5-reduced corticosterone
3.12 Representative time course of production of 5(3-THB from 5(3-DHB by 99
3aHSD
3.13 Lack of effects of bile acids on activity of 3a-HSD 101
3.14 RT-PCR gel of enzyme expression in H4IIE cells 102
3.15 Representative time course of production of 5a-THB from B by 103
5a-reductase 1 and 3aHSD activity in H4IIE cells
3.16 Impact of bile acids on 5a-reductase 1 activity in H4IIE cells 103
3.17 Effect of bile acids and bile salts on transcription of CYP7A1 104
3.18 Lack of effect of bile acids and bile salts on transcription of 105
5(3-reductase (A), 5a-reductasel (B), 3a-HSD (C) and 11(3-HSD1 (D)
mRNA
Chapter 4
4.1 Body weight following dietary manipulation 119
4.2 Impact of diet on liver lipid accumulation 122
4.3 Transcript abundance of CYP7A1 following dietary manipulation 123
4.4 lip-HSD l dehydrogenase activity following dietary manipulation 125
4.5 5(5-Reductase and 3a-HSD activity and expression following 126
dietary manipulation
4.6 Transcript abundance of glucocorticoid sensitive genes following 128
dietary manipulation
4.7 Indices reflecting HPA axis response to acute stress 130
XIV
Chapter 5
5.1 A Body weight following dietary manipulation 143
5.1 B Body weight change following dietary manipulation 144
5.2 Transcript abundance of CYP7A1 following dietary manipulation 147
5.3 Hepatic enzyme activity following dietary manipulation 148
5.4 Transcript abundance of glucocorticoid metabolizing genes 149
Chapter 6
6.1 11P-HSD2 activity following dietary manipulation 164
6.2 Size of zones within the adrenal cortex following dietary 165
manipulation
6.3 Lipid accumulation within the adrenal gland 166




1.1 Nomenclature of steroidogenic enzymes 4
1.2 Functions of anterior pituitary hormones 15
Chapter 2
2.1 Mass/charge ratio and retention time of ions monitored by GC-MS 61
2.2 Oligonucleotide primers used for amplification 5|3-reductase, 11(3-HSD1 64
3a-HSD and CYP7A1 cDNAs by RT-PCR
2.3 Master mix components for PCR 64
2.4 Conditions for PCR of genes of interest 65
2.5 Master mix solution for LightCycler PCR 70
2.6 Parameters for amplification of CYP11B1 and CYP11B2 by 71
LightCycler® real time PCR
Chapter 3
3.1 Concentration (IC50) of inhibitor causing 50% inhibition of the rate 88
of the reaction
3.2 Concentration (IC50) of inhibitor causing 50% inhibition of the rate 89
of the reaction
3.3 Inhibitory kinetics of CDCA on activity of 11|3-HSD1 91
3.4 Concentration (IC50) of inhibitor causing 50% inhibition of the rate 95
of the reaction
3.5 Concentration (IC50) of inhibitor causing 50% inhibition of the rate 96
of the reaction
3.6 Inhibitory kinetics of CDCA on activity of 5|3-reductase 98
3.7 RT-PCR screening of hepatoma cell lines 102
Chapter 4




5.1 Modified AIN-76A Rodent Diet With Alcohol-Extracted Casein, 141
70% Sucrose (w/w), No Added Fat and with and without 1%
chenodeoxycholic acid
5.2 Changes in physiological parameters following dietary manipulation 145
5.3 Plasma lipid profile following of animals fed standard chow 146
compared to fat-free chow
Chapter 6
6.1 Impact of bile acids on fluid and electrolyte balance 161
6.2 Impact of bile acids on the renin-angiotensin-aldosterone system 163
6.3 Impact of bile acids on the lip-hydroxylase (CYP11B1) and 163




ACE angiotensin converting enzyme
ACTH adrenocorticotrophic hormone
ACRD cortisone reductase deficiency
AKR aldo-keto reductase
AME apparent mineralocorticoid excess
ANG angiotensin
ANOVA analysis of variance
AR androgen receptor
ARR aldosterone : renin ratio
ASBT sodium-dependent bile acid transporter
AUC area under the curve
B corticosterone
BARE bile acid response elements
BDL bile duct ligation
P-LPH P-lipotrophin






CNS central nervous system














FBS fetal bovine serum
FSH follicle stimulating hormone
FXR farnesoid X (bile acid) receptor
GA glycyrrhetinic acid
GCDCA glyco-chenodeoxycholic acid
GC-MS gas chromatography mass spectrometry
GH growth hormone
GR glucocorticoid receptor
GRE glucocorticoid response element
XVIII
7aHC0H 7a-hydroxycholestenone
HDL high density lipoprotein
H6PDH hexose-6-phosphate dehydrogenase
HNFa hepatocyte nuclear receptor 4a
HPA hypothalamic-pituitary-adrenal
HPLC high performance liquid chromatography
HSD hydroxysteroid dehydrogenase
HSP heat shock protein
I-BABP ileum bile acid binding protein
IL-ip interleukin 1(3
JNK/c-Jun c-jun N-terminal kinase




LRH-1 liver receptor homologue-1
LXR oxysterol receptor





NTCP sodium-dependent taurocholate co-transport peptide
OFN oxygen-free nitrogen
PBC primary-biliary cirrhosis
PBS phosphate buffered saline
PCN pregnenolone 16a-carbonitrile
PCR polymerase chain reaction
PEPCK phosphoenolpyruvate carboxykinase
PFIC1 progressive familial intrahepatic cholestasis type 1
PRL prolactin
PVN paraventricular nucleus
PXR pregnane X receptor
RARa retinoic acid activated receptor a
RT room temperature
RXR retinoic acid X receptor
SDR Short Chain Dehydrogenase Reductase
SDS sodium dodecyl sulphate
SEM standard error of the mean
SHP-1 small heterodimer partner-1
SR-B1 scavenger receptor class B type 1
StAR Steroidogenic Acute Regulatory protein
SXR steroid and xenobiotic receptor
TAT tyrosine amino-transferase
TCDCA tauro-chenodeoxycholic acid








Cholesterol is the common precursor of both steroid hormones and bile acids.
This thesis will address the interaction between enzymes involved in steroid hormone
metabolism and bile acid biosynthesis.
1.1 The Endocrine System
Endocrinology describes study of the synthesis, secretion and action of
hormones, defined as "chemical messengers which co-ordinate the activities of
different cells in a multicellular organism" (Davidson's Medicine, 2004). Classically
the endocrine system functions via the release of hormones into the circulation which
would then act at a site distant from that of secretion. Many hormones can also act in
a paracrine manner, where the factor is not released into the circulation but acts upon
adjacent cells, for example regulation of the immune system; an autocrine manner,
whereby the factor acts upon the cell of origin, for example neurotransmitters; or an
intracrine manner whereby factors act upon the cell within the gland in which they
were synthesised. Hormones have diverse biological actions exerting inhibitory or
stimulatory roles and can be divided into three broad classes; steroid hormones,
peptides or proteins and amino acid derivatives.
1.1.1 Steroid hormones - this large class of hormones includes glucocorticoids,
mineralocorticoids and sex steroid hormones, all of which are structurally
derived from cholesterol.
1.1.2 Peptides and proteins- this class encompasses the majority of hormones
including adrenocorticotrophin hormone (ACTH), thyrotrophin-releasing
hormone (TRH), gonadotrophins such as follicle stimulating hormone (FSH)
and leutenising hormone (LH). Proteins belonging to this class include the
sex-bindig globulin (SBG).
1.1.3 Amino acid derivatives - this class of hormones includes neurotransmitters,
thyroid hormones and epinephrine (adrenaline).
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This thesis will focus upon the regulation of glucocorticoid action in the liver.
Glucocorticoids are steroid hormones synthesised de novo in the adrenal gland under
control of peptide hormones secreted by the pituitary gland.
1.2 Steroid hormones
1.2.1 Chemistry and nomenclature
Adrenal hormones such as Cortisol and aldosterone are steroid hormones
which are derived from the common precursor cholesterol. These hormones have a
basic structure which is conserved throughout the family. This structure is based
upon the steroid nucleus, comprising three cyclohexane rings and one cyclopentane
ring. Each steroid is given its unique properties by substitution of chemical groups at
various positions on the backbone of the molecule (Figure 1.1)
21
Figure 1.1 Basic steroid ring structure and conventional labeling of pregnane C21 steroid hormones.
The four carbon rings are assigned letters and the numbers correspond to individual carbon atoms.
Chemical groups are designated by the number of the carbon atom to which they are attached.




Steroid hormone are synthesised from the cholesterol by a complex series of
reactions carried out within the adrenal gland (Figure 1.2). The conversion of C27
cholesterol to 18-, 19-, and 21-carbon steroid hormones involves the irreversible
cleavage of a 6-carbon residue from cholesterol to produce pregnenolone (C21) plus
isocaproaldehyde in a reaction catalysed by P450-linked side chain cleaving enzyme
(P450ssc; CYP11A1; Table 1.1). This enzyme is found primarily within the
mitochondria of steroid producing cells. Pregnenolone acts as the common precursor
molecule for all Qg, Q9 and C21 steroids. Steroid hormones with 21 carbon atoms
are known systematically as pregnanes, whereas those containing 19 and 18 carbon
atoms are known as androstanes and estranes respectively. Following cleavage of the
6-carbon side chain, pregnenolone is further processed within the cytosol and the
final product depends on the cell (tissue) under consideration. The various
hydroxylases involved in the directed synthesis of the steroid hormones are members
of the cytochrome P450 class of enzymes. Their nomenclature is indicative of the
site of hydroxylation (e.g. the 17a-hydroxylase is also identified as P450ci7). In
recent years enzyme nomenclature has been standardised and is summarised in table
1.1.
Trivial name Previous name Present name
Cholesterol side chain cleavage P450scc CYP11A1
3p-hydroxysteroid dehydrogenase 3|3HSD HSD3B
17a-hydroxylase / 17,20-lyase P450ct7 CYP17
21-hydroxylase P450c2i CYP21A2
ll(3-hydroxylase P450cn CYP11B1
Aldosterone synthase P450ciias CYP11B2




Figure 1.2 Adrenocortical steroid biosynthetic pathway in man. Enzymes and steroid hormone
nomenclature are given in bold. Rodents do not express CY17 within the adrenal cortex and therefore
steroids can not be 17-hydroxylated. (Reactions within hatched box refer to man only). The major
glucocorticoid in rodents is therefore corticosterone.
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1.4 Steroid hormones
Corticosteroids are synthesized in the adrenal glands which are located within
close proximity of the kidneys. These organs along with the gonads are a major site
of production of steroid hormones. Each gland can be divided into two
morphologically and biochemically distinct regions, namely the cortex and medulla.
The adrenal medulla is embryologically and histologically distinct from the cortex
and is part of the sympathetic nervous system. Medullary cells synthesize, store and
secrete adrenaline, along with noradrenaline and dopamine. The adrenal cortex
which is situated around the perimeter of the adrenal gland is involved in the
synthesis of glucocorticoids and mineralocorticoids including Cortisol and
aldosterone respectively from the common precursor cholesterol. In humans, it also
represents a secondary site of androgen synthesis complementing the ovary, testes
and placenta. The adrenal cortex can be further subdivided into 3 distinct zones
based upon cell type and function (Figure 1.3). Although the pathway to synthesise
pregnenolone is common to all zones of the cortex, the exact steroid hormone
product is dependent upon the specific enzymes present in the cells of each zone
Capsule
Zona glomerulosa - aldosterone
Zona fasiculata - glucocorticoids
Zona reticularis - C19 steroids
medulla
Figure 1.3 Adrenal gland. Zones of the adrenal cortex and the predominating steroid hormone
synthesized within each zone
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1.4.1 Zona glomerulosa
The outermost zone of the adrenal cortex, the zona glomerulosa is the main
site of mineralocorticoid synthesis, primarily aldosterone and also the less potent
mineralocorticoid deoxycorticosterone which play a major role in regulating
electrolyte balance within the body. Cells within the zona glomerulosa lack the
enzyme 17-hydroxylase (CYP17) that converts pregnenolone and progesterone to
their C17 hydroxylated analogs. As such the pathways to produce glucocorticoids and
androgens are not active in these cells. Zona glomerulosa cells express aldosterone
synthase (CYP11B2) the enzyme responsible for converting 18-OH corticosterone to
aldosterone, the principal and most potent mineralocorticoid.
1.4.2 Zona fasciculata
The zona fasciculata is the primary site of glucocorticoid production in
humans of which ~ 95% is Cortisol. Cells within the fasiculata express high levels of
ll(3-hydroxylase (CYP11B1) which is absent from the zona glomerulosa and is
responsible for the conversion of 11-deoxycortisol and deoxycorticosterone to the
glucocorticoids Cortisol and corticosterone. In humans zona fasiculata cells also
express CYP17 whose activity is responsible for producing the androgens,
dehydroepiandosterone (DHEA) and androstenedione. Rodents do not express
CYP17 within the adrenal cortex therefore steroids cannot be 17-hydroxylated. Thus,
the major glucocorticoid in the rodent is corticosterone and rodents do not synthesise
adrenal androgens.
1.4.3 Zona reticularis
The zona reticularis represents the innermost zone of the adrenal cortex and is
the principal site of androgen production (DHEA, DHEA sulphate, and
androstenedione in humans). Analogous to the zona fasiculata, zona reticularis cells
express both CYP17 and CYP11B1 but not CYP11B2. Thus, cells within the




This thesis will focus upon glucocorticoids, a class of steroid hormones
named due to their intrinsic role in glucose metabolism and homoeostasis. The
principal active glucocorticoid in man is Cortisol (F) and corticosterone (B) in the
rodent. This thesis generates data from rodent models and therefore rodent
nomenclature will be used throughout.
Glucocorticoid metabolism provides the predominant means of clearing non-
sequestered hormone from the circulation, thus influences local circulatory levels and
tissue specific responses to hormones. The principal enzymes involved in
corticosterone metabolism and the resulting metabolites of corticosterone are shown
in figure 1.4. Enzymes directly involved in corticosterone metabolism include the
11 P-HSDs, the A-ring reductases (5a- and 5(3-reductase and 3a-hydroxysteroid
dehydrogenases; 3a-HSDs). Minor pathways of metabolism (not shown) include,























Figure 1.4 Metabolic pathway of glucocorticoid hormones in rat. Principal enzymes involved in
glucocorticoid metabolism; HSD = hydroxysteroid dehydrogenase ; 5a and 5p-reductase and 3a-HSD
= A-ring reductases
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1.5.1 11(3-hydroxysteroid dehydrogenase type 1 (11(5-HSD1)
lip-HSD type 1 (lip-HSDl), locally regenerates active glucocorticoids from










Figure 1.5 Interconversion of active and inactive glucocorticoids by isoforms of 1 ip-HSD. In situ,
11P-HSD1 acts predominantly in the reductase mode activating corticosterone from 11-
dehydrocorticosterone whilst 11P-HSD2 inactivates corticosterone
Within individual tissues lip-HSDl mainly acts to locally amplify levels of
glucocorticoids thereby ensuring adequate activation of the lower affinity
glucocorticoid receptor (GR). This enzyme is a low affinity NADP(H) dependent
enzyme which is highly expressed within glucocorticoid target tissues including the
liver (Jamieson et al. 1995; Bujalska et al. 1997), lung (Hundertmark et al. 1993),
adipose and skeletal tissue (Napolitano et al. 1998; Brern et al. 1995), adrenal cortex
(Shimojo et al. 1996) anterior pituitary and certain regions of the brain (e.g.
hippocampal and paraventricular nucleus (PVN) neurons (Sakai et al. 1992)). These
tissues also express high levels of GR and it is thought that lip-HSDl modulates
glucocorticoid access to these sites (Whorwood et al. 1992). Although this isozyme
shows bi-directional activity in tissue homogenates and when purified, it acts
predominantly as a reductase under physiological conditions and in vivo. Mice
9
homozygous for a targeted disruption of the lip-HSDl gene cannot regenerate
active corticosterone from inert 11-dehydrocorticosterone (Kotelevtsev et al. 1997).
Jamieson et al (1995) demonstrated that hepatic 11(1-HSD1 activity in isolated rat
liver acted predominantly as a reductase in vivo. The predominating reductase mode
of activity relates to the intracellular location of 11(3-HSD1 within inner leaflet of the
endoplasmic reticulum (ER) rather than any structural features and depends upon co-
factor access and supply. The microsomal enzyme hexose-6-phosphate
dehydrogenase (H6PDH), which plays an essential role in supplying NADPH co-
factor to 11(3-HSD1, is also associated within the lumenal side of the ER, directed in
the same orientation as the catalytic domain of Ilj3-HSD1. Mutations within exon 5
of H6PDH which attenuate or abolish H6PDH activity have been identified in
individuals with cortisone reductase deficiency (ACRD) (Draper et al. 2003).
H6PDH deficient mice, which are unable to convert 11-dehydrocorticosterone (11-
DHC) to corticosterone, have a reduction in lip-HSDl oxo-reductase activity
(Lavery et al. 2005).
1.5.2 11 fi-hydroxysteroid dehydrogenase type 2 (11y3-HSD2)
llp-HSD type 2 catalyses the oxidation of active corticosteroids to their
inactive keto metabolites (Funder et al. 1988; Brown et al. 1993) protecting the
otherwise non-selective mineralocorticoid receptor (MR) from occupation by
glucocorticoids (Edwards et al. 1988). 11(!-HSD2 is a high affinity (low nanomolar
Km for Cortisol), NAD-dependent dehydrogenase and is widely expressed in fetal
tissue including the placenta (Stewart et al. 1994). In adults however, this isozyme is
expressed in mineralocorticoid-sensitive tissues such at the distal nephron, salivary
glands, sweat glands and colonic mucosa (Hirasawa et al. 1997; Takahashi et al.
1998). Deficiency of renal 11|3-HSD2 was originally linked to the syndrome of
apparent mineralocorticoid excess (AME), in which glucocorticoids illicitly occupy
MR causing sodium retention, hypokalemia and hypertension (Ulick et al. 1979) and
more recently, genetic mutations within the 11(3-HSD2 gene have been identified in
patients with this disorder (Wilson et al. 1995; Li et al. 1997; Lovati et al. 1999;
Lavery et al. 2003). Mutations within llp-HSD2 also contribute towards the
10
development of essential hypertension due to illicit activation ofMR (Stewart et al.
1996; Krozowski et al. 1997).
1.5.3 A-ring reduction
The principal routes of Cortisol clearance in the liver are catalysed by the
hepatic A-ring reduction by the "A-ring reductases" (5a and 5(3-Reductase) (Kondo
et al. 1994; Onishi et al. 1991; Russell & Wilson 1994; Tomkins 1956). Reduction of
the steroid A-ring A4"5 double bond by 5a and 5(3-reductase is rapidly followed by a
second reductive step catalysed by 3a-hydroxysteroid dehydrogenase (3a-HSD)
(Figure 1.6). The former reactions are rate-limiting. The resulting tetrahydro
metabolites (5a or "alio" and 5p-tetrahydrocortisols) are then conjugated, the
principal conjugates being glucuronides although some sulphates are formed, making
them more water soluble prior to excretion via the kidneys. This two-step reductive
pathway, common to several other steroids including the reduction of aldosterone,
progestogens and androgens, is not reversible.
Figure 1.6 Glucocorticoid hydrocarbon skeleton. Structure of corticosterone highlighting sites of





5a-reductases catalyse the first step in the reduction of the A-ring, reducing
the 4-5 double bond in the A-ring to form 5a-dihydro metabolites. Two isoforms of
this enzyme have been cloned (Types 1 and 2) from different genes (Andersson et al.
1989a; Andersson et al. 1991) and a pseudogene has been identified in man (Jenkins
et al. 1992). These isoforms differ in both their biochemical characteristics and tissue
distribution and also show species specificity and sexual dimorphism (Russell &
Wilson 1994). Both isozymes are found within the microsomal and plasma
membrane/nuclear sub-fractions and utilise NADPH as a co-factor.
The type 1 enzyme is highly expressed within the liver (Thigpen et al. 1993),
brain, non-genital skin fibroblasts (Normington & Russell 1992; Andersson &
Russell 1990) and to a lesser extent in stromal cells of adipose tissue (Killinger et al.
1990). 5a-reductase type 1 is active over a broad range of pH (optimum pH 7.4) and
reduces most A4"5 unsaturated steroids with similar efficiency.
In contrast, 5a-reductase type 2 is primarily located within male reproductive
tissues e.g. prostrate and seminal vesicles and in regions of the developing central
nervous system (CNS) involved in reproductive behaviour (Russell & Wilson 1994)
and also within the human but not rat liver. The type 2 isozyme has an optimum pH
within the acidic range ® pH 5, and is primarily responsible for converting
testosterone to active 5a-dihydrotestosterone playing a key role in enhancing local
androgen receptor (AR) activation. This amplification process is essential for normal
development of the male reproductive development and secondary sexual
characteristics. Mutations in the type 2 isozyme in males can result in the condition
of male pseudohermaphroditism in which the male genitalia fail to develop properly
(Andersson et al. 1991). The relative contribution of each isozyme to glucocorticoid
metabolism within the liver in humans is as yet unknown but both contribute to first
pass metabolism (Andersson & Russell 1990).
Although 5a-reduced glucocorticoids were thought to be biologically inert,
recent data has demonstrated that 5a-reduced glucocorticoids can bind and activate
GR and therefore have the potential to induce GR responsive genes such as tyrosine
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amino-transferase (TAT) and phosphoenolpyruvate carboxykinase (PEPCK)
(Mclnnes et al. 2004).
1.5.3.2 5/3-Reductase
5p-reductase belongs to the aldo-keto reductase (AKR) super family, a family
of cytosolic, monomeric oxidoreductases catalysing the reduction of ketosteroids (i.e.
glucocorticoids, mineralocorticoids, androgens and progestogens) and bile acid
intermediates. Located within the cytosolic sub-fraction, 5|3-reductase catalyses
reduction of the steroid 4-5 unsaturated double bond resulting in the generation of cis
5p*reduced dihydro metabolites (Tomkins 1956). 5|3-reductase is highly expressed
within the liver (with much lower expression in the kidney) and utilises NADPH as
its preferred co-factor. At present only one form of this enzyme has been cloned in
both human and rat (Kondo et al. 1994; Onishi et al. 1991). A pseudogene has been
identified in humans (Charbonneau & The 2001) and there have been reports, as not
yet corroborated, suggesting a second 5p-reductase isoenzyme may exist (Furuebisu
et al. 1987).
1.5.3.3 3a-Hydroxysteroid Dehydrogenases (3aHSD)
The 5a- or 5|3- dihydro products of A-ring reduction undergo a further
reductive step catalysed by isozymes of 3a-hydroxysteroid dehydrogenases (3a-
HSDs), resulting in the formation of tetrahydro metabolites that are conjugated and
excreted from the body (Penning 1999). The 3a-HSD isozymes are expressed within
the microsomal and cytosolic sub-fractions and utilise NADPH as their preferred co-
factor. As with 5(J-reductase, these enzymes belong to the AKR superfamily (Jez &
Penning 2001) catalysing the reduction of ketosteroids and oxidised cholesterol
metabolites. Indeed, the 3a-HSDs perform an array of functions including the
hepatic clearance of steroid hormones, the transport and biosynthesis of bile acids,
the regulation of androgen metabolism and the formation of neurosteroids (Jin et al.
2001). At present 4 genes have been identified in human (AKR1C1-4). These
isoforms share >83% sequence identity at the amino acid level but differ in their
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biochemical and substrate specificity (Penning et al. 2000). Type 1 3a-HSD
(AKR1C4) is expressed specifically within the liver and is primarily involved in the
metabolism of steroid hormones and the formation and excretion of 5a- and 5|3-
tetrahydrosteroids. Type II 3a-HSD (AKR1C3) is highly expressed within the
prostate where it reduces the potent androgen 5a-dihydrotestosterone (5a-DHT) to
5a-androstane-3a, 17(3-diol (a weak androgen) (Lin et al. 1997) . Type III 3a-HSD
(AKR1C2) is also highly expressed within the prostate and is the only known 3a-
HSD isoform capable of activating 5a-androstane-3a, 17|3-diol to 5a-DHT (Stolz et
al. 1993). As high levels of 5a-DHT are linked with abnormal prostate growth,
inhibition of AKR1C2 may provide a good strategy for the clinical management of
prostate cancer and benign prostate hyperplasia. Also known as human bile acid
binding protein, 20a-(3a)-HSD (AKR1C1) is thought to function as an intracellular
bile acid transporter (Bahar & Stolz 1999). In contrast only one 3a-HSD protein has
been identified in the rat (AKR1C9) (Pawlowski et al. 1991). Rat liver 3a-HSD
shares 69% sequence identity with the human isoforms and, although more
catalytically efficient than the human 3a-HSDs, AKR1C9 lacks 17(1- or 20a-HSD
activities (Lin et al. 1999).
1.5.4 Polar SteroidMetabolism
The 20-reductases (20a and 20p-HSDs) (Abel & Back 1993) and cytochrome
P450 microsomal enzyme 6fl-hydroxylase (CYP3A)(Waxman et al. 1988) are also
directly involved in glucocorticoid metabolism generating 20a or p-
dihydrocorticosterones and 6(l-hydroxycorticosterones respectively. These pathways
account for only a small fraction (<10%) of corticosterone metabolites, the majority
being excreted as metabolites of the A-ring reductases. In addition to its role in
glucocorticoid hydroxylation, CYP3A hydroxylates a number of natural and
xenobiotic molecules and is inducible by drugs including the antibiotic rifampicin
(Chawla et al. 2001). 20a and 20(l-HSDs also catalyse the reduction of the tetrahydo
metabolites into cortols and cortolones in humans. Finally, P450scc (side-chain
cleavage enzyme) and 21-oxidase catalyse the terminal oxidation steps resulting in
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the formation of 11-hydroxyetiocholanolone and cortolic/cortolonic acids,
respectively.
1.6 Regulation of glucocorticoid secretion
1.6.1 The pituitary gland
The anterior pituitary is responsible for the secretion of a number of types of
hormone acting either on endocrine glands or target tissues e.g. glucocorticoid
secretion from the adrenal gland is stimulated by ACTH from the pituitary. Further
examples are given in Table 1.2. The pituitary gland is composed of two lobes, the
anterior and posterior, which are connected via the infundibular stalk to the
hypothalamus. Portal vessels within the infundibular stalk carry blood from the
median eminence of the hypothalamus to the anterior lobe and nervous fibres to the
posterior lobe.
Function Hormone Abbreviation
Adrenal glucocorticoid/ Adrenocorticotrophic hormone ACTH
mineralocorticoid production
Growth Growth hormone GH
Thyroid activity Thyroid stimulating hormone TSH
Sexual activity and fertility Luteinising hormone LH
Follicle stimulating hormone FSH
Lactation Prolactin PRL
Table 1.2 Functions of anterior pituitary hormones
ACTH release from the anterior pituitary is stimulated by hypothalamic
factors such as corticotrophin releasing hormone (CRH), which are carried in the
portal circulation. Hypothalamic function in turn is regulated by a variety of stimuli
of nervous, hormonal, physiological and metabolic origin. Feedback control by
hormones produced in target glands such as the adrenal cortex plays a fundamental
role in regulating hormone secretion.
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1.6.2 Hypothalanuc-pituitary-adrenal (HPA) axis
The levels of active glucocorticoid within the circulation are normally tightly
regulated through feed-forward and feed-back mechanisms at the level of the
hypothalamus, pituitary and adrenal gland, referred to at the hypothalamic-pituitary-
adrenal (HPA) axis (Figure 1.7).
Figure 1.7 Regulation of glucocorticoid synthesis in the rat via the HPA axis. Circulating levels of the
active glucocorticoids are detected by the hippocampus, hypothalamus and pituitary which then
stimulate or suppress CRH and ACTH secretion accordingly.
Circulatory levels of active glucocorticoid are detected by the hypothalamus
and pituitary, which then regulate secretion of ACTH, signaling to the adrenal cortex
to stimulate or suppress glucocorticoid synthesis accordingly. For example, when
circulating levels of active Cortisol are low, increased secretion of corticotrophin
releasing hormone (CRH) from the hypothalamus stimulates ACTH secretion from
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the anterior pituitary, which in turn induces glucocorticoid biosynthesis. Conversely
when glucocorticoid levels are elevated, secretion of CRH and ACTH are reduced
thus decreasing the rate of glucocorticoid production. As such the levels of
circulating hormone are largely determined by the rates of their biosynthesis and
elimination, primarily through glucocorticoid metabolism (Jacobson & Sapolsky
1991; Rask etal. 1999).
1.6.3 HPA axis regulation andmetabolism
There is now increasing evidence that peripheral metabolism of
glucocorticoids and the rate of metabolic clearance play an important role in
determining glucocorticoid action in target tissues and HPA axis response.
Individuals with an autosomal recessive disorder resulting in 11 (THSD2 deficiency
present with the condition of "Apparent mineralocorticoid excess" or AME (Ulick et
al. 1979), normally diagnosed in childhood with hypokalaemia (polyuria, myopathy),
severe hypertension, and complications including stroke and cardiac arrest (Stewart
et al. 1988). These patients show elevated ratios of the urinary metabolites of Cortisol
versus cortisone and the half life of [lla3H]-cortisol is prolonged indicating a
deficiency of 11 (1-dehydrogenase activity (Stewart et al. 1988). As such the rate of
Cortisol metabolite excretion is reduced (consistent with a compensatory fall in HPA
axis activation and Cortisol production) whilst urinary free Cortisol concentrations are
elevated (consistent with impaired Cortisol metabolism within the kidney) (Ulick et
al. 1991; Monder et al. 1986). The features of AME have since been recapitulated in
a transgenic 11(1-HSD2 knockout mouse, with a reduction in adrenal size and
suppression of the HPA axis (Kotelevtsev et al. 1999).
Conversely, where the rate of metabolic clearance is elevated e.g. Cortisone
reductase deficiency (ACRD) (Phillipov et al. 1996), over stimulation of the HPA
axis leads to enhanced production of adrenal steroids. Female sufferers of this
disorder often present with hirsutism and menstrual irregularity, whilst males suffer
from gonadotrophin-independent pseudo-precocious puberty and hyperandrogenism
which are thought to arise due to enhanced ACTH-dependent adrenal androgen
secretion. These subjects show elevated excretion of cortisone and total
glucocorticoid metabolites consistent with 11(1-HSD1 deficiency and compensatory
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activation of the HPA axis (Jamieson et al. 1999). To date mutations have not been
identified in the 11(3-HSD1 gene exons or exon/intron boundaries, although in some
cases lip-HSDl activity is compromised due to impaired co-factor regeneration by
H6PDH (Draper et al. 2003). Indeed H6PDH deficient mice have increased
corticosterone clearance and lower circulating corticosterone demonstrating the
important role for co-factor provision in determining directionality of 1 1J3-HSD1
(Lavery et al. 2005).
Enhanced 5(3-reduction of Cortisol and cortisone has also been identified in
sufferers suggesting that dysregulation of the A-ring reductases may also contribute
to the stimulation of the HPA axis in the manifestation in this condition (Phillipou &
Higgins 1985). Likewise, stimulation of the HPA axis is suppressed lip-HSDl
knockout mice which have heavier adrenal glands to compensate for impaired
glucocorticoid reactivation (Harris et al. 2001a). In addition, these animals
demonstrate an altered responsiveness of the HPA axis which can be corrected by re-
expressing this gene within the liver (Harris et al. 2001b; Paterson et al. 2004).
Taken together these findings confirm a fundamental role for metabolism of
glucocorticoids in the liver in regulation of the HPA axis.
There is little substantive evidence that changes in activity of the A-ring alter
HPA axis activation; however, enhanced glucocorticoid clearance by the 5a- and 5(3-
reductase is suggested to induce compensatory activation of the HPA axis in
idiopathic obesity in order to maintain circulatory glucocorticoid levels (Rask et al.
2001; Andrew & Walker 2005).
1.7 Glucocorticoid action
1.7.1 Nuclear hormone receptors
Glucocorticoids exert many of their effects via direct interaction with two
types of intracellular receptors: the glucocorticoid (GR; type 2 corticosteroid
receptor) and mineralocorticoid (MR; type 1 corticosteroid receptor) receptors. These
receptors belong to the nuclear hormone receptor (NHR) superfamily and function as
ligand-dependent transcription factors which induce and repress the expression of a
range of target genes. Members of this superfamily have three distinct domains: a
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ligand-binding domain, a DNA-binding domain and a transcriptional regulatory
domain. In the absence of ligand, GR is localised within the cytoplasm as part of a
multiprotein complex. When bound by ligand e.g. corticosterone, the resulting
complex is a non-DNA-binding oligmer. This complex consist of the heat shock
protein 90 (hsp90) dimer which binds to the DNA-binding domain of the receptor
along with heat shock protein 70 (hsp70) and FKBP52 (Figure 1.8). Dissociation of
the oligomeric complex yields the free GR subunit in the DNA-binding form. The
activated receptor forms a homodimer and is translocated to the nucleus through the
nucleopore. Once within the nucleus the receptor complex may bind to specific
nucleotide sequences in the DNA are referred to as glucocorticoid response elements
(GRE) located within the 5' promoter region of target genes modulating their
transcription. In contrast to the regulation of these classical GREs, the repression of
negatively regulated target genes is mediated by negative GREs (nGREs) or by
transrepression of positively acting transcription factors such as AP-1 and NF-kB.
Studies by Reichardt et al. (2000) (Reichardt et al. 2000) using dimerization-
defective GR mutant mice have shown that the repressive mechanisms by direct
DNA-binding of GR and by transrepression of other transcription factors can be
dissociated. GR can also regulate gene transcription indirectly by cross-talk with
other transcription factors such as API, NFkB and CREB (Funder 1997).
Glucocorticoids can activate both GR and MR but alter fuel metabolism mainly










Figure 1.8 Transactivation of glucocorticoid receptor. Corticosterone diffuses through the plasma
membrane where it binds to the GR complex. Activation of the oligomer releases GR which forms a
homodimer and undergoes cytoplasmic to nuclear translocation. Once within the nucleus GR binds to
specific GREs present stimulating transcription of the target gene. GR = glucocorticoid receptor; GRE
= glucocorticoid response element; Hsp = heat shock protein; FKBP = Immunophilin FKBP S2.
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1.7.2 Orphan nuclear receptors
In addition to acting via the classical nuclear hormone receptors, GR and MR,
recent evidence has highlighted several endogenous and exogenous steroids as
ligands for the orphan nuclear receptor, pregnane X receptor (PXR; NR1I2) (Kliewer
SA et al. 1998) alternatively called the steroid and xenobiotic receptor
(SXR)(Blumberg et al. 1998). PXR binds to DNA as a heterodimer with the 9-cis
retinoic acid receptor (RXR)(Mangelsdorf & Evans 1995) and is activated by a
myriad of compounds including several steroids, synthetic glucocorticoids, anti-
glucocorticoids and bile acids (Xie & Evans 2001). Thus activation of PXR may
represent a novel steroid signalling pathway that may account for some of the effects
of synthetic glucocorticoids and anti-glucocorticoids that are not mediated through
the classical GR signalling pathway. 5(3-reduced glucocorticoids, namely 5(3-
dihydrocortisol and 3a,5(3-tetrahydrocortisol are thought biologically inert since they
do not bind and activated GR. However, 5(3-reduced glucocorticoids and also 5(3-
cholestan-3a,7a,12a-triol, the bile acid precursor and product of 5(3-reductase, are
potent activators of PXR (Blumberg et al. 1998).
Activation of PXR induces expression of the CYP3A family of genes which
encode cytochrome P450 hemoproteins involved in the hydroxylation of a broad
range of substrates, including endogenous steroid hormones such as corticosterone,
progesterone and bile acids and play a crucial role in the detoxification and
metabolism of a variety of xenobiotics (Juchau 1990). For example, the human
CYP3A4 enzyme is reported to account for 50-60% metabolism of clinical drugs
(Maurel 1996). Upon activation, PXR induces CYP3A and inhibits HMG-CoA
reductase and cholesterol 7a-Hydroxylase (CYP7A1), the rate limiting enzyme in
the cholesterol catabolic pathway resulting in concomitant reductions in sterol
biosynthesis and bile acid secretion (Turley & Dietschy 1984; Kliewer et al. 1998).
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1.8 Roles of glucocorticoids in health and disease
Glucocorticoids regulate a number of key metabolic and homeostatic
processes (Andrews & Walker 1999). Their role in carbohydrate and lipid
metabolism and the provision of fuel to enable oxidative metabolism within the liver
is well recognised. In addition, glucocorticoids are also highly influential in
regulating electrolyte balance in the kidney and mediating the stress and immune
responses (Munck & Guyre 1986). During times of stress, glucocorticoids provide a
long-term signal to reduce many of the acute responses to illness, "re-setting"
metabolism in favour of providing immediate energy for the "fight-or-flight"
response.
This thesis will focus upon glucocorticoid metabolism and action within the
liver. Glucocorticoids play a number of essential roles within the liver including
lipid, carbohydrate and protein metabolism. Indeed, glucocorticoids act as potent
regulators of key enzymes involved in hepatic gluconeogenesis,inducing
transcription of PEPCK, the rate determining step in hepatic gluconeogenesis and
tyrosine animo transferase (TAT) thereby promoting glucose production (Nyirenda et
al. 1998). Likewise, glucocorticoids induce hepatic triglyceride storage (Mantha et
al. 1999) and promote fat accumulation within the liver (Stravitz & Sanyal 2003). In
addition, glucocorticoids activate hepatic CYP3A and induce cholesterol catabolism
and bile acid biosynthesis (Kliewer et al. 2002).
1.8.1 Regulation ofglucocorticoid metabolism
It has become apparent over recent years that tissue-specific regulation of
glucocorticoid metabolism can play a fundamental role in determining subsequent
action. A number of studies have demonstrated lip-HSDl to be regulated by
glucocorticoids, C/EBP, peroxisome proliferators-activated receptor-y agonists and
some pro-inflammatory cytokines (TNFa and IL-ip). For example glucocorticoids
and insulin have opposing effects upon llp-HSDl expression within primary rat
hepatocytes, glucocorticoids inducing gene transcription and insulin suppressing
llp-HSDl transcription (Jamieson et al. 1995). Similarly administration of
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dexamethasone in vivo induced 11|3-HSD1 within the liver and hippocampus. These
effects were ameliorated following adrenalectomy (Walker & Edwards 1994; Low et
al. 1994). Likewise, the inflammatory cytokine TNF-a increased activity and
expression of 11|3-HSD1 within renal cells (Escher et al. 1997) while interleukins 5
and 6 induced llp-HSDl activity in granulosA cells (Evagelatou et al. 1997). 11(3-
HSD1 is repressed by growth hormones (acting via IGF-1) (Tomlinson et al. 2003)
and the liver X receptor (LXR) (Stulnig et al. 2002). Likewise, sex steroids including
estradiol, progesterone and testosterone have also been shown to regulate 11(3-HSD1
activity and / or expression (Tomlinson 2005).
5a-Reductase is sexually dimorphically expressed and is under hormonal
control. Administration of testosterone to male castrated rats induces the
transcription and activity of both 5a-reductase types 1 and 2 within the ventral
prostate (Normington & Russell 1992). In contrast, testosterone is a negative
regulator of 5a-reductase 1 within the liver (Lopez-Solache et al. 1996) and adrenal
cortex (Lephart et al. 1991). Recent evidence has highlighted a role for insulin in the
regulation of 5a-reductase 1, as treatment of obese Zucker rats with the insulin-
sensitising drug metformin ameliorated the increase in activity and expression of 5a-
reductase 1 within the liver (Livingstone et al. 2005). There is some literature
showing that GH can induce 5a-reductase 1 activity in isolated female rat
hepatocytes (Miller & Colas 1982). In contrast to the 5a-reductases little is known
about the regulation of 5(3-reductase. Limited reseach suggests that carbenoxolone
may inhibit enzyme activity (Latif et al. 1990). Indeed, the relative excretion of 5(3-
tetrahydrocortisol falls following administration of licorice or carbenoxolone
(Stewart et al. 1987; Monder et al. 1989). A recent microarray study has suggested
that 5|3-reductase may be regulated by the bile acid receptor FXR (Pircher et al.
2003; Fukuhara et al. 2003). Studies in obese subjects have also demonstrated down-
regulation of A-ring reductase activity following weight loss on a very low calorie
diet suggesting that nutrition may have a role to play in enzyme regulation. However,
specific regulators of this enzyme remain elusive.
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1.8.2 Dysregulation ofglucocorticoid metabolism
Our understanding of the importance of glucocorticoid hormones in health is
largely based upon the pathological consequences of dysregulation in factors
governing synthesis, metabolism and /or excretion. Glucocorticoid excess epitomized
by "Cushing's Syndrome" leads to insulin resistance/type 2 diabetes, dyslipidemia,
central obesity and hypertension (Bujalska et al. 1997). Indeed, excessive Cortisol
secretion in Cushing's syndrome is one of the classical causes of obesity. In the
absence of adrenal pathology, the same cluster of clinical and biochemical features
are frequently observed together and have been termed the "Metabolic Syndrome or
Reaven's syndrome X" (Reaven 1988) and much research has focused upon
understanding how and if glucocorticoid actions are altered in this condition.
Conversely chronic glucocorticoid deficiency results in "Addison's Disease" first
described by Dr Addison in 1855, or adrenal insufficiency (Malerbi et al. 1988)
characterised by weight loss, muscle weakness, fatigue and hypotension.
1.8.3 Transgenic models ofglucocorticoid metabolism
The importance of metabolic enzymes in determining tissue responses to
glucocorticoids can be illustrated by studying transgenic animals. Targeted
disruption of lip-HSDl within the mouse prevents corticosterone regeneration
(Kotelevtsev et al. 1997; Morton et al. 2001). Upon starvation, 11(3-HSD1 null mice
show attenuated activation of the key hepatic gluconeogenic enzymes glucose-6-
phosphatase and phosphoenolpyruvate carboxykinase PEPCK, due to intra-hepatic
glucocorticoid deficiency. Moreover, these animals resist hyperglycemia induced by
stress or obesity indicating that hepatic 11(3-HSD1 plays a key role in the regulation
of gluconeogenesis (Morton et al. 2001). Conversely, mice over-expressing 11(3-
HSD1 within the liver only, by means of the apoliprotein E promoter have an
attenuated metabolic-syndrome-like phenotype with modest insulin resistance,
hypertriglyceridaemia, fatty liver and hypertension, but normal weight, fat depot
mass and glucose tolerance (Paterson et al. 2004). In contrast, transgenic mice
showing 2- to 3-fold higher levels of lip-HSDl specifically within the adipose
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tissue have increased levels of corticosterone within the adipose tissue but unaltered
plasma corticosterone (Masuzaki et al. 2003). These mice are obese, with fat
accumulating predominantly with the visceral depots, hyperphagic and develop all
the main features of the metabolic syndrome: glucose intolerance and insulin
resistance which can be exacerbated by high-fat feeding, dyslipidemia with elevated
levels of free fatty acids and triglycerides, apparent leptin resistance and
hypertension with associated activation of the renin/angiotensin/aldosterone system.
It has been proposed that tissue specific changes in glucocorticoid metabolism may
also contribute to the obese phenotype. The obese Zucker rat (fa/fa), displays many
characteristics of obese humans and has proved to be highly informative when
investigating the potential mechanisms that are dysregulated in obesity (Livingstone
et al. 2000). The obese Zucker rat expresses high levels of lip-HSDl within the
omental adipose tissue and has elevated expression and activity of the A-ring
reductases within the liver (Livingstone et al. 2005). The mechanisms of
dysregulation of glucocorticoid metabolism are poorly understood; however recent
evidence demonstrated a role for insulin with the administration of insulin-sensitising
drugs normalising 5a-reductase 1 activity in the obese Zucker rat (Livingstone et al.
2005).
1.8.4 Obesity
Increasing evidence supports a role for glucocorticoids in the aetiology of
idiopathic obesity and the pathophysiological consequences associated with this
condition e.g. cardiovascular and respiratory disease, arthritis, depression and
features of the "Metabolic Syndrome" - (hypertriglycridaemia, hyperglycaemia and
hypertension). Although obese individuals and the genetically obese Zucker rat show
increased Cortisol or corticosterone production rate, loss of diurnal variation of
plasma Cortisol levels, and increased responsiveness to Cortisol (Andrew et al. 1998;
Livingstone et al. 2000), circulating plasma levels are within the normal range. This
apparent paradox has been attributed to an increased rate of metabolic clearance,
mediated primarily via action of the A-ring reductases (5a- and 5(l-reductase)
(Walker et al. 2000; Livingstone et al. 2000; Andrew et al. 1998) and may result in
compensatory activation of the HPA axis (Hautanen & Adlercreutz 1993). This may
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therefore account for the normal or even lower circulating levels noted in obesity,
despite an increase in daily Cortisol production. Increases in the expression and/or
activity of these enzymes within the liver have been reported in rodent models of
obesity (Stewart et al. 1999; Livingstone et al. 2000).
In addition to changes in hepatic A-ring reductase activity, recent studies
have shown tissue-specific alterations in the expression and activity of 11(3-HSD1 in
obesity (Masuzaki et al. 2001b; Rask et al. 2001). This enzyme is down regulated in
the liver of obese individuals and conversely up regulated in visceral adipose tissue
(Wake et al. 2003). Reduced reactivation of glucocorticoids within the liver will
contribute to HPA axis activation whereas increased exposure to glucocorticoids
encourages fat accumulation within the visceral adipose tissue where it may be
responsible for "Cushing's disease of the omentum"(Bujalska et al. 1997).
It is interesting to note that both 5(3-reductase and llp-HSDl are also
involved in pathways of cholesterol metabolism. Oxysterols, the oxygenated
derivatives of cholesterol produced in the liver, play a pivotal role in maintaining
cholesterol homeostasis via suppression of target genes involved in cholesterol
synthesis including HMG-Co A reductase (Ulven et al. 2005). Oysterols act as
ligands for the Liver X receptor (LXR)-a and -(3 which play a role in the regulation
of lipid metabolism. Activation of LXR has been shown to down regulate 11(3-HSD1
mRNA in adipocytes and liver (Stulnig et al. 2002) and glucose-6-phosphatase
(Grempler et al. 2005) suggesting a novel role of these receptors in endocrine
function with the potential to exert positive effects on insulin sensitivity in conditions
such as diabetes type 2 and the metabolic syndrome. Moreover, certain oxysterols are
ligands for 11|3-HSD1 and 5(3-reductase and 3a-HSD are involved in the cholesterol
catabolism and bile acid biosynthesis. Bile acids act as potent transcriptional
regulators of enzymes involved in cholesterol metabolism and bile acid
detoxification and elimination via activation of the FXR (Chiang 2002). The
increasing depth of knowledge regarding modulators of cholesterol and bile acid
metabolism may therefore provide vital clues as to the mechanisms involved in the
regulation of 5(3-reductase and lip-HSDl.
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1.9 Cholesterol homeostasis and bile acids
The catabolism of cholesterol to hydrophilic bile acids represents the
predominant pathway through which cholesterol is eliminated from the body
(Danielsson & Sjovall 1975). In the rat 80-90% of cholesterol is catabolized to bile
acids whilst in man approximately 50% cholesterol is removed as bile acids and is
excreted in faeces (Nathanson & Boyer 1991a). Bile acids stimulate bile flow and
facilitating the direct excretion of hepatic cholesterol into bile thereby decreasing
whole body cholesterol levels and play a fundamental role in cholesterol homeostasis
(Russell 2003a). Newly synthesised bile acids are secreted into the bile and delivered
to the lumen of the small intestine where, along with bile acids secreted from the gall
bladder, they act as detergent emulsifiers forming mixed micelles of dietary lipids,
cholesterol and fat soluble vitamins (Danielsson & Sjovall 1975). This process
promotes the absorption of lipids and cholesterol from the body. Solubilization of
dietary cholesterol and efficient recycling of bile acids leads to increased levels of
whole body cholesterol and suppression of de novo biosynthesis.
1.9.1 Enterohepatic circulation
Within the intestine soluble nutrients are taken up by the enterocytes that line
the proximal segment of the gut while the remaining bile acids continue to move
distally. At the terminal end of the small intestine, bile acids that are transported
across the brush border membrane into the enterocyte are taken up by the the
sodium-dependent bile acid transporter (ASBT; SLC10A2) a membrane protein.
Once within the cell, bile acids bind to and activate the ileum bile acid binding
protein (I-BABP) which facilitates the efflux of bile acids to the portal circulation by
truncated ABST (tABST) protecting the cell from the detergent actions of
intracellular bile acids (Figure 1.9). Bile acids are then carried to the liver within the
portal circulation and transported across the apical surface of the hepatocyte by
sodium-dependent taurocholate cotransport peptide (NTCP). Once within the
hepatocyte bile acids can then re-secreied into bile across the canalicular membrane
via the bile salt export pump (BSEP) into the bile duct. During each cycle of the
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enterohepatic circulation approximately 95% bile acids are recovered, with those lost
in faeces being replaced by new synthesis within the liver (Figure 1.9)(Russell &
Setchell 1992).
Figure 1.9 Enterohepatic circulation of bile acids. Bile acids are extracted from the portal circulation
into the hepatocyte via NTCP and are excreted via BSEP. Within the distal region of the gut they are
transported across the enterocytes lining the gut via ASBT and I-BABP and are excreted via t-ABST.
These bile acids are then returned to the liver via the portal circulation.
1.10 Pathways of bile acid synthesis
The primary bile acids cholic (CA) acid and chenic (chenodeoxycholic;
CDCA) acid in humans and rats are synthesized from cholesterol within the liver by
the actions of 17 known enzymes. Two major pathways of bile acid biosynthesis
have been described in the mammalian liver, the "Classical" or neutral pathway and
the "Alternative" or acidic pathway.
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1.10.1 Classical (neutral) pathway
The classical pathway is the main pathway involved in bile acid biosynthesis
in man and is initiated by 7a-hydroxylation of cholesterol. This step represents the
first and rate-limiting step in the conversion of cholesterol to bile acids in the liver in
a reaction catalyzed by the enzyme cholesterol 7a-hydroxylase (CYP7A1), a
cytochrome P-450 containing monooxygenase located in the ER membrane (Myant
1977 (Nathanson & Boyer 1991b). This enzyme is subject to complex regulatory
mechanisms (Chiang 1998; Danielsson & Sjovall 1975). The subsequent steps
involved in the formation of CA and CDCA from cholesterol can be divided into two
main categories; those that modify the sterol ring structure or nucleus, e.g. formation
of a 5(3 (A/B, cis) saturated ring system by saturation of the A5double bond, and those
that those that oxidize and shorten the side chain of sterol e.g. oxidative cleavage of
the side chain between C-24 and C-25 (Chiang 1998) (Figure 1.10). In the Classical
pathway, modifications of the steroid nucleus, including hydroxylation at 7a- and
12a- positions, epimerization of the 3(3-hydroxyl group and saturation of the steroid
nucleus precede the oxidative cleavage of the terminal three carbons of the side
chain.
Similarly to the metabolism of pregnene steroids, 5|3-reductase and 3a-HSD
act upon the A-ring of 7a-hydroxy-4-cholesten-3-one and 7a,12a-dihydroxy-4-
cholesten-3-one, the product of a second microsomal cytochrome P-450 enzyme
12a-hydroxylase, to yield a sterol intermediate that is ultimately converted to CDCA
and CA respectively (Figure 1.10) (Chiang 2002). The reactions catalysed by 5(3-
reductase and 3a-HSD are chemically identical to those in glucocorticoid
































Cholic acid Chenodeoxycholic acid
Figure 1.10 Pathways of bile acid biosynthesis. Cholesterol is metabolised via the Classical and
Alternative pathway by the action of 17 different enzymes. The resulting primary bile acids









5P, cholestane-3a,7a,12a-triol 5p, cholestane-3a,7a,-diol
Figure 1.11 A-ring reduction of bile acid intermediates. 5p-Reductase catalyses reduction of the
steroid 4-5 double bond and 3a-HSD reduces the oxygen double bond at position 3.
1.10.2 Alternative (acidic) pathway
The alternative pathway is initiated by sterol 27-hydroxylase (CYP27A1),
which is expressed in many tissues and converts cholesterol to both 27-
hydroxycholesterol and 3P-hydroxy-5-cholestenoic acid (Pikuleva et al. 1998)
producing predominantly CDCA (Chiang 2002). Oxysterol 7a-hydroxylase
(CYP7B1) subsequently converts these intermediates to 7a,27-dihydroxycholesterol
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and 3p,7a-dihydroxy-5-cholestenoic acid, respectively. In the alternative pathway,
oxidative cleavage of the 3-carbon side chain precedes modification of the steroid
nucleus which is performed by the same enzymes as those within the Classical
pathway of bile acid biosynthesis (Andersson et al. 1989b). 5p-Reductase and 3a-
HSD are not directly involved in the alternative pathway of bile acid biosynthesis.
1.10.3 Conjugation
The final step in bile acid synthesis involves the addition of an amino acid,
usually glycine or taurine, via an amide linkage to carbon-24 in a reaction catalysed
by the peroxisomal enzyme N-acyltransferase (Figure 1.12). Approximately 98% of
bile acids excreted from the liver are amidated, which increases their amphipathicity
and enhances their solubility, making the cell membrane impermeable the bile acids.
The main substrates for N-acetyltransferase are bile acid coenzyme A and either









Glycochenodeoxycholic acid Taurochenodeoxycholic acid
Figure 1.12 Conjugation of chenodeoxycholic acid. N- acetyltransferase catalyses the addition
of either taurine or glycine at the C24 carboxylate position of the chenodeoxycholic acid
structure via an amide linkage.
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1.11 Regulation of bile acid biosynthesis
Cholesterol levels and bile acid synthesis are tightly regulated by a number of
factors including diet, bile acids and hormones. Indeed the mechanisms responsible
for regulating bile acid synthesis, elimination and detoxification have been an area of
much research in the past decade and it is now widely recognised that bile acid
"negative feedback" plays an integral role in regulating bile acid synthesis (Shefer et
al. 1969). Bile acid synthesis is stimulated in response to increases in newly
synthesized cholesterol (Myant & Mitropoulos 1977) and following biliary drainage
of bile acids by bile fistula (Danielsson & Sjovall 1975). The accumulation of bile
acids induces feedback inhibition of CYP7A1 and sterol 12a-hydroxylase (CYP8B1)
imposed by enterohepatic re-circulation of bile acids, thus repressing bile acid
synthesis.
1.11.1 Competitive inhibition ofsynthetic enzymes
A principle mechanism whereby bile acids regulate their own synthesis is via
inhibiting the activity of enzymes involved in their own biosynthesis. Indeed bile
acids act as competitive inhibitors of enzymes involved in cholesterol catabolism
including CYP7A1 and 27-hydroxylase (CYP27A1), the rate determining enzymes
in the Classical and Alternative pathways of bile acid biosynthesis respectively. It
has not been reported whether bile acids feedback and regulate other enzymes in the
biosynthetic pathway such as 5(l-reductase and 3a-HSD however bile acids have
been shown to act as competitive inhibitors of the 5(3-reduction of aldosterone (Latif
et al. 1994) and human type 4 3cx-HSD (AKR1C1) acts as a bile acid binding
protein.
1.11.2 Bile acids as transcriptional regulators
Bile acids also act as signalling molecules that can activate nuclear receptors
thereby regulating the transcription of enzymes involved in cholesterol and bile acid
metabolism (Parks et al. 1999). The identification of two bile acid response elements
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(BAREs), AGGTCA-like repeating within the promoter sequence of CYP7A1
(Chiang & Stroup 1994) which bind a number of nuclear receptors including the
retinoic acid receptor a (RXRa) and hepatocyte nuclear receptor 4a (HNFa) led to
the hypothesis that, bile acids may exert these effects via nuclear receptors which
regulate basal transcription as well as bile acid negative feedback (Stroup et al.
1997b) reducing intracellular bile acid concentrations within the hepatocyte. Since
then several members of the nuclear receptor (NR)1 family of nuclear receptors,
including the oxysterol receptors (LXRa and (3), the bile acid receptor (FXR;
NR1H4) and PXR have been shown to be activated by micromolar concentrations of
bile acids, lipids or sterols (Chiang 2002). Figure 1.13 demonstrates the central roles
for LXR and FXR in the co-ordinated regulation of bile acid synthesis, transport and
absorption within the liver and intestine and cholesterol metabolism within the liver
and peripheral tissues. The regulation of CYP7A1, the rate determining step in the
Classical pathway of bile acid biosynthesis has been studied extensively and the
mechanism involved in its regulation are now well characterised. When cholesterol
levels within the hepatocytes rise, oxysterols activate LXRa (NR1H3) which
stimulates transcription of CYP7A1 and cholesterol metabolism. Rising bile acid
levels induce FXR (Forman et al. 1995) which in turn activates short heterodimer
partner (SHP; NROB2). SHP acts as a negative regulator, which binds to and inhibits
liver receptor homologue-1 (LRH-1; NR5A2), which normally activates genes
involved in cholesterol catabolism including CYP7A1 (and also CYP8B1). As such
bile acid synthesis is reduced. In addition, and through similar receptors bile acid




Figure 1.13 The role of FXR and LXR in cholesterol and bile acid biosynthesis. Within the liver
cholesterol is converstcd to bile acids (BA) and also oxidised to oxysterols by sterol hydroxylases.
Oxysterols activate LXR which induces CYP7A1. Bile acids also activate FXR which suppresses bile
acid uptake via NTCP and induces excretion via BSEP into bile. FXR also inhibits CYP7A1 via SHP-
1 and LRH-1. Bile acids are secreted from the gall bladder and reabsorbed in the intestine via ABST.
FXR induces 1BABP which binds and facilitates the the efflux of bile acids by truncated ABST (t-
ABST) into the portal circulation to hepatocytes where they are taken up by NTCP. High levels of
cholesterol (Ch) within die enterocyte induce the formation of oxysterols which activate LXR
promoting efflux into the intestinal lumen via ABCA1. Within the intestine LXR induces ABCG5/G8
transporters and perhaps MDR2 which is responsible for the excretion of phosphatidylcholine into
bile.
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Additional SHP-independent pathways exist. For example, repression of
CYP7A1 and the Na+-independent organic anion transporter 2 (Oatp2) has been
demonstrated via activation of PXR, an orphan nuclear receptor usually associated
with the detoxification of xenobiotics and catatoxic steroids (Staudinger JL et al.
2001). Furthermore, bile acids have been demonstrated to activate the stress
signalling kinase pathway JNK/c-Jun (c-Jun N-terminal kinase). Indeed taurocholate
and the potent JNK activator tumour necrotic factor a (TNFa) have been
demonstrated to repress CYP7A1 mRNA expression in cultured primary hepatocytes
in a process independent of SHP mediated CYP7A1 repression (Gupta et al. 2001).
1.12 Bile acids and glucocorticoids
It is apparent from the literature presented in the introduction to this thesis
that maintaining glucocorticoid and cholesterol homeostasis is an essential
requirement for health. That 5(3-reductase, 3aHSD and 11|3-HSD1 are involved in
both cholesterol and glucocorticoid metabolism poses the intriguing prospect that
factors common to both pathways may be involved in regulation of these enzymes.
Obese individuals and the obese Zucker rat display an altered lipid profile with
elevated levels of circulating cholesterol, LDL-cholesterol and triglycerides, in
conjunction with altered metabolism and alterations in HPA axis activation
(Livingstone et al. 2000; Rask et al. 2001). Furthermore, liver fat accumulation has
been demonstrated to correlate with an increase in 5(3-reduced urinary Cortisol
metabolites, and was independently associated with insulin resistance and
hypertriglyceridemia (Westerbacka et al. 2003). Cholesterol metabolites (bile acids
and oxysterols) are potent signalling molecules, of paramount importance in
maintaing hepatic homeostasis and thus may play a role in regulating the activity if
hepatic enzymes involved in glucocorticoid metabolism. This raises the possibility
that cholesterol and/or bile acids may play a role in regulation of these enzymes
common to glucocorticoid metabolism. As such we propose that alterations in bile
acid levels may influence glucocorticoid action and metabolism. This in turn may
affect activation of the HPA axis. Manipulation of the bile acid pathway may
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therefore provide a target for normalising the altered metabolic clearance rate and
lipid profile of obese individuals
1.13 Hypothesis and aims
The experiments performed in this thesis were based upon the hypothesis that
bile acids may influence glucocorticoid metabolism catalysed by 5|3-reductase. This
in turn may impact upon activation and/or response of the hypothalamic-pituitary-
adrenal (HPA) axis.
The primary aim of this thesis was to investigate the impact of bile acids on
glucocorticoid metabolism by addressing the following aims:
1) To investigate the impact of bile acids on the activity of glucocorticoid
metabolising enzymes in vitro in tissue homogenates or cultured cells.
2) To establish the nature of inhibition by bile acids and the level at which
this occurs e.g. pre- or post-transcriptional.
3) To investigate the impact of alterations in hepatic bile acid concentrations
on glucocorticoid metabolising enzymes in vivo via the administration of
a diet supplemented with bile acids (CDCA; 1% w/w) or cholestyramine
(CT; 5% w/w) or reducing hepatic bile acid concentrations via the
administration of a fat-free diet.
4) To assess the impact of bile acids on HPA axis activation and
glucocorticoid target genes following dietary manipulation.
5) To investigate the impact of bile acids on the renin-aldosterone-






All chemicals and reagents were purchased from Sigma, Poole, UK unless
otherwise stated. HPLC grade solvents were from Rathburn Chemicals, Walkerburn,
UK. All epi-isomers of steroid standards were from Steraloids, Newport, USA.
Radioactive isotopically labelled products were from Amersham, Bucks, UK.
Sources other than these are indicated in parenthesis. Solutions were stored at ~21°C
(room temperature; RT) unless otherwise stated.
2.2 Commonly used buffers and solutions
Acetate buffer:
Sodium acetate was dissolved in distilled water to achieve a final concentration of
0.2M and the pH was adjusted to 4.6. The solution was stored at 4°C
Alkaline SDS:
Sodium dodecyl sulphate (SDS) and sodium hydroxide was dissolved in distilled
water achieve a final concentration of 0.1% (w/v) and 0.2M respectively. The
solution was prepared immediately prior to use.
Borate buffer:
Boric acid (8.25g), sodium hydroxide (2.7g), hydrochloric acid (3.5ml) and BSA
(Fraction VI; 5g) were dissolved in 1 litre of distilled water and the pH adjusted 7.4.
The solution stored at -20°C and thawed at room temperature before use.
Cesium Chloride/TE solution:
Cesium chloride (lOOg) was dissolved in TE buffer (100ml) (see below).
Charcoal Buffer:
Tris (6.07g), neomycin sulphate (2g), EDTA (1.85g), hydrocholic acid (5M; 5ml)
were dissolved in 0.5 litres distilled water. The pH was adjusted to 7.4. BSA
(Fraction VI; 5g) was sprinkled on to the surface and allowed to dissolve and the
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volume adjusted to 1 litre with distilled water. The solution was stored in volumes of
100ml at -20°C. Prior to use, Dextran T70 (0.062g) was dissolved in 5ml buffer and
added to Norit charcoal (0.6g) and buffer (95ml). The solution was stored at 4°C.
Denaturing solution:
Guanidium thiocyanate, sodium citrate and sarcosyl were dissolved in distilled water
to achieve concentrations of 4M, 0.025M and 0.5% (w/v) respectively. (3-
Mercaptoethanol added immediately prior to use to achieve a concentration of 0.1M.
DEPC-treated water:
Diethylpyrocarbonate (DEPC; 5 drops) was dissolved in distilled water (500ml) and
inverted to mix. The solution was allowed to stand (RT, lhr) prior to autoclaving.
Deionised formamide:
Amberlite ion exchange resin (15g ; BDH, Lutterworth, UK) was mixed with
formamide (150ml) for 1 hour. The solution was filtered twice through Whattman
filter paper (grade #4) to remove the resin.
Hanks Kreb's Ringer Bicarbonate Buffer.
Sodium chloride, potassium chloride, potassium phosphate, calcium chloride,
magnesium sulphate and sodium bicarbonate were dissolved in distilled water to
achieve concentrations of 118mM, 3.8mM, 1.19mM, 2.54mM, 1.19mM magnesium
and 25mM respectively. The pH was adjusted to 7.4 and the buffer stored at 4°C.
Glucose (0.2% w/v) was added to the buffer immediately prior to use.
Loading buffer:
Bromophenol blue (0.25% w/v), xylene cyanol (0.25% w/v), Ficoll (25 % w/v) were
diluted in DEPC-treated water.
1Ox MOPS buffer:
3-[N-morpholino]propanesulfonic acid, sodium acetate and EDTA were dissolved
in distilled water to achieve concentrations of 0.2M, 50mM and 5mM respectively.
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The pH was adjusted to 7 and the solution was autoclaved before use and stored at
RT wrapped in foil to avoid exposure to light.
Potassium Acetate:
Potassium acetate (5M; 60 ml), glacial acetic acid (11.5ml) were mixed and the
volume adjusted to 100ml with distilled water.
PrimaryAntibody Buffer:
Normal rabbit serum (1% w/v), Triton X-100 (0.1% v/v), aprotinin (200 KlU/ml;
Traysol) were dissolved in stock buffer and prepared immediately prior to use.
Sodium Acetate Buffer:
Sodium acetate (12.30g) was dissolved in distilled water (500ml) to give a final
concentration of 30mM and the pH adjusted to 4.8. The solution was autoclaved
before use and stored at 4°C.
Sodium Phosphate Buffer:
Sodium dihydrogen orthophosphate dehydrate dissolved in distilled water (500ml) to
achieve a final concentration of 40mM and the pH adjusted to 7.4.
Secondary Antibody Buffer:
As for tracer buffer
20x SSC Buffer:
Sodium chloride (175.32g) and sodium citrate (88.23g) were dissolved in 1 litre
distilled water to give a final concentration of 30mM. The solution was autoclaved
before use and stored at RT.
Stock Buffer:
Sodium phosphate, EDTA and sodium azide were dissolved in distilled water to
achieve final concentrations of 63mM, 13mM and 0.02% (w/v) respectively and the
pH was adjusted to 7.4. The solution was autoclaved before use and stored at RT.
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Standard Buffer:
BSA (Fraction VI; 3.5% w/v) and aprotinin (200 KlU/ml, Traysol) were dissolved in
Stock buffer. The solution was autoclaved before use and stored at 4°C.
IOxTBE Buffer:
Tris (0.9M; 56g), boric acid (1.9M; 57.5g), EDTA (0.5M; 20ml) were dissolved in
distilled water (500ml). The solution was autoclaved before use and stored at RT.
TE Buffer:
Tris-HCl and EDTA were dissolved in distilled water to achieve final concentrations
of lOmM and ImM respectively and the pH adjusted to 8. The solution was
autoclaved before use and stored at RT.
Tracer Buffer:
Triton X-100 (0.1% w/v) and aprotinin (200 KlU/ml, Traysol) were dissolved in
Stock buffer. The solution was prepared immediately prior to use.
Tris Buffer (50mM, pH7.4):
Tris (12.14g), hydrochloric acid (5M; 10ml), neomycin sulphate (3.5g) and human
serum albumin (1.75g) were dissolved in 2 litres of distilled water and the pH
adjusted to 7. The solution was stored as 10ml aliquots at -20°C.
Wash Buffer One:
SSC buffer (lx) and SDS (0.1% v/v) were dissolved in DEPC-treated water and
prepared immediately prior to use.
Wash Buffer Two:
SSC buffer (0.3x) and SDS (0.1%v/v) were dissolved in DEPC-treated water and
prepared immediately prior to use.
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2.3 Animal care and maintenance
2.3.1 Animalmaintenance
Male Wistar rats were obtained from Harlan Orlac, Bicester, UK at
approximately three to four weeks of age or weighing 75-100g. Animals were
maintained under controlled conditions of light (lights on, 0800-2000h) and
temperature (21°C) and allowed free access to standard rat chow (Special Diet
Services, Witham, UK) and drinking water. Prior to any experimental procedures rats
were under the care of animal technicians at the Biomedical Research Facilities at the
Western General Hospital (Chapter 4) or the Chancellors Building (Chapter 5).
During experimental periods, animals were housed individually. Body weight, food
and fluid intake were monitored on a daily basis. At all times animals were
monitored closely for any signs of distress or ill health. All procedures were carried
out according to Home Office guidelines under project license PPL 60/3293 and
personal licence PIL 60/9607.
2.3.2 Animal sacrifice and tissue collection
Animals were killed by surgical decapitation in an adjacent room to the one
in which they were housed within approximately 1 min of their cage being disturbed
to minimize stress to the animals. Trunk blood was collected in EDTA-tubes and
plasma prepared by centrifuged (lOOOOg, lOmins, 4°C) which was then snap frozen
on dry ice in Eppendorf tubes, and stored at -80°C. Tissues (liver, kidneys, adrenal
glands, thymus, sub-cutaneous fat, omental fat and peritoneal fat) were dissected
carefully within 5mins of sacrifice. Liver, adrenal glands and thymus weights were
recorded. Subsequently, several small sections (~100mg) were cut from the upper
right hand lobe of the liver and transferred to Eppendorfs for later use. Adrenal
glands were carefully cleaned of any residual adipose tissue and transferred to pre-





Plasma (lOf^l) was diluted 1 in 5 in borate buffer and denatured (65°C;
30mins). This allowed corticosterone (B) to dissociate from proteins present within
the plasma such as corticosterone binding globulin. A series of solutions representing
a range of concentrations of B were prepared (0, 0.6125, 1.25, 2.5, 5, 10, 20, 40, 80,
160, 320 nM) from which a standard curve was derived. Samples or standards (20pi
each) were pipetted in duplicate into a 96-well plate with 50pi of a mixture of [3H]4_
1,2,6,7 -B (specific activity 80Ci/mmol;final concentration 1.5nM) and B rabbit anti-
rat antibody (1 in 10,000 dilution to achieve ~30% binding; a kind gift from Dr CJ
Kenyon) in borate buffer in a total volume of 70pl. Corticosterone present in the
plasma and radio-labeled [3H]4 B were allowed to compete for binding with the anti¬
body (RT, 2hr). Following incubation, scintillation proximity assay beads (50pl,
anti-rabbit-SPA; Amersham, Bucks, UK) were added to each sample and the plate
was sealed, inverted to ensure even mixing, covered in foil to avoid exposure to light
and incubated (RT,16hr). During this incubation period a binding equilibrium was
achieved between antibody/B complex or antibody/ [3H]4-B complex and the SPA
beads. The light induced by |3 emissions emitted by the SPA beads when they are
within close proximity of primary antibody/B complex was measured for 1 min using
a Wallac Microbeta Plus counter. The concentration of corticosterone in each
sample was calculated from the standard curve constructed following 4-point
sigmoidal curve fit analysis where the average response of the duplicates for each
standard (Y-axis) was plotted against the concentration of each standard following
log transformation (X-axis). The inter- and intra-assay coefficients of variation were
9.2% and 9.4% respectively.
2.4.2 ACTH radioimmunoassay
Adrenocorticotrophic hormone (ACTH) was measured in plasma from
animals at baseline and following acute restraint stress. Plasma (25pi) was diluted in
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1:4 in Stock Buffer prior to assay. Solutions of ACTH were prepared (0, 3.90,
7.8125,15.625, 31.25, 62.5,125, 250, 500,1000, 2000 pg/ml) by serial dilution from
stock human ACTH (Peninsula Laboratories, UK) in Standard Buffer. In each assay
a blank (0 ACTH standard) and Non Specific Binding (NSB) (ACTH; lOOng/ml and
no antibody) control were included. The blank was used to demonstrate that
components within the Standard Buffer did not displace labeled ACTH, whilst the
NSB contained standard buffer and ACTH but not primary antibody demonstrated
specificity binding of ACTH with the antibody. Primary antibody (rabbit anti-
rat)(IgG Corporation USA, IgG-ACTH-1; diluted in Primary Antibody Buffer
1:1000,000 to give approximately 40% binding) was prepared in Stock Buffer (1ml)
containing Normal Rabbit Serum (1% w/v), and Aprotinin (200 KIU; diluted in
Stock buffer, Traysol, IgG Corporation USA IgG-Aprotinin 100,000 KIU). Diluted
samples or standards (100pi in duplicate) were pipetted into 2.5ml polypropylene
round bottom tubes (Roche) and incubated with primary ACTH antibody (100pi; RT,
16hr). Following incubation I125ACTH (100pl, 1:1000 in 0.1M acetic acid) was
added to each sample and incubated (RT, 7 hrs). A secondary anti-rabbit antibody
(ICN Pharmaceuticals, Diagnostic Division: Goat anti-rabbit IgG Precipitation
antiserum) was diluted 1:80 in Secondary Antibody Buffer and added (600pl) to each
sample and incubated (4°C, 16hr) to achieve an equilibrium between primary and the
secondary antibody. Pre-chilled (4°C) Wash buffer (1ml) was added and the anti¬
body complex precipitated by centrifugation (3000g, 4°C, 30 mins). The resultant
supernatant was decanted and the tubes inverted, dabbed gently on tissue to remove
any remaining supernatant and allowed to drain upside down in a wire rack leaving
an off-white precipitate at the bottom of the test-tube. Activity was counted using a
gamma counter (Wallac 1470 Wizard automatic gamma counter; 1 min). The
concentration of ACTH in each sample was calculated from a standard curve
generated by log/logit curve fit with average emission for the duplicates of each
standard on the Y axis (linear) and the corresponding standard ACTH concentration
on the X axis (logarithmic). The inter- and intra-assay coefficients of variation were
7.9 and 5.4% respectively.
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2.4.3 Renin radioimmunoassay
Plasma renin activity was measured as the generation of angiotensin I from
endogenous angiotensinogen present within plasma. Solutions representing a range
of concentrations of angiotensin I were prepared (0, 0.8, 1.6, 3.2, 6.4, 12.5, 25, 50,
100, 200, 400 ng/ml) by serial dilution in Tris buffer (50mM, pH 7.4) from stock
(lOOOng/ml) to allow the construction of a standard curve. Samples and standards
(lOpil each) were incubated in quadruplicate with rabbit anti-rat Angiotensin I
primary antibody at 4°C. Following centrifugation (2000g, 4°C, lmin) two of the
four tubes were allowed to remain at 4°C and samples in the other two tubes were
incubated (37°C, 30 mins) on a shaking platform. Iodinated Angiotensin I (I125 -
Angiotensin I; Amersham, UK) was prepared in Tris buffer (50mM, pH 7.4) and
150pl (containing approximately 4-5000cpm I125 Angiotensin I) added to each
sample. Following, centrifugation (2000g, 4°C, lmin) samples were incubated (4°C,
18hrs). Angiotensin I generated by endogenous renin present within the plasma was
separated from solution by the addition of a charcoal suspension (250pi) to which
free peptides present within the solution will bind. Following centrifugation (3000g,
4°C, 15mins) the resultant supernatant was aspirated from the samples leaving a
charcoal pellet at the base of the RIA cup. Radioactivity in the pellet was counted
using a gamma counter (Wallac 1470 Wizard automatic gamma counter; 1 min).
Renin activity was calculated as ng/ml/hr following curve fit analysis with average
emission for the duplicates of each standard on the Y axis (linear) and the
corresponding standard angiotensin 1 concentration on the X axis (logarithmic). The
limit of detection was 1.5ng/ml/hr. The inter- and intra-assay coefficients of variation
were 6.5 % and 5.4% respectively.
2.4.4 Aldosterone ELISA
Quantification of plasma aldosterone was quantified using a commercially
available kit (Coat-a-Count®, DPC, Gwynedd, UK). This assay is a solid-phase
radioimmunoassay based an aldosterone-specific antibody which is immobilized to
the wall of a polypropylene tubes. A calibration curve was prepared using supplied
calibrators (0, 25, 50, 100, 200, 600, 1,200 pg/ml). In addition a blank (deionized
water), a non-specific binding (NSB, 0 calibrator alone) and total count (T, 125I-
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aldosterone alone) controls were analysed. Plasma and standards (200pi each) were
pipetted in duplicate into tubes coated with antibody. Iodinated aldosterone (1ml)
was added to each sample and the samples subjected to centrifugation (lOOOg, RT,
lmin) The samples were incubated (RT, 18hrs) then the supernatant decanted (apart
from T) and any visible signs of moisture removed by striking the tubes against
absorbent tissue and allowing them to drain for 2-3 mins. Activity was counted in a
gamma counter (Wallac 1470 Wizard automatic gamma counter; 1 min) and
concentration determined from a logit-log representation of the standard curve. The
concentration of aldosterone in samples was calculated by interpolation from a
standard curve of percent bound against concentration following non-linear curve fit
analysis. This assay is sensitive to llpg/ml. The inter- and intra-assay coefficients of
variation were 6.5 % and 5.4% respectively.
2.4.5 Insulin ELISA
Insulin concentrations in plasma were measured using a commercially
available kit (Crystal Chem, IL, USA). This assay works on a dual reaction principle.
During the first reaction insulin binds to a mouse anti-insulin monoclonal antibody
coated on a microplate well. A mouse anti-insulin antibody is subsequently added to
each well thus a mouse anti-insulin monoclonal antibody/insulin/anti-insulin
antibody complex is immobilized on the microplate well. A horse radish peroxidase
(POD)-conjugated anti-mouse antibody in turn binds to the anti-insulin antibody
complex immobilized in the microplate well. The bound POD conjugate is detected
following its reaction with o-phenylenediamine substrate solution and absorbance of
product measured at a wavelength of 492nm. Solutions representing a range of
concentrations of insulin (0, 156, 313, 625, 1250, 2500, 5000, 10000 pg/ml) were
prepared from rat insulin stock solution (10000 pg/ml) by serial dilution in Diluent 2
(supplied with kit) to allow construction of a standard curve. Samples and standards
(lOpl each) were incubated in duplicate in plastic tubes with a mixture of iodinated
insulin (125I-insulin; l,000cpm per sample) and insulin primary antibody in buffer
(total volume 75pi) (RT, 4hr). Two tubes with 125I-insulin (total count; T) and two
with 125I-insulin and buffer but no antibody (non-specific binding; NSB) were
included in the assay as controls. Amerlex™-M magnetic separation beads (60pl)
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were then added to each sample and incubated (RT, 10 mins). The beads were
harvested by centrifugation (lOOOg, 4°C, 10 min), the supernatant discarded and the
radioactivity associated with the pellet counted in a gamma counter (Wallac 1470
Wizard automatic gamma counter; 1 min).The concentrations of insulin in samples
were determined from a standard curve generated by logit/log curve fit with mean
absorbance value for each standard on the Y axis (linear) and the corresponding
standard insulin concentration on the X axis (logarithmic). The inter- and intra-assay
coefficients of variation were 6.3% and 3.5% respectively.
2. 5 Quantitative analysis of bile acids
2.5.1 Serum bile acids
Bile acid concentrations were measured in serum, faeces and cytosol
enzymatically using a commercially available kit (Sigma-Aldrich Ltd, Poole, UK).
This assay utilizes the oxidative properties of 3a-HSD. During the oxidation of bile
acids to 3-oxo bile acids by 3a-HSD, an equimolar amount of nictotinamide adenine
dinucleotide (NAD+) is reduced to NADH (reaction 1). The NADH is subsequently
oxidised to NAD+ with concomitant reduction of nitro blue tetrazolium salt (NBT) to
formazan, a reaction catalysed by the enzyme diaphorase (reaction 2). Formazan has
an absorption maximum at 530nm, thus the intensity of colour produced is
proportional to the concentration of bile acids within the sample.
3a-HSD
(1) 3a-Hydroxybile Acids + NAD+ ► 3-Oxo Bile Acids + NADH
Diaphorase
(2) NADH + NBT ► NAD+ + Formazan
Figure 2.1 Enzymatic reactions involved in the determination of bile acids in bodily fluids
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Bile acid Test Reagents (A; 2.5mM NAD, 0.61mM NBT, 625U/1 Diaphorase) and
buffer (pH7) and (B; 1250U/1 3a-HSD) were reconstituted in deionized water
according to manufacturers' instructions and immediately mixed by inverting several
times. A Test reagent was prepared by combining Reagent A (4ml) with Reagent B
(lml), and a Blank reagent prepared by combining Reagent A (4ml) with deionized
water (lml) The reagents were then heated (37°C, 15 mins). Solutions representing a
range of concentrations of bile acids (0, 5, 25, 50, 100, 200pM) were prepared by
serial dilution using the supplied calibrator set. In each assay Calibrator (200pM bile
acid) and Control (deionized water) samples were quantified. Samples or controls
(5pi) were pipetted in quadruplicate into a 96 well plate and Test or Blank reagents
(125 pi) were added to the corresponding samples. The plate was shaken briefly to
mix and incubated (37°C, 5min). Absorbance was measured at 530nm using a
microplate reader (OPTImax tunable microplate reader) and the concentration of bile
acids calculated using Softmax Pro software by subtracting Blank absorbance from
the corresponding Test absorbance as follows:
Bile Acid concentration (pM)
= AST - ASB x Concentration of Calibrator
ACT - ACB
Where: AST = Absorbance of Sample with Test reagent
ASB = Absorbance of Sample with Blank reagent
ACT = Absorbance of Calibrator with Test reagent
ACB = Absorbance of Calibrator with Blank reagent
2.5.2 Hepatic bile acids
For measurements of hepatic bile acids, tissue (lOOpg wet weight) was
homogenised in double distilled water (lml, 37°C). Bile acids were extracted from
the homogenate (lOOpl) by incubation with ethanol (lml, 85°C, 1 min) according to
the method described by Miyata et al (2004). Following centrifugation (lOOOg, RT, 5
mins) supernatant (~ lml) was removed and transferred to glass culture tubes. This
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process was repeated twice. The resultant supernatant (3 x 1ml fractions) was
reduced to dryness under a stream of oxygen free nitrogen (OFN) at 60°C and the
residue reconstituted in deionized water (20pi). Bile acid concentration was then
measured as described in section 2.5.1 and expressed as pmoles/mg tissue.
2.5.3 Fecal bile acids
Fecal bile acids were measured according to methods described by Moundras
et al 1997. Faeces (lg from a 24hr collection) were incubated (60°C, 90mins) in
KOH (0.5M, 10 vol). Hexane (1ml) was added to the resultant suspension (100pi)
and the sample vortexed briefly and the organic and non-organic layers allowed to
separate. The upper organic layer containing neutral sterols was removed and
retained for analysis and the process repeated. The resultant fraction (2ml) was
reduced to dryness under OFN at 60°C and the residue reconstituted in deionized
water (20pl). Bile acid concentration was then measured as described in section 2.51
and expressed as pmoles/g faeces.
2.6 Spectrophotometric assays
2.6.1 Hepatic triglycerides
Hepatic triglycerides were measured in liver homogenates using Triglyceride
reagent (ThermoTrace®, UK) with an assay based upon the methods described
previously by McGowan et al (McGowan et al. 1983) and Fossati et al (Fossati &
Prencipe 1982). Triglycerides were hydrolyzed enzymatically by hepatic lipase to
yield free fatty acids and glycerol. The glycerol was then phosphorylated by
adenosine triphosphate (ATP) in the presence of glycerol kinase (GK) to produce
glycerol-3-phosphate and adenosine diphosphate (reaction 2). Glycerol-3-phosphate
was oxidized subsequently to dihydroxyacetone phosphate (DAP) by glycerol
phosphate oxidase (GPO) producing hydrogen peroxide (H2O2). The H2O2 reacted
with 4-aminoantipyrine (4 AAP) and 4-chlorophenol (4-CP) catalyzed by peroxidase,
resulting in the production of a red dye (Quinoneimine dye). The absorbance of a
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Quinoneimine dye at 500nm is proportional to the concentration of triglycerides
present in the sample.
lipase
(1) Triglycerides + H2O Glycerol + Free Fatty acids
GK
(2) Glycerol + ATP Glycerol-3-phosphate + ADP
GPO
(3) Glycerol-3-phosphate + O2 DAP + H202
Peroxidase
(4) H2O2+4-AAP + 4-CP Quinoneimine dye + 2H2O
This assay has a linear range of 0 - 10 mmol/1. To quantify hepatic triglycerides, liver
(lOOmg wet weight) was homogenized in isopropanol (10 vol i.e 1ml) in glass
culture tubes. The samples were shaken (RT, 45 mins) and the solid matter separated
from the supernatant by centrifugation (3000g, 4°C, lOmins). Triglycerides were
quantified in the resultant supernatant. A series of solutions of triglycerides (0,
0.3125, 0.625, 1.25, 2.5mmol/l) was prepared in deionized water by serial dilution
from which a standard curve was generated. Samples and calibrator (2.5mmol/l, 10pi
each) were incubated in duplicate with Triglyceride reagent (1ml) (37°C, 5mins).
Absorbance was then measured at 500nm using Shimadzu® UV-160A visible
recording double beam spectrophotometer zeroed against a blank cell containing
Triglyceride reagent alone. The concentration of triglycerides was calculated using
the following equation:




Hepatic glycogen concentrations were inferred following their conversion to
glucose based upon the method described by Van Handel 1965. Liver (50mg) was
digested in KOH (1M, 250pi; 95°C, 30 mins) then excess alkali neutralized with HC1
(1M, 250pl). Following digestion, homogenate (lOOpl) was incubated (30°C, 2 hrs)
in sodium acetate (0.3M, pH4.8) containing amyloglucosidase (lOmg/ml) (Roche
Molecular Biochemicals). The content of glucose in the supernatant formed
following centrifugation (6000g, RT, 10 mins) was measured using glucose
hexokinase reagent (Sigma, St.Louis, MO) as described in section 2.63. Glycogen
content is inferred from mg glucose produced per g tissue. The inter- and intra-assay
coefficients of variation were 4.5% and 1.5% respectively. This assay is linear
between 0 and 45mmol/l.
2.6.3 Plasma glucose
Quantification of plasma glucose was performed using Infinity™ glucose
hexokinase reagent (ThermDMA, Louisville, CO, USA). This assay works using the
Hexokinase / glucose-6-phosphate method in which glucose is phosphorylated by
ATP by hexokinase producing ADP and glucose-6-phosphate (G-6-P) (reaction 1).
Glucose-6-phosphate is then oxidized to 6-phosphogluconate (6-PG) with the
reduction of NAD+ to NADH by glucose-6-phosphate dehydrogenase (G-6-PDH)
(reaction 2). The amount of NADH produced is proportional to the amount of
glucose in the sample and can be measured by and increase in absorbance at 340nm.
Hexokinase
1. Glucose + ATP -* G-6-P + ADP
G-6-PDH
2. G-6-P + NAD+ -> 6-PG + NADH + H+
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Plasma (3pl) was incubated (37°C, 3mins) in duplicate with glucose hexokinase
reagent (450 pi) which contains ATP, hexokinase, NAD+ and G-6-PDH. The
absorbance of NADH in the samples was measured at 340nM using a Shimadzu®
UV-160A UV/visible recording spectrophotometer zeroed against a blank cell
containing reagent only. The amount of glucose in the sample was calculated from a
standard curve (0, 12.5, 25, 50, 100, 200, 400, 800 mg/dL glucose diluted in
deionized water) constructed following linear regression analysis with mean
absorbance (Y axis) plotted against standard concentration (X axis).The inter- and
intra-assay coefficients of variation were <2%.
2.7 Analysis of glucocorticoid metabolites
2.7.1 Extraction ofsteroidsfrom urine
Rat urine was collected over 72 hours using metabolic cages which
minimised contamination of the urine with food or faeces. Urine (10ml) representing
the final 24hr of a 72hr collection period containing epi-THB and epi-B (250ng each
in ethanol) was passed through Sep-pak C18 columns (Waters, Herts, UK)
containing 360mg packing material. Columns were pre-conditioned with methanol (5
ml) followed by water (5ml). A calibration line of A, B, THA, 5(3-THB and 5a-THB
representing a range of concentrations (0, 10, 20, 50, 100, 150, 200, 250, 300, 400,
500, 600, 800 and lOOOng) was prepared in water (5ml) to which internal standards
of epi-THB and epi-B (250ng each) were added. Following application of the
sample/standard and internal standards the columns were washed (5ml water) and the
steroids eluted from the column with methanol (5ml). The eluant was dried under
OFN at 60°C.
2.7.2 Hydrolysis ofsteroids
Glucocorticoids are conjugated with either glucuronic acid or sulphate to
make them more hydrophilic and thus aid in their excretion. Prior to analysis, these
esters were hydrolysed. The dried samples (section 2.7.1) were resuspended in
sodium acetate buffer (2ml; 0.2M, pH4.6) vortexed thoroughly to ensure the steroids
were in solution and (3-glucuronidase (lOOpl; Type H2 from Helix pomatia) added.
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^-Glucuronidase enzyme cleaves the glucuronic acid from the steroid and also has
sulphatase action to remove sulphate groups. The samples were incubated in a water
bath (37°C, 48hr).
2.7.3 Extraction ofsteroids from hydrolysate
Following hydrolysis, the steroids were re-extracted through the same Sep-
pak columns primed as described previously with methanol (5ml) and water (5ml).
The hydrolysate was applied to the column, the column washed with water (5ml) and
the steroid eluted with methanol (5ml). The resultant eluant was evaporated to
dryness under OFN (60°C). The dried steroids were dissolved in a mixture of ethyl
acetate and water (15:1), vortexed thoroughly and the upper organic phase removed
and evaporated to dryness under OFN (60°C) into Reacti-Vials ® (3.5ml).
2.7.4 Derivatisation ofsteroids
The extracted steroids underwent two sequential derivatisation steps in order
to mask polar groups which could interfere with the chromatography of the resulting
steroids. Firstly, samples were incubated (60°C, 30min) with methoxyamine.HCl
(2%) in dry pyridine (50ptl) which reacts with ketone groups. The samples were then
reduced to dryness under OFN (60°C) and incubated (100°C, 2h) with
trimethylsilylimizadole (50pi; Sigma Aldrich, UK) which reacts with hydroxyl
groups.
2.7.5 Extraction ofderivatised steroids
Following derivatisation, steroids were separated from other reagents using
Lipidex 5000 columns prepared by adding Lipidex 5000 (1- 2 cm; Canberra Packard,
UK) to glass pasteur pipettes loosely plugged with silanised glass wool. The Lipidex
was prepared in mobile phase (cyclohexane; hexamethylsisilazane; pyridine; 98:1:1)
and the columns washed with mobile phase (3 x 1ml) prior to use. The samples were
then mixed with mobile phase (1ml) applied to the columns and allowed to drip
through the columns. A further 2ml mobile phase was applied to the column to
ensure all steroids were eluted from the column. The samples were subsequently
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reduced to dryness under OFN (60°C) and reconstituted in decane (60pl; Sigma
Aldrich, UK) in preparation for analysis by GC-MS.
2.8 Measurements of enzyme activity
2.8.1 Subcellularfractionation
Cytosolic and microsomal subfractions were separated by repeat differential
centrifugation according to methods described by Fleischer et al (Fleischer &
Kervina 1974). Liver (lOOmg) was homogenized using a Ystral mechanical
homogeniser (Scientific Instruments Centre, Liverpool) in sucrose buffer (1ml;
0.25M, pH7.5) containing HEPES (lOmM) and dithiothreitol (DTT;lnM).
Homogenates were centrifugated (lOOOg, 4°C, lOmin) and the supernatant removed
and subjected to further centrifugation (34000g, 4°C, 30 min). Centrifugation
(124000g, 4°C, 60 mins) of the resultant supernatant yielded cytosolic and
microsomal sub-fractions, for analysis of 5(l-reductase and lip-HSDl activity
respectively.
2.8.2 Determination ofconcentration ofprotein
Concentrations of protein in tissue homogenates, cytosolic and microsomal
sub-fractions were determined colorimetrically using the Bio-Rad Protein Assay
based on the Bradford dye-binding procedure (Bradford 1976). A differential colour
change occurs in response to various concentrations of protein. Binding of protein to
an acidic solution of Coomassie® Brilliant Blue G-250 dye results in a shift in
absorbance maximum from 465nm to 595nm. The Coomassie blue dye binds
primarily to basic and aromatic amino acids, especially arginine. The extinction
coefficient of a dye-albumin complex solution is constant over a 10-fold
concentration range. Dye reagent was prepared by diluting 1 part Dye Reagent
Concentrate (Biorad, UK) with 4 parts deionized water and filtered through
Whatman #1 filter paper to remove particulates and was prepared immediately prior
56
to the test. A standard curve (0, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2mg/ml)
composed of a series of solutions of Bovine Serum Albumin (BSA) (Sigma-Aldrich,
Poole, UK) was prepared in deionised water for each experiment. Samples were
diluted in appropriate buffer to ensure protein concentrations were within the range
of the standard curve. Diluted sample or standard (2pi each) followed by dye reagent
(lOpl) was pipetted in duplicate into a 96 well plate (Costar, Corning, NY) and
incubated (RT, lOmin). Absorbance of samples/standards were measured on a
microplate reader (Optimax tunable microplate reader) at 595nm using Softmax Pro
software (Version 2.0, Microsoft Windows). The protein concentration was
determined by interpolation from the BSA standard curve following linear regression
analysis with mean absorbance of each sample (Y axis) against concentration of
standard (X axis). The inter- and intra-assay coefficients of variation were 5.8% and
4%, respectively.
2.8.3 5fi-Reductase activity
5|3-reductase catalyzes the conversion of corticosterone to its 5(3-dihydro
metabolites by reduction of the steroidal ring-A 4-5 double bond. In liver this
reaction is rapidly followed by a second reductive step catalysed by 3a-HSD,
resulting in the formation of 5(1-THB. Measurements of hepatic 5fl-reductase activity
were determined in cytosolic sub-fractions from liver homogenates. Cytosolic
preparations (lOOpg/ml protein) together with [3H]4 -1,2,6,7-corticosterone (50 nM),
and unlabeled corticosterone (1950 nM) were incubated in duplicate with sodium
phosphate buffer (40mM, pH 7.5) containing sucrose (0.32M) and DTT(lmM),
NADPH (2mM), glucose-6-phosphate (5mM) and glucose-6-phosphate
dehydrogenase (0.1 units/ml) in a total volume of 250pl. Control samples containing
buffer, NADPH co-factor and substrate but no protein (Blank) and buffer, substrate,
protein but no co-factor (No CF) were included in each assay. Reactions were
performed at 37°C for 4 hours. Following incubation, the reaction was terminated by
the addition of ethyl acetate (10 vol) and water (1 vol). The upper organic phase
containing the steroids was removed and reduced to dryness under a stream of
oxygen free nitrogen (OFN, 60°C). The resultant steroid residues were dissolved in
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mobile phase (600pl; methanol; acetonitrile; water; 25:15:60). Steroids were
quantified by high performance liquid chromatography (HPLC) as described in
Section 2.9.1.
2.8.4 11J3-HSD1 dehydrogenase activity
In vivo, lip-HSDl is mainly a reductase, converting inactive 11-
dehydrocorticosterone to corticosterone. However, in vitro, the dehydrogenase
direction is preferred, and reductase activity is less stable. llp-HSDl protein was
therefore quantified in the dehydrogenase direction as the conversion of
corticosterone to 11-dehydrocorticosterone under conditions in which dehydrogenase
activity is proportional to enzyme protein added.
Microsomal preparations (100pg/ml protein) together with [3H]4
corticosterone (25 nM), were incubated in duplicate with Hanks Krebs Ringer Buffer
(KRB; pH7.4) containing glucose (1% w/v) and NADP+ (2mM). Reactions were
performed at 37°C for 30mins. Blank and no co-factor controls were included in each
assay as for 5(3-reductase. Reactions were performed at 37°Cfor 30 mins. Following
incubation, the reaction was terminated as described in section 2.73 and the upper
organic phase containing the steroids was removed and reduced to dryness under a
stream of OFN (60°C). The resultant steroid residues were dissolved in mobile phase
(600ul; methanol; acetonitrile; water; 25:15:60). Steroids were quantified by HPLC
as described in Section 2.91.
2.8.5 11J3-HSD2 dehydrogenase activity
Renal llp-HSD2 activity was determined in kidney homogenates as
conversion of corticosterone to 11-dehydrocorticosterone as with lip-HSDl.
Kidneys were halved and homogenised in KRB (1ml) as described in section 2.92
and protein concentration was measured as described in section 2.93. Homogenates
(50pg/ml) were incubated in duplicate with NAD+ (2mM), [3H]4-corticosterone (25
nM) in KRB (total volume 250pi) at 37°C for 30 mins. Blank and no co-factor
controls were included in each assay as for 5(3-reductase. Following incubation, the
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reaction was terminated and steroids recovered and quantified as described in section
2.76. Activity was assessed in renal homogenates that had only been defrosted once.
2.8.6 3a-HSDActivity
Analysis of 3a-HSD activity was performed by measuring the conversion of
5|3-dihydrocortiocosterone (5(3-DHB) to 5|3-tetrahydrocorticosterone (5|3-THB).
Cytosolic preparations (50pg/ml protein) containing unlabeled 5(3-DHB (500ng)
were incubated in duplicate with sodium phosphate buffer (40mM, pH 7.5)
containing sucrose (0.32M) and DTT (ImM), NADPH (2mM), glucose-6-phosphate
(5mM) and glucose-6-phosphate dehydrogenase (0.1 units/ml) as described
previously for 5(l-reductase activity.
Reactions were performed at 37°C for 10 minutes and terminated by the
addition of ethyl acetate (10 vol) and water (200pl). Epi-tetrahydrocorticosterone
(epi-THB; 250ng in methanol) was then added as an internal standard. The organic
layer was reduced to dryness under a stream of nitrogen at 60°C. Analysis of the
conversion of 5J1-DHB to 5(3-THB was achieved by converting the steroids in the
dried steroidal extracts to their methoxime-trimethylsilyl derivatives using a method
based upon that reported by Shackleton & Honour (1976) and quantified by gas
chromatography-mass spectrometry (GC-MS) as described in section 2.9.2.
2.9 Analysis of steroid metabolites
2.9.1 High pressure liquid chromatography
High pressure liquid chromatography (HPLC) was used to separate
and quantify steroids following bioactivity assays. The HPLC system consisted of a
auto-injector (Waters 717 plus ; Herts, UK), mobile phase pump set at a constant
flow rate (lml/min), a reverse phase Symmetry® shield C8 column (pore size =5 pm;
length =150mm; internal diameter = 3.9 mm; Waters, Ireland) maintained at 35°C.
Radioactive metabolites were detected by on-line liquid scintillation counting
(Quicksafe Flow 2, Zinsser, Berks, UK; flow rate 2ml/min; model LB-509, Berthold
Instrument). Radioactive standards of [3H]4 A and [3H]4B were injected at the start of
each run to confirm the identity of the steroids. Further confirmation of identity was
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achieved using unlabelled steroids, detected by UV detection (Waters A2487 Dual
Absorbance Detector) at A254nm (B and A) or 195nm (THB). The area under each
radioactive steroid peak was integrated using Dionex Chromeleon software (UK) and
the proportion each peak represented of the total area of radioactive peaks was used
to determine the conversion of substrate to product and hence enzyme velocity.
Velocity was expressed as nmoles of product per mg tissue per hour.
2.9.2 Gas chromatography / mass spectrometry
Steroids were quantified by gas chromatography mass spectrometry under the
following conditions:
1. Urinary metabolites
Analysis of urinary metabolites was carried out using Voyager electron
impact gas chromatography mass spectrometer operated in selected ion mode fitted
with a CP sil 5CB capillary column (Varian 100% dimethyl polysiloxane; length
25m, internal diameter 0.32mm, film thickness 0.12pm; Chrompak, UK). The initial
oven temperature was 50°C; this was increased by 30°C/min to 200°C, by 8°C/min to
250°C and then by 6°C/min to 300°C, and maintained for 6 minutes. Injection, source
and interface temperatures were 280, 200 and 250°C respectively.
2. Bioactivity assays
Products generated in bioactivity assays were analysed using a PolarisQ ion
trap electron impact gas chromatography mass spectrometer operated in selected ion
mode (Thermo Finnigan) fitted with a Db5MS capillary column (Crossbond 5%
diphenyl; 95% dimethyl polysiloxane; length 30m, internal diameter 0.25mm, film
thickness 0.25pm; Alltech, Camforth, UK). The initial oven temperature was 150°C;
this was increased by 30°C/min to 200°C and then by 8°C/min to 300°C and
maintained for 8 minutes. Injection, source and interface temperatures were 240, 200
and 280°C respectively. Ionization was performed in electron impact mode at 70eV.
The mass (m/z) and typical retention times of the ions monitored are shown
in table 2.1. Quantification was achieved by integrating the area under each steroidal
peak and calculating the ratio of each steroid peak relative to that of the internal
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standard. The concentration of steroid was then be determined by interpolation of the
calibration line where r>0.99 was deemed acceptable.
Compound Ion monitored (m/z) Retention time (min)
Corticosterone (B) 548 14.66 + 14.71
Epi-B 548 14.29±14.46
5a-Tetrahydro-B (5a-THB) 564 12.89
5p-Tetrahydro-B (5(3-THB) 564 12.75
Epi-Tetrahydro-B (Epi-THB) 564 13.00
Table 2.1 Mass/charge ratio and retention time of ions monitored by GC-MS.
2.10 Culture of Rat Hepatoma Cells (H4IIE)
The cell line H4IIE, is a rat hepatoma cell line. This cell line retains many of
the properties of rodent hepatocytes cells such as a cobblestone appearance and the
expression of liver-specific enzymes such as cholesterol 7a-hydroxylase and 5a-
reductase 1.
The H4IIE cells were obtained from the European Collection for Animal Cell
Culture (ECACC, Salisbury, UK). Cells were maintained in continuous culture in
Dulbecco's Modified Eagle's Medium (DMEM, Sigma, Poole, UK) supplemented
with heat inactivated fetal bovine serum (10%, FBS; Labtech International, East
Sussex, UK), glutamate (2mM), streptomycin (lOOIU/ml) and penicillin (lOOpg/ml;
Invitrogen Life Technologies, Paisley, UK) and incubated at 37°C in a humidified
atmosphere containing 5% CO2.
Once a confluent monolayer has formed in 75 cm2 tissue culture flasks
(Costar, Corning, NY), cells were washed in serum-free media and harvested with
Trypsin-EDTA (2.5 ml; Invitrogen Life Technologies, Paisley, UK). After incubation
(37°C, 2-3 mins) cells were detached from the flask and an equal volume of complete
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media was added to inactivate the trypsin. The cells were collected by centrifugation
(lOOOg, RT, 5mins) and the cell pellet re-suspended in fresh media. Cells were then
seeded at the concentration for the required experiment (1.6 x 106 cells/ml) or diluted
in complete media for continuous culture.
2.11 Qualititative analysis of gene transcription
2.11.1 Isolation oftotal cellularRNA
Total cellular RNA was isolated from tissues and cells using TRIzol® Reagent
(Invitrogen Life Technologies/Life technologies, Inc., Paisley, UK) based upon the
method of Chomczynski et al (1987). TRIzol is a mono-phasic solution of phenol
and guanidine isothiocyanate which disrupts cells and dissolves cellular components,
yet maintains RNA integrity. TRIzol (1ml) was added per lOOmg tissue or 10cm2
tissue culture dish and the tissues homogensied (3 x lOsec) using a Ystral
homogeniser The samples were incubated (RT, lOmins) to allow complete lysis of
nucleoprotein complexes. To isolate total cellular RNA, choloroform (200pi per ml
TRIzol) was added, shaken vigorously (15sec) and incubated (RT, 3min). Samples
were separated into an upper, clear aqueous phase containing RNA, an interphase
containing DNA and a lower organic phase containing protein and cellular debris by
centrifugation (12000g, 4°C, 15 mins). The clear aqueous phase containing RNA was
transferred to sterile 1.5ml Eppendorfs (1.5ml) and the RNA precipitated by the
addition of isopropanol (500ul; BDH, UK). Following incubation (4°C, lOmin), the
precipitated RNA was harvested by centrifugation (12,000g, 4°C, lOmins). The RNA
pellet was washed in ice cold ethanol (75%) followed by further centrifugation
(7,500g , 4°C , 5 mins) the wash solution removed and the pellet allowed to air-dry.
The RNA pellet was resuspended in 20pi RNAse free H2O (DEPC H2O), heated at
55-60°C to ensure that the RNA was in. solution and quantified
spectrophotometrically using a GeneQuant spectrophotometer at X 260/280
(Pharmacia Diagnostics, UK). The intergrity of purified total RNA was verified by
ethidium bromide staining following electrophoresis through a 1.2% agarose gel.
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2.11.2 Preparation ofcomplementary DNA (cDNA)
Complementary DNA (cDNA) is a single-stranded DNA complementary to
an RNA molecule. cDNA was generated by reverse transcription of total RNA (0.5 -
lpg) using a first-strand cDNA synthesis kit (Promega Ltd, UK). RNA was diluted
to give a final concentration of 0.25 -0.5pg/pl. RNA (5pi diluted) was incubated with
master mix (25pi; 60°C, 30mins). The master mix contained reverse-transcriptase
derived from moloney murine leukaemia virus (M-MLV)(Promega, Southampton,
UK), oligo(dT) primer (Promega) which anneals to the poly(A) tail of the mRNA
and enables transcription in the 5'-3' direction and deoxynucleotide triphosphates
(dNTPs) (Promega) which have energy-rich phosphate groups aiding nucleic acid
synthesis. The resultant cDNA was stored at -20°C until required.
2.11.3 Amplification ofcDNA by polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) was used to determine transcripts from
the genes of interest in H4IIE cells. cDNA (5 pi) prepared from H4IIE cell RNA as
described in section 2.11 was subjected to PCR amplification using appropriate
forward and reverse primers (20pmoles of each; TAG Copenhagen A/S, Denmark;
primer sequences are shown in Table 2.2) prepared in primer mix (40pl; Table 2.3)
and TagBeads™ polymerase (1 bead per sample; Promega Ltd, UK). Control samples
with no RNA (no template) and no reverse transcriptase (no RT) were included in
each cycle.
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Table 2.2. Oligonucleotide primers used for amplification 5p-reductase,
11P-HSD1, 3a-HSDand CYP7AlcDNAs by RT-PCR
Component Amount per sample
10 x buffer 5pi
MgCb 3pi
dNTPs lpl
Sense primer (20pmol/pl) 2pl
Anti-sense primer (20pmol/pl) 2pl
Nuclease free water 32pl
Table 2.3 Master mix components for PCR
Thermal cycling was performed using an Eppendorf Thermal Cycler according to
table 2.4.
The amplified PCR products (5 pi) were separated by electrophoresis on a
agarose gel (1.2% w/v) For each gel, DNA fragments of known fragment sizes (lkb
ladder; Promega) were resolved to indicate the size of the RT-PCR product.
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Conditions
Denaturation Annealing Extension Final Extension No. Cycles
99°C 55°C 72°C 72°C 34
45 s 30 s 90 s 10 mins
Table 2.4 Conditions for PCR of genes of interest.
2.11.4 DNA purification
Complementary DNA (cDNA) products generated by RT-PCR were isolated
from gel fragments using a gel extraction kit (Roche Molecular Biochemicals). All
solutions were provided with the kit which did not identify individual components of
each buffer, thus buffers are referred to by the manufacturers chosen names. RT-PCR
products were excised carefully from the gel using a sterile scalpel, weighed in a
sterile Eppendorf tube and incubated (60°C, 10 mins) with buffer A (50pl/mg gel).
The resultant solution containing the RT-PCR product was passed through a filter
catch tube to remove any unsolubilised gel fragments. The effluent was discarded
and the filter washed twice by centrifugation (1300g, RT, lmin) in wash buffer
(lOOpl/ml gel). Following centrifugation (1300g, RT, lmin), the purified DNA was
eluted from the filter in elution buffer (20pi). The concentration of DNA was
determined following electrophoresis of the purified DNA (1 or 2pl) and low or
high-molecular weight ladder (depending on the molecular weight of the gene of
interest, Promega) on an agarose gel (1.2%, w/v; 80V; 60min).The amount of DNA
was calculated by comparing the relative intensity of bands to that of the DNA mass
ladder. All purified RT-PCR products were verified by sequencing performed using
the Applied Biosystems 3730 DNA Analyser at Wellcome Trust Clinical Research
Facility, Western General Hospital, Edinburgh.
2.12 Quantification of messenger RNA (mRNA) by Northern blot
analysis
2.12.1 Separation ofRNA
Total RNA (10 or 20ug) isolated as described in section 2.10 was separated
by electophoresis on an agarose formaldehyde denaturing gel (1.2% w/v). All
65
equipment was soaked in hydrogen peroxide for 2 hours prior to use and rinsed in
nuclease free water (x3 times) to minimise contamination. A gel (100ml) was
prepared by melting agarose (1.2g) in DEPC water (88ml) then adding formaldehyde
(40%; 2ml) and lOx MOPS (10ml). The solution was mixed gently, poured into a gel
casting tray with an appropriately sized comb and allowed to set in a fume hood.
Once set the gel was transferred to an electrophoresis tank and soaked in lx MOPS.
RNA was diluted in DEPC water to give a concentration of 1 to 2pg/pl. Diluted
RNA (lOpl) was denatured (55°C, 15min) in mixture containing deionized
formamide (lOpl), formaldehyde (40%; 2.5ul) and lOx MOPS (2.5pi). Following
denaturation, loading buffer (2pi) containing ethidium bromide (lpl per 50pl loading
buffer) was added to each sample, mixed gently by pipetting, loaded on to the gel
and subjected to electrophoresis (60V, 2-4 hr) or until the front band of the loading
dye was 3A way down the gel. The gel was briefly photographed under UV light
(254nm) to check the integrity of the RNA, then soaked in 20x SSC buffer for
15min.
2.12.2 Blotting
Resolved RNA was blotted on to a Zeta-Probe nylon membrane (Bio-Rad
Laboratories, Inc. Richmond, Ca) by capillary transfer. A wick of Whatman #1 3MM
filter paper was placed over an upturned gel casting tray and placed in a sterile
plastic tray containing 20x SSC. The upper left hand corner of the gel was removed
for identification, the gel inverted and placed upon the wick. A piece of membrane
was cut to the size of the gel, soaked in 20x SSC and placed carefully upon the gel,
followed by 3 sheets ofWhatmann #1 3MM paper. Saran wrap was placed along all
sides of the membrane to ensure that the membrane did not make contact with the
wick, which would short circuit the system thus preventing transfer of the RNA to
the membrane. Paper towel (approximately 5cm thick) was placed upon the
membrane/Whatman paper. A weight was balanced upon the glass plate and the
assembly incubated (RT, 16hr) allowing capillary transfer to occur. Following
transfer, the membrane was washed in 20x SSC to remove any residual gel fragments
and dried between two sheets of Whatman 3MM #1 paper (60°C, 2hr). The RNA was
then cross-linked to the membrane under UV light.
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2.12.3 Hybridisation to 32P-labelled probe
The dried membrane was soaked in 20xSSC (5min) then placed in a Hybaid
hybridisation bottle containing a pre-warmed (55°C) hybridisation buffer of SDS
(20%; 3ml) and sodium phosphate buffer (6ml) to which denatured salmon testes
DNA (0.5mg/ml; Sigma Aldrich, UK) was added. The membrane was pre-hybridised
for at least 2hr at 55°C. Complementary DNA probes were labelled with [a-
32P]dCTP (3000Ci/mmol) (Amersham Pharmacia Biotech) using a random primed
labelling kit (Roche Molecular Biochemicals). The probe was purified by passing
through a NICK column (Amersham Pharmacia Biotech) which removes any
unincorporated radioactivity. The NICK column was primed with TE buffer (3ml),
the probe applied to the column, the column washed with TE buffer (400pi) and the
labelled DNA eluted from the column with TE buffer (400pl). The activity of the
probe was checked by mixing probe (lpl) with Cocktail T scintillant (1ml) and
counting in a beta counter (lmin). Only probes with specific activity > 10,000cpm
were used for subsequent hybridisation. The labelled DNA probe was subsequently
denatured (100°C, 5min), added to the pre-hybridisation buffer and the membrane
hybridized with the probe (55°C, 16hr). Following hybridisation, the probe was
discarded and the membrane rinsed in wash buffer one (lx SSC, 0.1% SDS. The
membrane was subjected to a further two washes in buffer one (and on wash in
buffer two (0.5x SSC, 0.1% SDS; 55°C, 30min). The membrane was wrapped in
cling-film and exposed to an imaging screen (Fujifilm, London, UK) for 6hr. The
level of hybridized probe was quantified using Fuji FLA2000 fluorescent image
analyzer and imaging software (Aida, Raytek Scientific, Sheffield, UK). Membranes
were rehybridised with a probe for U1 using the same method, to control for
differences in RNA loading and transfer. The level of expression of the gene of
interest was expressed as a ratio of the RNA of interest to that of U1 and expressed in
arbitary units (A.U).
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2.13 Quantification ofmessenger RNA (mRNA) by real-time PCR
2.13.1 Taqman® real-time PCR
Quantification of 5(3-reductase, 3a-HSD and llpHSDl in H4IIE cells and
hepatic 5[l-reductase, 5a-reductase, lipHSDl, 3a-HSD, angiotensinogen, PEPCK,
TAT, SR-B1, HMG Co-A reductase and CYP7A1 was performed with real time
PCR primer/probe sets using the ABI PRISM 7900 Sequence Detection System
(Applied Biosystems, Southampton, UK). Gene sequences were obtained from
Ensembl Gene Browser (http://www.ensembl.org/).Primers and probes were either
designed using Primer Express Software (Applied Biosystems, Southampton, UK) or
purchased directly from Applied Biosystems (Southampton, UK). Primer: Tm 58-
60°C, 20-80% GC, length 9-40 bases, <2°C difference between primers, maximum of
2 G/Cs in the last 5 bases at 3' end. Probe: Tm 10°C higher than primer Tm, 20-80%
GC, length 9-40 bases, no G on the 5' end, <4 contiguous Gs, must have more Cs
than Gs All primer/probe sets were designed with at least one primer or probe
spanning an intron to prevent amplification of genomic DNA. Primer and probe
sequences used were:
llpHSDl forward primer 5'- TCA TAG ACA CAG AAA CAG CTT TGA AA-3';
reverse primer 5'-CTC CAG GGC GCA TTC CT-3'; probe 5'-6-FAM-CTG GGA
TAA TCT TGA GTC AAG CTG CT CCC-TAMRA-3'
5P-reductase forward primer 5'- GCC TTT AAG CCT GGA GAG GAA-3' reverse
primer 5'- ACG TGG CAC ACA GAT TTG ATT T-3'; probe 5'-6-FAM- TGG TAT
ATC ACT CGG CCA TTC TCA TCT TTA GGA T-TAMRA-3'
3aHSD forward primer 5'- TCT ATA CTT CAA AGC TTT GGA GCA CTT-3'
reverse primer 5'- CCA GTT GAG TGC TTT TCA GTG TCT-3'; probe 5'-6-FAM-
TCC AAG CAA GTT CGG ACC AGA TCT G-TAMRA-3'
Cyclophilin A forward primer 5'- CCC ACC GTG TTC TTC GAC AT-3' reverse
primer 5'- GAA AGT TTT CTG CTG TCT TTG GA-3'; probe 5'-6-VIC-CAA GGG
CTC GCC ATC AGC CGT-TAMRA-3'
68
All other primer/probe sets were purchased from Applied Biosystems Taqman®
Gene Expression Assays on line catalogue (http://www.appliedbiosystems.com/).
cDNA was incubated with lx Taqman mastermix (Applied Biosystems, Cheshire,
UK), primers (25pM) and probe (5pM; lpl cDNA per 10 pi, made up to volume
with NF-water) and transferred to 384 well PCR plates with optical heat sealing
cover (Applied Biosystems, Cheshire, UK). Reagents were concentrated at the
bottom of the well by centrifugation (lOOOg, RT, 5mins) and transferred to ABI
PRISM 7900 Sequence Detection for cycling/ detection as per manufacturers'
instructions. (50°C, 2 min; 95°C, 10 min; 95°C, 15 sec and 60°C, 1 min, repeated for
40 cycles).
Cyclophilin A (liver) or (3-actin (adrenal) primers/probes were used to
normalize the transcript levels. A standard curve for each primer probe set was
generated in triplicate by serial dilution of cDNA pooled from several samples. Each
sample was run in triplicate and the mean values of the triplicates were used to
calculate transcript level from the standard curve. The results are expressed as a ratio
to cyclophylin A or (3-actin using the Relative Standard Curve method. In this
method a standard curve is generated for both the target and endogenous reference.
For each experimental sample, the amount of target and endogenous reference is
determined from the appropriate standard curve. The target amount is divided by the
endogenous reference amount to obtain a normalized target value.
2.13.2 LightCycler® real-time PCR
One-step real-time quantitative PCR was used to assess the abundance of
ll(3-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) within the
adrenal glands and performed using the LightCycler® System (Roche Diagnostics,
Mannheim, Germany) and LightCycler® RNA Master Hybridization Probes kit
(Roche Diagnostics, Mannheim, Germany). Two pairs of gene sequence-specific
hybridization probes homologous to exon 3 of rat CYP11B1 or CYP11B2 were
designed and synthesized by TIB Molbiol (Berlin, Germany). Each pair of probes
consists of a fluorescein-labelled and LightCycler Red 705 labelled probe. The
sequences of the oligonucleotide probes are selected such that they hybridize to the
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amplified DNA fragment in a head to tail arrangement within close proximity (1-8
base pairs). When the two probes are brought into close proximity, energy transfer -
Fluorescence-Resonance Energy Transfer (FRET) between the two dyes results in
the excitation of LightCycler Red by fluorescein, leading to the emission of light by
LightCycler Red which is detected by the LightCycler apparatus (Roche Diagnostics,
Mannheim, Germany).
Primer pairs (RBI and RB2) were manufactured by MGW-Biotech
(Ebersberg, Germany) and were exon-spanning to minimise amplification of any
contaminating genomic DNA. The primers used were:
RBI sense 5' -GTCTATAAACATTCAGTCCAA- 3'
RBI antisense 5' -ATCTCGGATATGACACTCC- 3'
RB2 sense 5' - GGATGTCCAGCAAAGTCTC- 3'
RB2 antisense 5' - ATTAGTGCTGCCACAATGC- 3'
A master-mix solution was prepared as shown in table 2.6, mixed gently
and aliquots (19pl) transferred into pre-cooled LightCycler Capillary tubes (Roche
Diagnostics, Mannheim, Germany) along with lpl RNA (lpg/pl). The capillaries
were sealed with stoppers, placed into adapters. Following centrifugation (700g, 5
sees) the capillaries containing the samples were placed into the rotor of the
LightCycler instrument (Roche Diagnostics, Mannheim, Germany). Annealing
temperatures were 52°C for CYP11B1 probes and 55°C for CYP11B2 probes and the
cycle programs were performed as described in table 2.6.
Component Volume Final concentration
H20, PCR grade 6.2pl
Mn(OAc)2 stock solution, 50nM 1.3pi 3.25mM
B1 Fluorescein (FL) or B2 Fluorescein (FL) lpl 0.2pM
B1 LightCycler Red705 dye (LC) lpl 0.2pM
or B2 LightCycler Red705 dye (LC)
Primer RBI sense or RB2 sense lpl 0.5pM
Primer RBI antisense or RB2 antisense lpl 0.5pM
LightCycler RNA Master Hybridization Probes, 2.7 x cone lx
Total volume 19pl
Table 2.5 Master mix solution for LightCycler PCR. Volume column was multiplied by the number
of samples plus one additional sample
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Cycle Program Data RT Denature Amplification Cooling
Cycles 1 1 45 1
Analysis mode None None Quantification None
Temperature targets SI SI SI S2 S3 SI
Target temperature (°C) 61 95 95 52/55 72 40
Incubation time 20 min 30 s 1 s 15 s 13 s 30 s
Temperature transition rate (°C/s) 20 20 20 20 2 20
Secondary target temperature (°C) 0 0 0 0 0 0
Step size (°C) 0 0 0 0 0 0
Step delay (cycles) 0 0 0 0 0 0
Acquisition mode None None None Single None None
Table 2.6 Parameters for amplification of CYP11B1 and CYP11B2 by LightCycler® real time PCR
Fluorescent data were collected during a single acquisition phase. A standard curve
was constructed by sequential 10-fold dilutions of standard mRNA amplified from
lpg tissue RNA. Sample copy number was then interpolated from the standard curve
on the base of the samples crossing point. Each sample was measured three times. In
each run controls containing no RNA (Blank) were included. Data are expressed as
the mean of each triplicate ± S.E.M..
2.14 Histology
2.14.1 Adrenal histology
In order to assess changes in adrenal morphology transverse sections were cut
from snap frozen (Hematoxylin and Eosin) or formalin fixed (Oil red O) glands.
Glands were fixed to 1cm x 1cm cork tiles using cryomatrix fixation agent and then
mounted on to cryostat chucks using water ensuring that the adrenal gland was in the
correct orientation. Sections were cut to a thickness of 30 pm (Oil red O) or 15 pm
(H and E) and mounted on to super-frosted microscope slides and stained using
either H and E to look at gross morphology or Oil red O to assess lipid accumulation.
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2.14.2 Hematoxylin andEosin stain
Hematoxylin is isolated from an extract of logwood, Hematoxylin
campechuanun Linnaeus, whose oxidation product, hematein, produces a blue/purple
colour when combined with a mordant metallic ion such as aluminium salt. The
positively charged aluminium hematin complex combines with negatively charged
phosphate groups of nucleic acid producing the characteristic blue/purple colour
characteristic of hematoxylin stains. Eosin, a xanthene dye was used as a
counterstain to demonstrate structural characteristics of the cytoplasm and connective
tissue.
2.14.3 Oil red O stain
Oil red O is an oil soluble dye which exhibits greater solubility in lipoid
substances such as fat and is therefore frequently used to evaluate normal or
abnormal fatty tissue. This stain was utilised to examine fat distribution and
accumulation within different zones of the adrenal gland. Frozen sections were
allowed to come to room temperature, rinsed briefly in nuclease free water,
immersed in propan-2-ol (60%; 30secs) and then submerged in Oil red O (lOmins).
Following this time the sections were washed thoroughly in nuclease free water to
remove any excess dye then immersed in hematoxylin (lmin). Slides were rinsed in
nuclease free water to remove any excess dye, then briefly immersed in ammonia
(1%; 30secs) then rinsed in nuclease free water and mounted using mounting
medium.
2.14.4 Liver histology
Lipid accumulation within the liver was assessed in sections (30pm) cut from
snap-frozen livers as described for the adrenal gland section 2.14.1. Sections were
stained with Oil red O as described in section 2.14.3.
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2.15 Statistical analysis
For all experiments using animal tissues individual experiments were
conducted using tissues from 8 independent animals (unless otherwise stated). Each
assay was performed duplicate and the mean of each duplicate taken as the final
value for that individual animal. For all experiments using cultured cell lines,
indivdual experiments were performed using cells from 3 sepearate passages. Each
assay was performed 6 times and the mean of these 6 cultures taken as the final value
for that individual cell passage. All future analysis was performed using the mean of
these replicates. The data in each figure represents the mean ± standard error of the
mean (SEM). For in vitro experiments statistical significance was determined using
one way analysis of variance (ANOVA) followed by post hoc least squared
difference test for all groups. All analysis was performed using Statistica (Version 9)
or Graphpad prism (Version 4). For in vivo experiments, where three groups were
studied, data were analysed by one-way and repeated measure ANOVA followed by
post-hoc least squared difference tests. Where two groups were studied, data were
analysed by Students t-tests. All analysis was performed using Statistica (Version 9).
For acute restraint stress, analysis of plasma B and ACTH was carried out by
measuring area under the curve (AUC) using a Kinetica program (InnaPhase, USA).




Inhibitory effects of bile acids on glucocorticoid




The liver is the major organ involved with peripheral glucocorticoid
metabolism. In this tissue the interconversion of active (Cortisol (F) human;
corticosterone (B) rodent) and inactive (cortisone (E) human; 11-
dehydrocorticosterone (A) rodent) glucocorticoids is mediated by the type 1 isozyme
of lip-HSD (Agarwal et al. 1989). 11(5-HSD1 is bi-directional, although it acts
predominantly in the reductase mode {in situ) activating B from A in contrast to the
type 2 enzyme (11[5-HSD2) found in the kidney and acting as a dehydrogenase,
inactivating B to A. Pre-receptor metabolism by 11(5-HSD1 plays a key role in
determining access of glucocorticoids to the hepatic GR. Indeed, it is evident from
humans and rodent models that tissue specific differences in enzyme activity and
expression, primarily within the liver and adipose profoundly influence homeostatic
and stress responses in health and disease. (Morton et al. 2001; Paterson et al. 2004;
Wake et al. 2003). This is exemplified in humans by the syndrome of "Apparent
Cortisone Reductase Deficiency" which is characterised by hirsutism, menstrual
irregularity in the female and gonadotrophin-independent pseudo-precocious puberty
and hyperandrogenism in male and has been attributed to adrenal activation due to
impaired hepatic Cortisol regeneration or resulting from lljl-HSDl deficiency
(Phillipou et al. 1996). Furthermore, administration of carbenoxolone, the
hemisuccinate derivative of glycyrrhetinic acid (GA) and inhibitor of hepatic 11(5-
HSD1 activity (Stewart et al. 1987) improves insulin sensitivity (Walker et al.
1995b; Andrews et al. 2002; Livingstone & Walker 2003; Livingstone et al. 2005).
The principle of peripheral reactivation of glucocorticoids by 11 (5-HSD1
regulating both HPA axis and glucocorticoid action has been elegantly demonstrated
in murine models of transgenic over or under expression of the enzyme (Masuzaki et
al. 2001b; Morton et al. 2001; Paterson et al. 2004; Kotelevtsev et al. 1996). In
disorders of insulin resistance associated with obesity the activity of hepatic 11|3-
HSD1 is often impaired, perhaps as a means of protecting the liver from the action of
excess glucocorticoids.
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Irreversible glucocorticoid inactivation in the liver is mediated by the "A-
ring reductases" (5a and 5p-reductase) which catalyse the reduction of the steroid 4-
5 double bond at the A/B ring position (Russell & Wilson 1994; Kondo et al. 1994;
Okuda & Okuda 1984). This reaction is rapidly followed by a second reductive step
catalysed by 3a-HSD resulting in the formation of tetrahydro-metabolites (Okuda &
Okuda 1984; Onishi et al. 1991). It is poorly understood what causes dysregulation
of glucocorticoid metabolic pathways in the Metabolic Syndrome; however it is
recognised that these changes contribute to increased glucocorticoid clearance rates
and hence hyperactivation of the HPA axis (Seckl et al. 2004). A change in the
balance of A-ring reduction in favour of 5a-reduction vs 5(f-reduction has been
demonstrated in insulin resistance and obesity (Livingstone et al. 2005; Andrew et
al. 2000), whereas in hypertension and fatty liver 5(3-reduction predominates (Ulick
et al. 1977; Westerbacka et al. 2003)
There is limited evidence that bile acids may act as inhibitors of hepatic
enzymes, particularly those integral to bile acid synthesis (Chiang 1998).
Bile acid biosynthesis is under both feed-forward and feed-back control. For
example, several enzymes, most notably CYP7A1 and 27-hydroxylase are regulated
by concentrations of bile acids, with increased levels resulting in suppression of
activity either by acting as competitive inhibitors or transcriptional inhibitors (Gupta
et al. 2001). Bile acids are endogenous ligands for the Farnesoid X receptor (FXR),
which regulates expression of CYP7A1 via interaction with bile acid response
elements within the promoter region of CYP7A1 (Malerod et al. 2005).
There is limited evidence that bile acids may inhibit metabolism by 5(1-
reductase and 3aHSD and also influence their transcription (Latif et al. 1990). There
have been several reports of bile acids inhibiting the activity of 11(3-HSD1 (Walker
et al. 1995a; Monder et al. 1989). The experiments presented in Chapter 3
demonstrate detailed characterisation of bile acids as regulators of activity and
transcription of enzymes involved in glucocorticoid metabolism.
76
3.2 Research Aims
The aims of the research in this chapter were
1. To investigate the impact of bile acids and bile salts on the activity of hepatic
glucocorticoid metabolising enzymes in tissue homogenates.
2. To investigate the impact of bile acids and bile salts on the activity of
glucocorticoid metabolising enzymes in cultured cells.
3. To investigate the impact of bile acids on mRNA abundance of
glucocorticoid metabolising enzymes.
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3.3 Methods and method development
Methods to measure the metabolism of glucocorticoids were developed in
vitro and in cultured cells and subsequently used to assess the inhibitory capacity of
bile acids on glucocorticoid metabolising enzymes. The procedures for bioactivity
bioassays are described in full in section 2.8. In all assays control samples containing
buffer, co-factor, corticosterone but no protein (Blank) and buffer, corticosterone,
protein but no co-factor (No CF) were included.
3.3.1 11J3-HSD1 activity in tissue homogenates
3.3.1.1 Establishing assay conditions of 11/3-HSD1
An initial validation experiment was performed in order to establish the
optimal conditions under which to perform subsequent kinetic studies. Bioactivity
assays were performed as described in section 2.84. A study of the time course of the
reaction was performed using protein (lOOpg/ml) and the velocity of the formation of
product quantified after 0, 10, 30, 60 and 90 minutes. All subsequent assays were
performed using the optimized first order conditions.
3.3.1.2 Impact ofbile acids and bile salts on activity of 11J3-HSD1
Bile acids, CDCA, CA and DCA, and Glyco- and tauro-conjugates of CDCA
were dissolved in ethanol to give stock solutions of 2M concentration from which
solutions of a range of concentrations of bile acid (final concentration x 10~2' "3'~4' "5' ~6'
"7' "8 M) were prepared by serial dilution in buffer. Bioactivity assays were
subsequently performed in the presence of bile acid or bile salt.
3.3.1.3 Enzyme kinetics of 11 (3-HSD1
A solution of corticosterone (ImM) was prepared in ethanol and standards
prepared by serial dilution in ethanol (final concentrations: 0 - 5pM). Bioactivity
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assays were performed in duplicate at each substrate concentration and activity
assessed in the absence (Control) and presence of CDCA at the approximate IC50
value (4pM).
3.3.1.4 Impact ofbile acids on 11/3-HSD1 reductase activity
11P-HSD1 reductase activity was assessed in lysates of human embryonic
kidney cells (HEK293) stably transfected with human llp-HSDl (kind gift from Dr
Scott Webster, University of Edinburgh) prepared by centrifugation (7000g, RT,
5mins). Bioactivity assays were performed in the presence of bile acids as described
in section 3.3.1.2 with following modifications. Reaction mixtures were incubated
(37°C, 30mins) with the substrate [3H]2 cortisone (20nM), the human equivalent of
11-DHB. Activity was measured by HPLC as described in section 2.91 with the
following modifications: mobile phase (water: acetonitrile: methanol; 60:10:30) and
a Reverse phase Symmetry C18 column (length 15cm, internal diameter 3.9mm, pore
size 5pm).
3.3.2 5/3-reductase activity in tissue homogenates
3.3.2.1 Establishing conditions of5/3-redutase assay
As described for llfl-HSDl an initial time course study was performed using
the bioactivity assay for 5(3-reductase as described in section 2.8.5 to establish the
optimal conditions under which to carry out subsequent kinetic studies. Bioactivity
assays were performed using 40 and lOOpg/ml protein and velocity quantified after
0, 1, 2, 4, 8 and 24 hr. Activity was assessed by HPLC as described in section 2.91.
All subsequent assays were performed using the optimized first order conditions.
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3.3.2.2 Impact of competing substrate (7a-hydroxycholestenone) on 5(3-reductase
activity
In order to investigate possible substrate competition, bioactivity assays were
performed as in 2.8.4 in the presence of 7a-hydroxycholestenone (7aHCOH; final
concentrations x 103r4' ~5' 6' ~7' "8 M; Steraloids, London, UK), an intermediate
cholesterol metabolite produced during the conversion of cholesterol to bile acids
and a substrate for 5|3-reductase.
3.3.2.3 Impact ofbile acids and bile salts on 5/3-reductase activity
Bioactivity assays were performed in the presence of endogenous bile acids
and bile salts to determine IC50 values as described in sections 3.3.1.2 and 3.3.1.3
respectively. Assays were performed using the optimised conditions established in
the validation study (section 3.3.2.1)
3.3.2.4 Enzyme kinetics of5/3-reductase
The impact of CDCA on the kinetics of the reaction catalysed by 5(3-
reductase was assessed over a range of concentrations of corticosterone as described
for 11(3-HSD1 (section 3.3.1.4).
3.3.3 3a-HSD activity in tissue homogenates
3.3.3.1 Establishing conditions of3a-HSD assay
To assess the impact of bile acids on 3a-HSD alone, conditions were
optimised for subsequent kinetic analysis. Bioactivity assays were performed as
described in section 2.8.6. Activity was measured using the substrate 5(3-
dihydrocorticosterone (5(3-DHB; 1 pM), protein (lOOpg/ml) and velocity quantified
after 5, 10, 15, 30, 60 and 120 minutes. Standards of 5(3-THB (0, 50, 100, 200, 400,
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500, 600, 800, 1000 ng/ml) were included in each assay. An internal standard of epi-
THB (250ng) was added to each sample prior to concentrating the samples with OFN
(60°C). Samples and standards were subsequently derivatised and quantified by GC-
MS as described fully in section 2.9.2.
3.3.3.2 Impact of bile acids and bile salts on 3a-HSD activity
Bioactivity assays were performed in the presence of bile acids and bile salts
at the approximate IC50 value calculated for 5(3-reductase. Bile acids and bile salts
were prepared as described in sections 3.3.1.3 and 3.3.1.4 respectively and
bioactivity assays performed using the optimised conditions for 3a-HSD established
in section 3.3.3.1.
3.3.4 5a-Reductase 1 activity in cultured rat hepatoma cells
3.3.4.1 Screening ofhepatoma cell lines for genes of interest
Due to the instability of hepatic 5a-reductase 1 activity in vitro (Eicheler et
al. 1995), activity cannot be assessed in tissue homogenates and so a cell culture was
utilized to examine the effect of bile acids on the 5a-reduction of corticosterone. As
with 5(3-reductase, the sequential reduction of corticosterone to 5a-THB catalysed by
5a-reductase 1 and 3a-HSD was assessed. Three hepatoma cell lines were screened
to determine the presence of mRNA for 5a-reductase 1 and 3a-HSD; rat H4IIE and
2SFAZA and human HepG2 cells. RNA was extracted from cells with Trizol® as
described in section 2.11.1. RT-PCR performed with primers for 5a-reductase 1 and
3a-HSD (rat for H4IIE and 2SFAZA and human for HepG2) as described fully in
section 2.11.3.
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3.3.4.2 Establishing conditions of5a-reductase 1 activity
Activity of 5a-reductase 1 was quantified in H4IIE cells maintained as
described in section 2.10. An initial time course study was performed to ascertain the
optimal conditions. Cells were washed in PBS (1M) and fresh media applied 1 hour
prior to application of the substrate. Corticosterone (990pM) with 3[H]4-
corticosterone (lOpM) were prepared in ethanol giving a final concentration of ImM.
Cells were treated with corticosterone (lpM) and media (1ml) removed at 1, 2, 4, 8
and 16 hours. Steroids were extracted from media by passing through Sep-pak
columns (lg) pre-conditioned with methanol (5ml) followed by water (5ml). The
column was washed with water (5ml) and steroids eluted with methanol (5ml). The
resulting solvent was removed under a stream of OFN (60°C). The dried residue was
dissolved in ethyl acetate (2.5ml) and water (200pi) and vortexed thoroughly. The
upper organic phase containing the steroids was removed and dried under OFN
(60°C). Samples and standards were subsequently derivatised and products
quantified by GC-MS as described in 2.9.2.
3.3.4.3 Impact ofbile acids on 5a-reductase 1 activity
Cells were prepared as described in section 3.3.4.2. Bile acids (lOOmM;
Sigma Aldrich, UK) were prepared in ethanol as described in section 3.3.1.2 and the
cells incubated (37°C, 2 hr) in the presence of corticosterone (lpM) with or without
bile acids (lOOpM; 1:1000 dilution in media; Control cells were treated with ethanol
which always <1% v/v). Media was removed and steroids extracted using Sep-pak
columns as described in section 3.3.1.2. Samples and standards were subsequently
derivatised and activity assessed by GC-MS as described in 2.9.2.
3.3.4.4 3a—HSD activity in cultured cells
An initial time course study was performed in order to establish the optimum
conditions under which to assess enzyme activity. Cells were prepared as described
in section 3.3.4.2 and incubated with substrate 5(3-DHB (lpM prepared in ethanol).
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Media (1ml) was harvested after 15, 30, 45, 20, 60, 90 and 120 minutes and steroids
extracted using pre-conditioned Sep-pak columns following addition of the internal
standard epi-THB (250ng) as described in section 3.3.1.2. Samples and standards
were subsequently derivatised and products quantified by GC-MS as described in
section 2.9.2.
3.3.4.5 Impact ofbile acids on 3a-HSD activity in cultured cells
The impact of bile acids on 3a-HSD activity was assessed as described for
5a-reductase (section 3.342) with the following amendments. Bile acids (ImM;
Sigma Aldrich, UK) were prepared in ethanol and the cells incubated (37°C, 15
mins) in the presence of 5|3-DHB (lpM) and bile acids (lOOpM). Media was
removed and passed through Sep-pak columns following addition of the internal
standard epi-THB (250ng) as described in section 3.3.12. Samples and standards
were subsequently derivatised and activity assessed by GC-MS as described in
section 2.9.2.
3.3.5 Impact ofbile acids on gene transcription
H4IIE cells were maintained as described in section 2.10. On the day of the
experiment cells were washed in PBS (1M) and fresh media applied 1 hour prior to
application of the bile acid. Bile acids were prepared in ethanol (lOOmM) and
subsequently dissolved in the media (1:1000 dilution). Cells were therefore incubated
with bile acids (lOOpM; 37°C, 16 hr). Control cells were incubated with ethanol
(<1% v/v) and maintained as with bile acids treated cells. Following incubation, the
media was removed, the cells washed twice in PBS (1M) to remove any residual
media/bile acid and RNA extracted using Trizol® as described in section 2.11.1.
Abundance of gene transcripts was assessed using Taqman® real-time PCR (2.13.1)
with rat primer/probe sets specific for 11 (THSD1, 5|3-reductase, 5a-reductase 1 and
3a-HSD. Typical CT values for llp-HSDl and 5|3-reductase were 32 cycles and for
5a-reductase and 3a-HSD 28 cycles.
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3.3.6 Data analysis
The velocity of product generation is described by the Michealis Menten
equation (Equation 1), frequently presented as the reciprocal plot of 1/V versus 1/[S].
This Tineweaver -Burk plot yields a straight line with an intercept of 1/Vmax and a
slope ofKm/Vmax (2).
^ V = Vmax [S]
Km + [S]
Equation 1 Michealis Menten equation, describing enzyme velocity as a function of time, where V =
velocity of the reaction, [S] = substrate concentration, Vmax = maximum velocity and Km= the
Michaelis constant or concentration of substrate required to achieve half-maximum velocity
(2) J_ = Km + _L
V Vmax [S] Vmax
Equation 2 Lineweaver Burke double reciprocal plot of enzyme kinetics. Competitive inhibition
results in a reduction in Km but no change in Vmax. Non-competitive inhibition causes a change in
Vmax but no change in Km.
Kinetic parameters of Vmax and Km were calculated using GraphPad Prism Version
4.0. Data were fitted to the Michaelis-Menten equation and an equation of
Competitive Inhibition (3)




For all experiments using animal tissues individual experiments were
conducted using tissues from 6 independent animals (unless otherwise stated). Each
assay was performed duplicate and the mean of each duplicate taken as the final
value for that individual animal. For all experiments using cultured cell lines,
indivdual experiments were performed using cells from 3 separate passages. Each
assay was performed 6 times and the mean of these 6 cultures taken as the final value
for that individual cell passage. All future analysis was performed using the mean of
these replicates. The data in each figure represents the mean ± standard error of the
mean (SEM). Statistical significance was determined using one way or repeated
measure analysis of variance (ANOVA) followed by post hoc least squared
difference test for all groups. All analysis was performed using Statistica (Version 9)






Figure 3.1 shows representative radio chromatograms of [3H]4 corticosterone
(B) and the product of lip-HSDl dehydrogenase activity, [3H]4ll-DHC (A).
Conversion was not apparent in either blank or no co-factor control samples
indicating the absence of non-enzymatic reactions (blank) or background reactions
within the enzyme preparation (e.g. due to endogenous co-factor). Reaction products




Figure 3.1 Radiochromatograms demonstrating peaks corresponding to [ H]4 B (Rt 25.9 mins) and
[ H]4 A (Rt 17.5 mins) (A). Products were not are detected in control samples lacking protein (B).
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3.4.1.2 Time course of 11J3-HSD1 dehydrogenase activity
A study of the time course conversion of [3H]4B to [3H]4A catalysed by 11(3-
HSD1 is shown in Figure 3.2. During the initial phase of an enzymatic reaction the
reaction proceeds by first order kinetics where velocity is directly proportional to
time. Based on this study, all subsequent assays were preformed using 100p,g/ml




Figure 3.2 Time course of production of rH]4A with time in tissue homogenates. Bioactivity assays
were performed in the presence of lOOpg/ml protein, co-factor NADP+ and a substrate concentraion of
luM B. Products were quantified by HPLC as data expressed as the % conversion of [3H]4 B to
[3H]4 A. Data are mean±SEM, n=6
3.4.1.3 Impact ofbile acids on 11J3-HSD1 dehydrogenase activity
All bile acids tested inhibited 11(3-HSD1 dehydrogenase activity as shown by
a dose-dependent reduction in formation of [3H]4A (Figure 3.3A). Inhibition
constants (IC50 values), which represent the concentration of inhibitor which reduces
enzyme activity to half that of the maximum, were calculated using Graphpad Prism
software. CDCA was the most potent inhibitor of 11|3-HSD1 dehydrogenase activity,
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with an order of potency CDCA>CA>DCA (Table 3.1). As CDCA was the most
potent inhibitor, all subsequent kinetic analysis was performed with this bile acid.





Figure 3.3 A Impact of bile acids on 11 (3-HSD1 dehydrogenase activity in rat liver homogenates.
Chenodeoxycholic acid (CDCA; filled square), cholic acid (CA; filled triangle) and the secondary bile
acid deoxycholic acid (DCA; open circle) cause a dose-dependent reduction in lip-HSDl






Table 3.1 Concentration (1C50) of inhibitor causing 50% inhibition of the rate of the reaction. Data
are mean; n=6;*p<0.05 vs CDCA; "p<0.05 CA vs DCA.
88
3.4.1.4 Impact ofbile salts on 11/3-HSD1 dehydrogenase activity
Taurine and glycine conjugates of CDCA were equally as potent as the free



















Figure 3.3 B Impact of bile salts on llfi-HSDl dehydrogenase activity in rat liver homogenates.
Glycine (GCDCA; open circle) and taurine (TCDCA; cross) conjugates of CDCA were equally as








Table 3.2 Concentration (IC50) of inhibitor causing 50% inhibition of the rate of llp-HSDl
dehydrogenase activity. Data are mean ± SEM; n=6; p=ns.
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3.4.1.5 Enzyme kinetics of11J3-HSD1 dehydrogenase activity
Parameters of Km and Vmax were calculated using Michaelis Menten
kinetics (Figure 3.4 A).
[S] (pmol/l)
Figure 3.4A Michaelis Menten plot demonstrating inhibition of 1 tp-HSDl dehydrogenase activity by
CDCA. Data are mean±SEM; n=6; Control (filled circle); CDCA (open square).
Figure 3.4 B illustrates the Lineweaver-Burke double reciprocal plot demonstrating
that CDCA acts as competitive inhibitor of enzyme activity
-1
1/[S]nM
Figure 3.4 B Lineweaver burke plot demonstrating inhibition of 1 lp-HSDl by CDCA. CDCA acts as
a competitive inhibitor as shown by an increase in Km but not in Vmax. Data are mean ± SEM; n=6;
Control (filled circle); CDCA (open square).
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Using a global fit model of competitive inhibition, CDCA increased the Km of the
reaction but did not alter Vmax (Table 3.3) confirming that CDCA is a competitive
inhibitor of lip-HSDl dehydrogenase activity.
11P-HSD1
Vmax (nmoles/mg/hr) 3.6±1.8 v 3.8±1.2
Km(pM) 3.2±1.0 v 12.8±6.1*
Ki(pM) 2.39±0.23
R2 of curve fit 0.995
Table 3.3 Inhibitory kinetics of CDCA on dehydrogenase activity of 11(3-HSD1 measured in rat liver
cytosol. CDCA acted as a competitive inhibitor as shown by an increase in Km but not in Vmax. Data
are mean ± SEM; n=6; *p<0.05 vs Control.
3.4.1.6 Impact ofbile acids on 11 (3-HSD1 reductase activity
Reductase activity of 11(3-HSD1 measured in HEK293 cell stably
transfected with human 11(3-HSD1. Activity assays were preformed using
lysates prepared by centrifugation. Reductase activity was significantly
reduced in the presence of the primary bile acid chenodeoxcholic acid
(CDCA). Inhibition occurred in a dose dependent manner with an ICso value of
3.45pM, (Figure 3.5). Using a global fit model of inhibition, CDCA was a









Figure 3.5 Impact of chenodeoxycholic acid (CDCA) on 11P-HSD1 reductase activity. CDCA acted
as a potent inhibitor of lip-HSDl reductase activity in HEK293 cell lysates in the presence of co-




Figure 3.6 A shows representative radiochromatograms of peaks
corresponding to [ HJaB and its 5(3-reduced product [ H]4 5|3-THB. Reaction




Figure 3.6 Radiochromatograms demonstrating peaks corresponding to [3H]4B (Rt 30.2 min)and [3H]4
5P-THB (Rt 42.5 min). Products were not detected in control samples lacking co-factor NADPH (B).
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3.4.2.2 Time course of5^-reductase activity
Figure 3.7 represents the production of 5(3-tetrahydrocorticosterone (5(3-
THB) from corticosterone (B) in rat liver cytosol with time. For subsequent kinetic
studies lOOpg/ml protein was used with an incubation time of 4 hr. These conditions
ensured that activity was measured during the initial linear phase of the reaction
where reaction velocity is directly proportional to protein concentration and time.
Time (Hr)
Figure 3.7 Representative time course of production of [3H]45(3-THB with time. Bioactivity assays
were performed in the presence of lOOpg/m) protein isolated from 6 animals, co-factor NADPH and
lpM substrate (B) for 4 hr. Activity were quantified by HPLC and data expressed as the % conversion
of [3H]4B to [3H]45(3-THB. Data are mean±SEM, n=6
3.4.2.3 Impact ofbile acids on 5(3-reductase activity
The activity of 5(3-reductase was significantly reduced in the presence of all
bile acids tested (Figure 3.8A). Inhibition occurred in a dose-dependent manner with
an order of potency CDCA>DCA>CA. Calculation of the IC50 value for each bile






Figure 3.8 A 8A Impact of bile acids on enzyme 5(3-reductase activity. Chenodeoxycholic acid
(CDCA; fdled square), cholic acid (CA; filled triangle) and the secondary bile acid deoxycholic acid
(DCA; open circle) caused a dose-dependent reduction in 5P-reductase activity measured in rat liver





Table 3.4 Concentration (IC50) of inhibitor causing 50% inhibition of the rate of the reaction
catalysed by 5P-reductase. Data are mean ± SEM; n=6;*p<0.05 vs CDCA; #p<0.05 vs DCA.
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3.4.2.4 Impact ofbile salts on 5(3-reductase activity
Conjugation with glycine or taurine did not alter the inhibitory potency of















Figure 3.8 B Impact of bile acids and bile salts on 5P-reductase enzyme activity. GCDCA (open
circle) and TCDCA (cross) were equally as potent as unconjugated free CDCA (filled square) as





Table 3.5 Concentration (IC50) of inhibitor causing 50% inhibition of the rate of the reaction ctalysed
by 5P-reductase. Data are mean ± SEM; n=6;p=ns.
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3.4.2.5 Enzyme kinetics of5(3-reductase
Figure 3.9 demonstrates that CDCA acts as a competitive inhibitor of 5P-
reductase activity (Figure 3.9A). Competitive inhibition was confirmed by a global











Figure 3.9 A Michaelis Menten plot demonstrating inhibition of 5P-reductase by CDCA. Data are









Figure 3.9 B Lineweaver Burke plot demonstrating inhibition of 5p-reductase by CDCA. Data are
mean ± SEM; n=6.
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Global fit modelling of competitive inhibition from which the inhibitory constant
(Ki) could be calculated demonstrated that CDCA acts as a competitive inhibitor of
5(3-reductase (Table 3.6).
5 (3-reductase
Vmax (nmoles/mg/hr) 27.6±.04 vs 15.4±0.8
Km(pM) 10.7±0.8 vsll.9±1.0
Ki(pM) 9.19±0.4
R2 of curve fit 0.998
Table 3.6 Inhibitory kinetics ofCDCA on activity of 5P-reductase. Data are mean±SEM; n=6
3.4.2.6 Impact of 7a-hydroxycholestenone on 5(3-reductase activity
7a-Hydroxycholestenone (7a-HCHO) is an intermediate cholesterol
metabolite in the catabolic breakdown of cholesterol to bile acids, and a substrate of
5p-reductase. 7a-HCHO did not influence activity of 5[3-reductase at any of the








vP 0-| 1 1 1 1 1 1 1
-10 -9 -8 -7 -6 -5 -4 -3
Figure 3.10 Impact of 7aHCOH on activity of steroid 5p-reductase. 5P-reductase activity was
determined by measuring the conversion of [,H4]B to [3H4]5P-THB in rat liver cytosol in the absence
(control) and presence of 7aHCOH . Data are expressed as mean ± SEM; n = 6 per group.
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3.4.3 3a-HSD
3.4.3.1 Mass chromatography of3a-HSD
Figure 3.11 represent a mass chromatogram showing methoxyamine-
trimethylsilimizadole (MO-TMS) derivatives of corticosterone (B), the 5a- and 50-
reduced metabolites of corticosterone (5a- and 50-THB) and the 1 la-isomer epi-
TFIB which was used as an internal standard. The stereo epi-isomer is of the same
mass as both 5a- and 50-THB but has a different retention time.
Time (min)
Figure 3.11 Mass chromatogram of methoxyamine-trimethylsilimizadole (MO-TMS) derivatives (m/z
564) 5a- and 5p-reduced corticosterone. 5a-THB = 5a-tetrahydrocorticosterone Rt 12.59 min, 50-
THB =5P-tetrahydrocorticosterone Rt 13.00 min, epi-THB = internal standard Rt 12.75 min. RT =
retention time in minutes.
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3.4.3.2 Time course of3a-HSD activity
Figure 3.12 represents the production 5p-THB with time by 3aHSD. Product
accumulated in a linear manner in relation to velocity until 40 min when reaction
velocity began to plateau indicating that either substrate was becoming depleted or
that there was end-product inhibition of the reaction. Conversion was not apparent in
the blank and no co-factor controls. As such all subsequent assays were performed
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Figure 3.12 Representative time course of production of 5(3-THB from 5f5-DHB by 3aHSD in rat
liver cytosol. Activity assays were performed in the presence of 50|ig/ml protein, co-factor NADPH
and lpM 5P-DHB substrate. Products were quantified by GC-MS and data expressed as the %
conversion of 5(3-DHB to 5(3-THB. Data are mean±SEM, n=6 per group
3.4.3.3 Impact of bile acids and bile salts on 3a-HSD activity
The presence of bile acids and bile salts did not influence activity of 3a-HSD
alone (Figure 3.13). These findings indicate that the inhibitory potential of bile acids
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demonstrated in 3.5 is mediated predominantly through 5(3-reductase. As such




Figure 3.13 Lack of effects of bile acids on activity of 3a-HSD. 5|3-DHB (lpM) was incubated with
rat liver cytosol in the presence of chenodeoxycholic acid (CDCA), TCDCA and GCDCA (10"6M).
3a-HSD activity was determined by measuring the conversion of 5(3-DHB to 5P-THB in the absence
(control) and presence of bile acids. Data are expressed as mean ± SEM; n = 6 per group; p=ns.
3.4.4 5a-Reductase 1
3.4.4.1 PCR screening ofhepatoma cell lines
Due to the instability of hepatic 5a-reductase 1 activity in disrupted cells in
vitro, hepatic cell lines (Table 3.7) were screened to identify a hepatoma cell line
expressing this gene. All cell lines expressed low levels of 11 (3-HSD1 and 5(3-
reductase mRNA, with variable levels of abundance ofmRNA of 5a-reductase 1 and
3a-HSD (Table 3.7). The H41IE cell line, a rat hepatoma cell line expressed highest
levels ofmRNA both of 5a-reductase 1 and 3a-HSD and was used subsequently to
assess the impact of bile acids on 5a-reductase 1 activity and gene transcription.
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Species llp-HSDl 5p-reductase 5a-reductase 1 3cc-HSD
H4IIE rat + + ++ +++
2SFAZA rat + + + ++
HepG2 human + + + ++
Table 3.7 RT-PCR screening of hepatoma cell lines. RNA (1 pg) was reverse transcribed and
subjected to PCR using specific primer sequences (section 2.11,3)Abundance is expressed semi-





Figure 3.14 RT-PCR gel of enzyme expression in H4IIE cells. RT-PCR was performed on RNA
isolated from H4I1E cells to establish presence or absence of enzymes.
3.4.4.2 Time course of5a-reductase 1 activity in cultured cells
A mass chromatogram demonstrating a peak corresponding to the MO-TMS
derivative of 5a-THB with m/z 564 was shown previously in figure 3.11. The
activity of 5a-reductase 1, assessed by the velocity of conversion of corticosterone to
5a-tetrahyrocorticosterone (5a-THB), was linear over a 4 hour period with product
accumulation directly proportional to time (Figure 3.15). The velocity plateaued at
after 8 hours suggesting that either substrate became depleted or there was end
product inhibition. A 2 hour incubation period was therefore selected for all
subsequent assays
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Figure 3.15 Representative time course of production of 5a-THB from B by 5a-reductase 1 and
3aHSD activity in H4IIE cells. Cells were incubated in the presence of corticosterone (IpM).
Products were quantified by GC-MS and expressed as the % conversion of B to 5|3-THB. Data are
mcan±SEM of 6 assays performed using cells from 3 independent passages.
3.4.4.3 Impact ofbile acids on 5a-reductase 1 activity in cultured cells
Bile acids did not influence the rate of 5a-reduction of corticosterone in





Figure 3.16 Impact of bile acids on 5a-reductase 1 activity in rat hepatoma H4IIE cells. Cells were
incubated in the presence of chenodeoxycholic acid (CDCA), glyco-CDCA (GCDCA) and tauro-
CDCA (TCDCA) (lOOpM) and substrate corticosterone (lpM). The conversion of corticosterone to
5a-THB is expressed relative to control (100%). Data are mean±SEM; n=6, p=ns.
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3.4.5 Impact ofbile acids on gene transcription
The transcription of cholesterol 7a-hydroxylase (CYP7A1) is repressed by
bile acids (Chiang 1998). CYP7A1 was therefore used as a positive control. As
anticipated CYP7A1 transcript abundance was suppressed in the presence of CDCA
and the bile salts (GCDCA and TCDCA)(Figure 3.17). CDCA and glyco- and tauro-
conjugates of CDCA did not alter abundance of 5p-reductase (Figure 3.18 A), 5a-
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Figure 3.17 Effect of bile acids and bile salts on transcription of CYP7A1. H4IIE cells were incubated
in the presence of CDCA, GCDCA and TCDCA (lOOpM) for 16 hours. The abundance of gene
transcript was quantified by Taqman® real time PCR. mRNA abundance is expressed as a ratio to the
house keeping gene cyclophilin A. Values are Mean±SEM. Each experiment was performed in


















































Figure 3.18 Lack of effect of bile acids and bile salts on transcription of 5p-reductase (A), 5a-
reductase 1 (B), 3a-HSD (C) and lip-HSDl (D) mRNA. H4IIE cells were incubated in the presence
of CDCA, GCDCA and TCDCA (lOOpMJ for 16 hours. The abundance of gene transcript was
quantified by Taqman® real time PCR. mRNA abundance is expressed as a ratio to the house keeping
gene cyclophilin A. Values are Mean±SEM. Each experiment was performed in triplicate.
105
3.5 Discussion
In this chapter, data are presented showing that the primary bile acids CDCA
and CA and the secondary bile acid DCA are competitive inhibitors of the
glucocorticoid metabolising enzymes, 5|3-reductase and lip-HSDl dehydrogenase in
hepatic tissue homogenates and of lip-HSDl reductase in cell lysates. Conjugation
of the most potent inhibitor CDCA with glycine or taurine did not alter the inhibitory
potency of CDCA. In contrast to our finding with 5(f-reductase and lip-HSDl, bile
acids did not inhibit 5a-reductase 1 activity in cultured cells or 3a-HSD activity in
tissue homogenates. Enzyme inhibition occurred at a post-transcriptional level as bile
acids, both free and conjugated did not reduce transcript abundance of 5p-reductase,
5a-reductase, 3a-HSD or lip-HSDl.
Chenodeoxycholic acid possesses a 3a,5|3-ring A steroidal configuration
similar to other known competitive inhibitors of lip-HSDl including glycyrrhetinic
acid (GA)(Monder et al. 1989; Morris et al. 1992) and carbenoxolone
(CBX)(Andrews et al. 2003; Livingstone & Walker 2003). The competitive
inhibition of lip-HSDl exerted by bile acids is therefore as predicted. A key
catalytic residue motif, Y-S-A-S-K is present within the core structure of lip-HSDl
and the crystal structure of human 11P-HSD1 has recently been reported (Hosfield et
al. 2005).This motif along with the recently identified essential interactions between
Asn-111 and the active site residues are highly conserved across the Short Chain
Dehydrogenase Reductase (SDR) family of enzymes to which lip-HSDl belongs
(Obeyesekere et al. 1998). These highly conserved residues play a fundamental role
in maintenance of the active site configuration by orientating the substrate/inhibitor
within the active site, and catalysing proton transfer to and from reduced and
oxidised reaction intermediates (Shafqat et al. 2003). Site-directed mutagenesis of
residues within the active site of the enzyme diminishes enzyme activity
(Obeyesekere et al. 1998). The ds-orientated A/B ring juncture of CDCA also gives
the molecule flexibility in a similar manner to the steroidal detergent CHAPS
(Lakshmi & Monder 1985b). Studies have demonstrated that this detergent is
accommodated within the active site of lip-HSDl via its A-ring which is localised
to the catalytic region of the enzyme. This is the opposite conformation to
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glucocorticoids in which the D-ring penetrates the active site of the enzyme
suggesting that bile acids may bind in the reverse orientation to the natural ligand
within the active site of the enzyme in similar manner to that demonstrated between
ursodeoxycholic acid and 3a-HSD (Jin et al. 2001).
The inhibitory potency of CDCA has also been reported by Lakshmi and
Monder 1985, who utilised the detergent like properties of bile acids to disrupt lipid
membranes and purify lip-HSDl protein (Lakshmi & Monder 1985a). The latency
observed in Figure 3.3A where enzyme activity was above control levels in the
presence of low concentrations of bile acids prior to inhibition is similar to that
described for 11(3-HSD oxidase activity on disruption of the lipid environment
(Lakshmi & Monder 1985a). CDCA, one of the two primary acids and the most
prevalent in the rat, was the most potent inhibitor of 11(3-HSD1 inhibiting both
dehydrogenase and reductase activity of 11(3-HSD1 with equal potency. It is unlikely
that these effects are due to the detergent properties of bile acids as CDCA was
significantly more potent that either CA or DCA. Using a global fit model, CDCA
was a competitive inhibitor of 11(3-HSD1 (dehydrogenase and reductase activity).
In similar manner to 11(3-HSD1, bile acids acted as potent competitive
inhibitors of 5(3-reductase, a member of the AKR superfamily (AKR1D). Although
very little is known about this enzyme, limited data have shown that bile acids can
act as inhibitors of 5(l-reduction of aldosterone (Latif et al. 1990) with the same
order of potency for inhibition of 5(3-reductase (CDCA<DCA<CA) as demonstrated
for glucocorticoids here. In addition, recent purification and protein modelling of rat
3a-HSD (AKR1C9) may provide some insight into the nature of the binding pocket
and catalysis of this enzyme and other associated enzymes (Jez et al. 1996). Rat liver
3a-HSD (AKR1C9) is highly homologous to steroid 5(3-reductase. Indeed a single
point mutation (H117E) within a conserved catalytic tetrad (Tyr55, Lys84, Hisll7
and Asp50)(Bennett et al. 1997) of AKR1C9 introduces 5|3-reductase activity (Jez &
Penning 1998a), suggesting the two genes are the result of divergent evolution. One
may anticipate that bile acids interact with 5(3-reductase in a similar manner. The
binding pocket of AKR1C9 has been modelled by crystaling with ursodeoxycholate.
This bile acid binds backwards relative to testosterone in the binding pocket of
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AKR1C9 with the A-rings of the two steroids at the opposite end of the pocket (Jin
et al. 2001). Interaction between the catalytic tetrad of 5p-reductase and the
carboxylate moiety of the bile acids may account for the inhibition of enzyme
activity seen in vitro. In addition, if the A-ring is involved in inhibition (Jin et al.
2001) it is understandable why conjugation with either glycine or taurine via an
amide bond at position 24 of the D-ring did not impact upon the inhibitory potential
of the bile acids as, this should be extruded from the active site of the enzyme.
Rat 3a-HSD/DD (AKR1C9) is the single dominant species of 3a-HSD/DD
mRNA present in the rat liver (Lin et al. 1999) and has 67% sequence identity at the
protein level with the four human isoforms of 3a-HSD. AKR1C9 is frequently used
as model for the human AKR1C subfamily (Pawlowski et al. 1991). Indeed,
AKR1C1 represents the human orthologue of rat AKR1C9. AKR1C2 (3aHSDIII) is
a bile acid binding protein and the protein structure has been determined by
crystallography with UDCA (Jez & Penning 1998b; Jin et al. 2001). Co-factor and
substrate bind two distinct highly conserved active sites within the protein with the
nicotinamide moiety of the co-factor positioned at the core of the (a/(5)8 barrel and
the carboxylate moiety of the bile acid anchored deeply in the core active site of the
protein by interactions between Tyr55 and Hisll7 (Penning et al. 2004). These
residues along with Lys84 and Asp50 form a catalytic tetrad which acts as a "proton-
relay" in which Tyr55 acts as a general acid/base catalyst (Schlegel et al. 1998).
Despite these similarities, by comparing the steroid binding pockets of AKR1C2 and
AKR1C9 one sees that AKR1C2 possess a relatively large substrate channel
allowing the steroid a degree of freedom to occupy several different orientations
within the active site of the enzyme, whilst still maintaining contact with the
hydrophobic residues which line the binding pocket. In contrast, the steroid binding
cavity of AKR1C9 appears to limit the entry of substrates, which may therefore
restrict interaction between inhibitor and enzyme (Jin et al. 2001). Indeed, the
position in AKR1C9 corresponding to the oxyanion hole formed by the tetrad of
AKR1C2 into which ursodeoxycholate binds is occupied by the C3 ketone of
testosterone in the AKR1C9 complex (Heredia et al. 2003) suggesting different
moieties may be involved in steroid and bile acid interaction within the rat and
human isosforms, perhaps explaining the lack of inhibition observed. The lack of
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inhibition may also be related to a difference in one of the key amino acid residues
within the catalytic tetrad (Tyr24, Val54 and Trp227), highly conserved in the AKR
superfamily and thought to be essential for catalytic efficiency of AKR1C9 (Jin et al.
2001). In the rat enzyme, position 54 is a Leu rather than the Val in human AKR1C2.
The position of Val54 appears to be critical for this inhibition and is thought to
partially explain the functional differences between AKR1C1 and AKR1C2
(Matsuura et al. 1997) and along with Tyr24 and Trp227 plays a crucial role in the
binding of UDCA within the oxyanion hole of AKR1C2. It is therefore possible that
the amino acid substitution may explain why rat 3aHSD is not inhibited by bile acids
and also suggests that the human orthologue AKR1C1 may not be inhibited.
5(3-Reductase catalyses the rate determining step in the dual reduction of
glucocorticoids to their 5(l-tetrahydro metabolites. All members of the AKR
superfamily follow a sequential ordered bi-bi mechanism in which co-factor binds
first and leaves last (Penning 1999). Although the binding and release of co-factor
are thought to be the rate determining steps for overall catalysis of aldehyde and
aldose reductase reactions (Grimshaw et al. 1995), AKR1C2 and AKR1C9 lack a
salt-link "safety-belt" which is present in members of the aldehyde reductase
(AKR1A) and aldose reductase (AKR1B) subfamilies (Jin et al. 2001). As such, the
conformational changes associated with co-factor binding may be only partially rate-
determining. Furthermore, as bile acids were shown to act as competitive inhibitors
of enzyme activity, it is unlikely that co-factor binding will interfere with substrate
binding. Alternatively, it is possible that 3a-HSD has a higher affinity for the
substrate 5(3-DHB than for bile acids. In support of this, activity of 3a-HSD was 16
fold faster than that of 5(3-reductase in tissue homogenates, with standard assay times
of 15 minutes and 4 hours respectively. Conversion of 5|3-DHB to 5(3-THB and a
rapid on-off time of substrate/enzyme may therefore limit access of bile acid to the
active site of the enzyme.
Due to the instability of 5a-reductase 1 in hepatic tissue preparations
(Eicheler et al. 1995), the activity of 5a-reductase activity was assessed in the H4IIE
hepatoma cell line which expressed only the type 1 isozyme in keeping with rat liver.
Although 5(1-reductase was also expressed within this cell line its abundance was
much less. One may have anticipated a compensatory up-regulation in the velocity of
109
5a-reductase 1 in the presence of more substrate due to inhibition of 513-reductase.
However it is hard to interpret this interaction with such stark differences in
abundance in this cell line. These differences were demonstrated by cell based
activity assays where only 4% corticosterone was metabolised by 5(3-reductase
within a 24 hour period (data not shown), whilst nearly 40% corticosterone had been
reduced by 5a-reductase 1 within the same time span.
In cultured cells it was also possible to investigate the impact of bile acids on
transcription of the 11(1-HSD1, 5a- and 5(3-reductase 1 and 3a-HSD. Several
enzymes involved in the catabolism of cholesterol to bile acids including CYP7A1
and CYP8B1 are regulated at the level of gene transcription by bile acids (Chiang
1998). In support of this, CYP7A1 mRNA abundance was significantly reduced in
H4IIE cells treated with CDCA indicating that the bile acid transporters are present
within this cell line. Despite this, transcript abundance of 5|3-reductase, 5a-reductase
1, 3a-HSD or lip-HSDl were not altered following bile acid treatment. In recent
years, bile acids have been identified as endogenous ligands for several nuclear
hormone receptors including the liver X receptor a (LXRa;NRlH3)(Willy et al.
1995) and the famesoid X receptor (FXR;NR1H4) (Forman et al. 1995). Several bile
acids including CDCA and its glycine and taurine conjugates bind and activate FXR
at physiologic concentrations (Malerod et al. 2005; Miyata et al. 2005). Moreover,
Makishima et al 1999 demonstrated that the rank order in which bile acids activate
FXR correlates with the repression of CYP7A1 in a hepatocyte-derived cell line with
CDCA being significantly more potent than DCA, CA or the tertiary bile acid
lithocholic acid (LCA)(Makishima et al. 1999). These findings indicate that FXR
plays a key role in the negative effect of bile acids on gene expression. Although
FXR response elements (FXRE's) have been identified in the promoter regions of
both mouse and human forms of the intestinal bile-acid binding protein (I-BABP)
which is stimulated by bile acids, these elements were not identified in the promoter
region of CYP7A1 (Landrier et al. 2003). It has now been demonstrated that bile
acids exert their inhibitory effects on CYP7A1 gene expression via indirect
mechanism. FXR regulates the expression of small heterodimer partner 1 (SHP-1),
an atypical orphan member of the nuclear receptor which lacks a functional DNA
binding domain. SHP-1 interacts and represses the transcriptional activities of other
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nuclear receptors including the liver receptor homolog 1 (LRH-1; NR5A2), an
orphan receptor that binds as a monomer to response elements within the promoter of
CYP7A1 inducing transcription (Goodwin B et al. 2000). A potential FXR response
element has been identified within the up-stream promoter (-15 to +30) of 5(1-
reductase (unpublished data, O'Flaherty 2006). Recent data would suggest that this
response element is expressed at low levels in 5(l-reductase, as use of the specific
FXR agonist GW4064 at high concentrations was required inorder to induce
activation.
Thus bile acids inhibit the activity of glucocorticoid metabolising enzymes as
competitive inhibitors at a post transcriptional level. The findings in this chapter
would suggest that direct interaction with the functional protein preventing
interaction of substrate within the active site of the enzyme is the most likely
explanation for the enzyme inhibition. The data presented in this chapter however is
performed using two different in vitro systems and therefore it is inappropriate to
extrapolate these findings to an in vivo system where a myriad of factors may
influence enzyme activity and expression. It is therefore essential to study the effects
of bile acids on glucocorticoid metabolism in an in vivo model such as the rat.
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Chapter 4
Effect of increased concentrations of bile acids on




Bile acids represent the predominant means of eliminating excess cholesterol
from the body and play an essential role in facilitating the absorption, transportation
and elimination of lipid soluble vitamins and dietary fats (Chiang 1998). In excess
however, bile acids can be highly cytotoxic leading to progressive liver disease. Bile
acid levels within the circulation are under feed-forward and feed-back control
resulting in the induction of genes involved in their detoxification and /or elimination
e.g. cytochrome P4503A (CYP3A) and suppression of those involved bile acid
biosynthesis e.g. CYP7A1. In addition, bile acids act as signaling molecules and play
a pivotal role in regulating cholesterol homeostasis in mammals (Parks et al. 1999).
Bile acids and oxysterols derived from cholesterol act as potent agonists for the
nuclear receptors FXR and LXR respectively thus regulating bile acid, cholesterol
and triglyceride metabolism in order to maintain lipid homeostasis (Lu et al. 2000;
Repa & Mangelsdorf 1999).
In Chapter 3, bile acids and bile salts were shown to act as competitive
inhibitors of 5p-reductase an enzyme involved in cholesterol catabolism and
glucocorticoid metabolism, and also of llfl-HSDl (reductase and dehydrogenase) in
tissue sub-fractions. However, these studies were preformed in vitro and therefore do
not address potential interactions with factors within the surrounding physiological
environment which can have profound effects upon enzyme activity. In this Chapter
experiments were performed to test the hypothesis that bile acids inhibit the activity
of hepatic glucocorticoid metabolism in vivo. Alterations in glucocorticoid
metabolism influence HPA axis activation (Harris et al 2001) and the regulation of
hepatic homeostatic pathways regulated by glucocorticoids e.g. TAT and PEPCK.
Enhanced glucocorticoid clearance by the A-ring reductase in obese humans and
rodent models of obesity are thought to induce compensatory activation of the HPA
axis (Rask et al. 2001; Livingstone et al. 2000).
Two approaches were used to increase bile acids levels in a rodent model.
The first approach was to increase the bile acid pool via the administration of a diet
supplemented with the exogenous bile acid CDCA. This method has been used
previously to increase hepatic bile acid concentrations (Gustafsson et al. 1981).
Several studies have demonstrated that this treatment was associated with
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suppression of enzymes involved in bile acid biosynthesis and up-regulation of those
involved in bile acid detoxification and elimination (Stroup et al. 1997a).
In the second approach, bile acid synthesis was increased by administration
of a diet supplemented with the bile acid binding resin cholestyramine.
Cholestyramine sequesters bile acids within the ileum thus reducing bile acid levels
within the enterohepatic circulation and stimulating cholesterol catabolism and bile
acid biosynthesis. Several investigators have reported an increase in enzyme activity
and bile acid synthesis following dietary administration of cholestyramine
(Fukushima et al. 1995; Pandak et al. 1994). Following these treatments the impact
of elevated bile acid concentrations on glucocorticoid metabolism and HPA axis
activation in vivo was investigated.
4.2 Research aims
The aims of the research in this chapter were:
1. To investigate the effect of elevated levels of bile acids following
administration of CDCA and of increased bile acid synthesis following
administration of a bile acid sequesterant cholestyramine on pathways of
glucocorticoid metabolism in vivo.
2. To assess the effect of each diet on HPA axis activation
3. To assess the effect of each diet on glucocorticoid responsive pathways within
the liver.
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4.3 Methods and method development
4.3.1 Animals
Male Wistar rats (3-4 weeks; Harlan Orlac, Bicester UK) were maintained as
described in section 2.3.1. Animals were matched for age and weight and allocated
into three groups of eight. Control group received standard rat chow. A second group
received standard rat chow supplemented with chenodeoxycholic acid (CDCA; 1%
w/w) and a third group received standard rat chow supplemented with
cholestyramine (CT; 5% w/w). Animals were housed singly and maintained on their
respective diets for 4 weeks. Body weight, food and fluid intake were recorded on a
daily basis.
4.3.2 Administration ofdiet
Standard rat chow was ground manually using a hand rotor creating a fine
powder. CDCA or cholestyramine were mixed with the powdered chow each day.
Control animals received powdered chow alone. Each day animals received chow
(approximately 50g) in glass containers which were placed in shallow metal tins to
catch chow dropped or spilled by the animal during feeding. Each morning
(approximately 0800h), rats received a fresh pot of chow and any food left from the
previous day collected, separated from any debris e.g. saw dust or faeces by sifting
through a tea-strainer and weighed. Fluid intake was recorded daily.
4.3.3 Restraint stress
An acute restraint stress test was performed to assess changes in HPA axis
activation. Rats were handled for approximately 5 minutes between 0700 and 0800
hrs for 7 days prior to initiation of the test to obtain low basal corticosterone levels.
On the day of the experiment, blood was obtained by tail venesection into EDTA-
microtubes, and the rats were immediately placed in restraint tubes for 20 minutes.
After the 20 minute stressor, a second blood sample was taken as above and the
animals were placed back into their original cages where they were allowed free
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access to food and water. Further blood samples were taken by tail venesection at 20,
40, 60 and 90 mins post stress. All blood samples were collected into EDTA-
microtubes and centrifuged (lOOOg, RT, lOmin). The resultant plasma was frozen on
dry ice and stored at -80°C.
4.3.4 Metabolic cages
To study food and fluid intake and steroid metabolite excretion rats were
housed singly in metabolic cages (Techniplast, Exton, PA.,US). Animals were placed
in the cages after 3 weeks on their respective diets where they remained for 6 days.
Body weight, food and fluid intake were monitored daily. Faeces and urine were
collected over the final 72 hours and stored a -20°C for subsequent analysis. The
animals were then placed back into their original cages for a minimum of 1 day prior
to sacrifice.
4.3.5 Animal sacrifice and tissue collection
Animals were killed by surgical decapitation and tissue and blood samples
collected and stored as described in section 2.3.2.
4.3.6 Analysis ofhepatic enzyme activity
Activities of hepatic cytosolic 5(l-reductase (substrate cone: 25nM and 2pM)
and 3a-HSD (substrate cone: 2pM) and microsomal llp-HSDl (substrate cone:
25nM and 2pM) were measured in tissue subfractions as described in sections 2.8.3,
2.8.4 and 2.8.6.
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4.3.7 Abundance of transcripts
Transcript abundance of hepatic 5p-reductase, 5a-reductase 1, 3aHSD,
llpHSDl, angiotensinogen, TAT, PEPCK and CYP7A1 were quantified using
Taqman® real-time PCR as described in section 2.13.1
4.3.8 Analysis of plasma hormones and intermediate metabolites
Plasma corticosterone, insulin and glucose were measured as described in
sections 2.4.1, 2.4.5 and 2.6.3.
Plasma cholesterol, HDL cholesterol, triglycerides and non-esterified fatty acids
were quantified by dry slide chemistry using a Vitros analyzer. This work was
performed by Dr P Ashby, Clinical Biochemistry Department, Western General
Hospital, Edinburgh.
4.3.9 Analysis of liverfat intermediates
Hepatic triglyceride and glycogen concentrations were measured in tissue
homogenates using Triglyceride reagent and glucose hexokinase reagent respectively
as described in sections 2.6.1 and 2.6.2.
4.3.10 Analysis ofurinary steroids
Steroids were extracted from aliquots of urine (10ml) collected over a 72hr
collection for each animal and derivatised along with epi-corticosterone and epi-
tetrahydrocorticosterone as internal standards (described in full in section 2.7).
Analysis was performed by GC-MS (section 2.9.2) and data presented as
concentrations excreted per animal per 24hr.
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4.3.11 Bile acid analysis
Plasma, hepatic and faecal total bile acid concentrations were measured by
enzyme-colorometric method using Total bile acid kit (sections 2.5.1, 2.5.2 and
2.5.3).
4.3.12 Histology
Liver morphology was assessed in transverse sections prepared as described
in section 2.14.1 and lipid accumulation determined by staining with Oil red O
(section 2.14.3)
4.3.13 Statistical analysis
Data were analysed by one-way or repeated measure ANOVA followed by
post hoc least squared difference test for all groups. All analysis was performed
using Statistica (Version 9) or Graphpad Prism (Version 4). For acute restraint stress,
analysis was carried out by measuring area under the curve (AUC) using Kinetica
Program (InnaPhase, USA). Individual experiments were conducted in duplicate and
data are expressed as mean ± standard error of the mean (SEM). The following
nomenclature was used to denote significance *p<0.05; **p<0.01. In all experiments
8 independent animals were used per group; n=8 unless otherwise stated.
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4.4 Results
4.4.1 Effect of CDCA and cholestyramine on physiological parameters
4.4.1.1 Body weight
Baseline body weight of bile acid treated animals was comparable to Control
animals. However, cholestyramine (CT) treated animals were significantly heavier
than Control and CDCA animals (p<0.05; Figure 4.1). The pronounced weight gain
of cholestyramine treated animals could be attributed to greater food intake




Figure 4.1 Body weight following dietary manipulation. Animals were fed standard chow (Control),
chow supplemented with CDCA (1% w/w) or chow supplemented with cholestyramine (CT; 5% w/w)
for four weeks and body weight recorded daily. Hatched box = time in metabolic cage. Data are
meantSEM; n=8;*p<0.05 Control vs CT; CT vs CDCA.
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4.4.1.2 Organ weight
Animals treated with CDCA but not with cholestyramine had slightly smaller
adrenal glands (p<0.05, Table 4.1). Thymus and prostate weight were unaltered by
either treatment (Table 4.1). Cholestyramine but not CDCA treated animals had
smaller livers (p=0.10, CDCA; p<0.05 CT; Table 4.1) and a reduction in liver
glycogen (Table 4.1). Both treatments tended to reduce hepatic triglycerides but this
did not reach statistical significance (p=0.06, CDCA, p=0.06 CT; Table 4.1). Liver
histology revealed a marked reduction in lipid accumulation in both treatment groups




Basal body weight (g) 207.5±14 155.8±20* 186.6±18
Body weight change (g) 161.4±7.1 121.9±7.0* 156.9+13.5
Daily food intake (g/g body weight) 0.108±0.002 0.105±0.002 0.114±0.003*
Adrenal weight (mg/g body weight) 0.082±0.006 0.066±0.005* 0.083±0.004
Thymus weight (mg) 0.73±0.04 0.69+0.03 0.73±0.07
Prostate weight (mg/g body weight) 0.83±0.09 0.98±0.13 0.96±0.09
Liver
Weight (mg/g body weight) 45.3±0.9 43.7±1.06 39.6±1.4*
Glycogen (mg/g) 3.85±0.42 3.44±0.42 2.45±0.32*
Triglycerides (mg/g) 14.7±1.8 10.4±1.5* 10.9±1.3
Cholesterol (mM) 1.89±0.09 2.18±0.11 1.63±0.09
HDL (mM) 1.33±0.08 1.59±0.09* 1.02+0.05*
NEFA (mM) 0.250±0.03 0.275±0.03 0.375+0.04*
Triglycerides (mM) 1.54±0.16 1.25±0.14 1.94±0.23
Plasma (0800h)
Corticosterone (nM) 78±19 82+26 115±54
ACTH (pg/ml) 27.3±6.3 23.5±5.5 32.6±9.6
Glucose (mg/ml) 8.42+0.73 5.42±0.74* 6.75±0.63
Insulin (ng/ml) 4740±597 2870±577* 3540±357
Bile acids
Hepatic (pmoles/mg) 38.3±8.89 57.9±8.20 27.7±2.24
Plasma (pM) 28.0±8.75 73.6±15.9* 27.9±4.80
Fecal (pmoles/g) 105.5±0.9 243.3±0.1* 294.9±0.3*
Urine steroids (ng/24hr)
5P-THB 377±68 213±45* 126±58*
5a-THB 132±32 187+39 107±33
5|3-THB:5a-THB 4.15+0.9 1.92±0.5* 0.68±0.03*
Total 508±77 400+47 251±80*
Table 4.1 Changes in physiological parameters following dietary CDCA or cholestyramine. Animals
were fed standard chow (Control), chow supplemented with CDCA (1% w/w) or chow supplemented
with cholestyramine (CT; 5% w/w) for 4 weeks. Urine and faeces were collected over a 72 hr period
and tissues and plasma harvested at cull. Values are mean ±SEM; n=8 per group.
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A Control (x 10)
B CDCA (x 10)
C Cholestyramine (x 10)
Figure 4.2 Lipid accumulation within the liver following dietary manipulation. Serial transverse
sections (30p.M) were cut from the liver and stained with stained with the neutral lipid stain Oil red.
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4.4.1.3 Bile acids
The total bile acid content of plasma and faeces were significantly elevated
following administration of CDCA (p<0.05; Table 4.1). Cholestyramine increased
bile acid contents of faecal matter (p<0.05) but not that of plasma or liver tissue
(Table 4.1). Transcript abundance of CYP7A1, the rate determining enzyme in the
Classical pathway of bile acid biosynthesis was suppressed following treatment with
CDCA and up-regulated following treatment with cholestyramine (Figure 4.3).
Figure 4.3 Transcript abundance of CYP7A1 following dietary manipulation. mRNA abundance was
quantified by northern blot analysis and values corrected for the house keeping gene Ul. Data are
expressed as mean±SEM, n=8 per group; *p<0.05 vs Control
4.4.1.4 Blood and serum parameters
Plasma glucose (p<0.05) and insulin (p<0.05) were significantly reduced in
CDCA but not cholestyramine treated animals (Table 4.1). Bile acid treatment
caused an increase in plasma HDL cholesterol levels (p<0.05) (Table 4.1). The
converse was observed with cholestyramine treated animals (Table 4.1). Levels of
non-esterified fatty acids (NEFA) -were significantly elevated in cholestyramine
treated animals (p<0.05) but not following bile acid treatment (p=0.5; Table 4.1).
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4.4.2 Impact of CDCA and cholestyramine on hepatic glucocorticoid
metabolizing enzymes
4.4.2.1 Hepatic enzyme activity
Hepatic ll^-HSDl dehydrogenase activity was decreased with CDCA but
not cholestyramine when measured in an assay using 25nM substrate (3H4 -
corticosterone; Figure 4.4 A). Inhibition was not observed when assayed with 2pM
substrate (Figure 4.4 B). Changes in enzyme activity were not accompanied by
changes in transcript abundance of llp-HSDl which were unaltered by either
treatment (Figure 4.4 C).
Hepatic 5|3-reductase activity was reduced in animals treated with either
CDCA or cholestyramine when measured using the lower substrate concentration
(25nM; Figure 4.5 A) but not at the higher substrate concentration (2p,M; Figure 4.5
B). Abundance of mRNA of 5(3-reductase was unaltered by either treatment. In
addition, treatment with CDCA and cholestyramine did not influence 3a-HSD
activity (Figure 4.5 D) or transcript abundance (Figure 4.5 E). Transcript abundance
of 5a-reductase 1 was comparable between groups (0.19±0.05 Control; 0.13±0.03









Figure 4.4 11(3HSD1 dehydrogenase activity following dietary manipulation. (A) Dehydrogenase
activity of lipiISDl measured in rat liver microsomes was significantly reduced by CDCA but not
cholestyramine (CT) when assayed with 25nM corticosterone. (B) Inhibition was abolished when
assayed at a higher substrate concentration (2p,M). (C) Transcript abundance of lipHSDl was
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Figure 4.5 5(3-reductase and 3oc-HSD activity and expression following dietary manipulation. (A)
Activity of steroid 5p-reductase measured in rat liver cytosol was reduced by treatment with CDCA
and cholestyramine (CT) when assayed with 25nM corticosterone. (B) Inhibition was abolished at
higher substrate concentration (lpM). (C) No difference was observed in transcript abundance. (D)
Dietary manipulation of bile acid concentration did not influence 3a-HSD activity or (E) mRNA
abundance. Data are mean±SEM; n=8 per group; *p<0.05 vs Control.
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4.4.2.2 Urinary metabolites
Animals treated with cholestyramine excreted lower total quantities of
urinary metabolites of corticosterone (p<0.05 CT). Both cholestyramine and CDCA
treated animals excreted fewer 5p-reduced metabolites (p<0.05; Table 4.1). These
altered patterns of metabolism were confirmed by changes in the ratio of 5a -to 5p
reduced metabolites (p<0.05 in both cases). Changes in lip-HSDl could not be
assessed due to an inability to detect 11-dehydrocorticosterone (A) metabolites
within urine.
4.4.2.3 Glucocorticoidsensitive genes
A reduction in abundance of mRNA of the glucocorticoid sensitive gene
angiotensinogen was observed following both treatments (Figure 4.6 A; p<0.05).
Although a trend towards reduction was observed in TAT (Figure 4.6 B) and PEPCK
(Figure 4.6 C) following CDCA treatment and in PEPCK (Figure 4.6 C) following






Figure 4.6 Transcript abundance of glucocorticoid-sensitive genes following dietary manipulation.
mRNA abundance of hepatic (A) angiotensin, (B) TAT and (C) PEPCK were quantified by northern
blot analysis and values corrected for the house keeping gene Ul. Data are expressed as mean±SEM,
n=8 per group; *p<0.05 vs Control.
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4.4.3 Effect ofCDCA or cholestyraminefeeding on HPA axis activation
Baseline plasma corticosterone (Table 4.1; Figure 4.7 A) and ACTH (Table
4.1) levels were comparable between groups. Following acute restraint stress (20
mins) animals treated with CDCA but not cholestyramine showed a delay in the
return to basal corticosterone levels compared to Control treated animals (Figure 4.7
A and B). A difference was not apparent in the response of ACTH following acute





Figure 4.7 Indices reflecting HPA axis response to acute (20 min) restraint stress (hatched box). (A)
Animals treated with CDCA showed a delay in return to basal corticosterone levels following stress
(B) calculated as area under the curve (AUC) (C) Neither CDCA (filled square) nor CT (open




The data presented in this chapter provide evidence that bile acid induced
inhibition of glucocorticoid metabolism also occurs in vivo. Dietary administration
of CDCA reduced activity of hepatic 5p-reductase and lip-HSDl without changes
in mRNA or protein levels. Enzyme inhibition was reflected by a reduction in total
urinary metabolites of corticosterone, primarily due to a fall in 5(3-reduced
metabolites. These findings were confirmed by a marked rise in the ratio of 5a:5(3-
reduced metabolites. Of note, the decline in 5(l-reductase activity was not
accompanied by a compensatory rise in 5a-reductase 1. Furthermore, despite altered
activity, changes were not observed in transcript abundance of 5p-reductase or 11(3-
HSD1 again suggesting that bile acids are exerting their inhibitory effect at a post-
transcriptional level
In this study, two approaches were used to assess the impact of bile acids on
glucocorticoid metabolism. The first method, namely the dietary administration of
bile acids is a well utilized method of increasing total bile acid content (Pandak et al.
1994; Gustafsson et al. 1981). The success of this manipulation was evident as
transcript abundance of CYP7A1 within the liver was reduced in bile acid
supplemented animals. Furthermore, plasma and faecal bile acid contents were
elevated in CDCA treated animals when compared to Control animals. The
consequences of impaired endogenous bile acid synthesis were also evident from the
increase in plasma FIDL cholesterol concentrations.
In the second method, bile acid synthesis was stimulated via the
administration of cholestyramine, a bile acid binding resin sometimes prescribed to
patients with hypercholesterolemia. Cholestyramine sequesters bile acids within the
intestine preventing their reuptake into the portal circulation depleting their hepatic
levels thereby stimulating cholesterol catabolism into bile acids. It is well established
that in response to cholestyramine there is acute up-regulation of CYP7A1 activity
and transcription and a reduction in total circulatory cholesterol (Heuman et al. 1992;
Ren et al. 2003; Vlahcevic et al. 1996). As anticipated CYP7A1 mRNA abundance
was 2-fold greater in Cholestyramine-treated animals compared to Control while
HDL cholesterol levels were significantly reduced. In addition faecal bile acid
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content of cholestyramine-treated animals was greater than 2-fold that of Control
animals; however, hepatic and plasma bile acids were surprisingly unaltered.
As anticipated from the data obtained in vitro increasing cytosolic bile acids
altered glucocorticoid metabolism with a reduction in total urinary metabolites of
corticosterone, primarily due to a reduction in 5p-reduced metabolites. The
measurement of urinary metabolites over a 24 hour period provides valuable insight
into the overall steady state conditions within the liver, accounting for diurnal
fluctuations or acute post prandial changes in enzyme activity or hormone levels.
Supplementation of the diet with CDCA and stimulation of bile acid biosynthesis via
cholestyramine caused a significant reduction in glucocorticoid clearance over a 24
hour period. In fact cholestyramine appeared to be more potent than CDCA resulting
in a 60% reduction in 5p-reduced metabolites and 50% fall in total urinary
metabolites of corticosterone. In addition inhibition of hepatic 5(3-reductase and 11|3-
HSD1 was observed in CDCA-treated animals when assayed with low substrate
concentration (25nM). This inhibition was abolished when a higher substrate
concentration (2pM) was used. These finding corroborate those obtained in Chapter
3, in which bile acids were found to act as a competitive inhibitor of both 5(3-
reductase and 11 (3-HSD1. As with CDCA, 5(3-reductase activity was inhibited in
animals treated with cholestyramine at low (25nM) but not high (1 pM) substrate
concentration, however, a difference was not observed in 11(B-HSD1 activity at either
substrate concentration. The disparity between the two models may reflect
differences in enzyme localization and bile acid accumulation within the cell.
Cholestyramine inhibited 5(3-reductase, a cytosolic enzyme, but not 11(3-HSD1
whose active site is embedded within the inner leaflet of the endoplasmic reticulum
membrane. These findings may reflect the site of bile acid accumulation within the
cell. For example cytosolic accumulation may only occur in response to
pharmacological loading not due to increased synthesis rates.
Bile acids are reabsorbed within the ileum via active transport mechanisms
and carried back to the liver via the portal venous circulation (Myant & Mitropoulos
1977). From the venous circulation they are transported into the hepatic cytosol via
high-affinity Na+-dependent bile salt transporter (Ntcp/NTCP) which can transport
only conjugated bile acids and a family of multi-specific organic anion transporters
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(Oatps/OATPS) that can mediate sodium independent bile salt uptake along with
neutral steroids and organic anions (Trauner & Boyer 2003). It possible that in the
presence of excess bile acids these transport mechanisms may be saturated or
damaged due to the cytotxicity of the accumulating bile acids within the cells of
CDCA treated animals. The bile salt pool undergoes an enterohepatic circulation that
is regulated by distinct bile salt transport proteins, including the canalicular bile salt
export pump BSEP (ABCB11), the ileal Na(+)-dependent bile salt transporter ISBT
(SLC10A2), and the hepatic sinusoidal Na(+)-taurocholate cotransporting
polypeptide NTCP (SLC10A1), whose expression is regulated by both
transcriptional and post-transcriptional mechanism (Trauner & Boyer 2003). This
mechanism would protect the hepatocytes from the potential hepatotoxic effects of
bile acid accumulation. In support of this hypothesis, bile acids are known to exert
feedback regulation on NTCP, the principal hepatic bile acid transporter by bile acid-
activated FXR via induction of SHP feedback (Denson et al. 2001). Although plasma
and fecal bile acid levels were elevated in CDCA-treated animals, there was no
apparent change in bile acid content of hepatic tissue homogenates in response to
either pharmacological loading with CDCA or the induction of bile acid synthesis
with cholestyramine. In the case of CDCA it is possible that intracellular
accumulation of bile acids within the cytosol may have been obscured due to dilution
with other cellular components when homogenized.
Despite alterations in glucocorticoid metabolism and clearance, there was no
difference in transcript abundance of TAT or PECK, enzymes that are known to be
regulated by GR. In contrast, angiotensinogen mRNA abundance was reduced by
both treatments. It must be noted however, that angiotensinogen is regulated by a
number of factors in addition to GR-mediated expression. Indeed, angiotensin II is a
potent stimulator of angiotensiogen (Ben Ari & Garrison 1988). Furthermore, a
recent study in HepG2 cells demonstrated direct inhibition of human
angiotensinogen mediated through the inhibitory effect of SHP on HNF-4 (Yamagata
et al. 2004). As such, the changes in angiotensinogen expression observed in this
study would appear to be independent of alterations in glucocorticoid levels and may
be a direct effect of bile-acid-mediated suppression.
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The HPA-axis is under both feed-forward and feedback control and the role
of glucocorticoid metabolizing enzymes in HPA axis regulation is an area of much
research. The paradox that idiopathic obese individuals can have normal or even
lower circulatory glucocorticoid levels has been attributed to a reduction in
glucocorticoid clearance and compensatory activation of the HPA axis (Hautanen &
Adlercreutz 1993). These findings have been recapitulated in the obese Zucker rat
(Livingstone et al. 2000) where tissue specific alterations in glucocorticoid
metabolism are frequently accompanied by changes in HPA axis activation and/or
response (Rask et al. 1999; Livingstone et al. 2000). Indeed, enhanced glucocorticoid
clearance, brought about by an increase in activity of the hepatic A-ring reductases
(5a- and 5(l-reductase) and a reduction in hepatic 11(1-HSD1 are associated with
compensatory activation of the HPA axis, thus circulatory levels of Cortisol are
maintained within a normal physiological range (Hautanen et al. 1997). The
generation of transgenic models including global 11(1-HSD1 knock out (Paterson et
al. 2004; Kotelevtsev et al. 1996) and adipose 11(3-HSD1 (Morton et al. 2004;
Masuzaki et al. 2001a) over expressing mice support the theory that tissue specific
alterations in glucocorticoid metabolizing enzymes play a fundamental role in HPA
axis activation. From this work it is clearly evident that one must consider the role
that individual tissues play in maintaining whole body glucocorticoid homeostasis.
The A-ring reductases (5a- and 5|3-reductase) act as the predominant means
of clearing excess glucocorticoids from the body. Bile acid supplementation and
induction of synthesis caused a reduction in glucocorticoid clearance, used routinely
in humans as an index of glucocorticoid production rates. In addition, HPA axis drive
was substantially reduced in bile-acid-treated animals and adrenal gland weight was
reduced but only in CDCA-treated animals. Basal levels of corticosterone and ACTH
were comparable between all groups, and thymus weight, which may be used to infer
circulatory glucocorticoid concentrations, was unaltered by dietary manipulation.
Thus it would appear that in the face of diminished 5p-reduction animals reset their
HPA axis and maintain circulatory levels of corticosterone. It is hard to predict the
change in intracellular corticosterone levels. Diminished regeneration of active
corticosterone from inert 11-keto by llp-HSDl inhibition would reduce hepatic
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concentrations of active steroid, opposing inhibition of 5(3-reductase which would
predict an increase in corticosteroid due to reduced clearance.
HPA axis responsiveness was tested by subjecting animals to a 20 min acute
restraint stress. Following restraint, animals treated with CDCA or cholestyramine
showed similar peak responses in corticosterone and ACTH 40 minutes post stress
which was comparable to Control animals. However, CDCA treated animals showed
a delay in the return to basal corticosterone levels. This was most apparent 40-120
minutes post stress in keeping with an impaired clearance of glucocorticoids by 5(3-
reductase. Although animals treated with cholestyramine also demonstrated a delay
in return to basal levels of corticosterone, this was less pronounced than that of
CDCA-treated animals and may reflect plasma levels of bile acids which were
unaltered in cholestyramine treated animals.
It is interesting to note that CDCA treatment lowered plasma glucose and
insulin, reduced triglyceride contents of the liver and impeded lipid accumulation
within the liver. This improved metabolic phenotype is very similar to that of 11(3-
HSD1 null mouse (Kotelevtsev et al. 1997). Furthermore, this phenotype was more
pronounced in CDCA treated animals in which 11(3-HSD1 was potently inhibited.
Although it is tantalizing to infer that these effects are mediated through 11(3-HSD1
one must also consider the direct impact of bile acids on glucose metabolism. Recent
work has established a novel role of FXR in the regulation of peripheral insulin
sensitivity and adipocyte function (Cariou 2006). Indeed, treatment with the
synthetic FXR agonist GW4064 improved insulin sensitivity of genetically obese
ob/ob mice in vivo. Furthermore, it has been demonstrated that activation of FXR in
db/db mice repressed hepatic gluconeogenic genes and increased hepatic glycogen
synthesis and glycogen content by a mechanism that involves enhanced insulin
sensitivity (Zhang 2006).
In this study, supplementing the diet with CDCA reduced 11(3-HSD1 and 5(3-
reductase activity within the liver and an altered HPA axis response. In contrast
stimulating bile acid synthesis with cholestyramine did not affect 11(3-HSD1 activity.
It would therefore appear that inhibition of 5(3-reductase impacts upon HPA axis
activation whilst inhibition of 11 (3-HSD1 alters glucocorticoid-regulated genes.
Where both occur as in CDCA-treated animals, a metabolic phenotype analogous to
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the llp-HSDl null mouse is observed. Thus disorders with changes in these
enzymes could be brought about increased bile acids.
Chapter 5
Effect of decreased bile acids by a fat-free diet on
glucocorticoid metabolism and HPA axis activation
5.1 Introduction
In Chapter 4 the concentration of bile acids within the liver was increased by
the administration of a diet supplemented with CDCA. In addition, bile acid
synthesis was stimulated with cholestyramine. In both models, bile acids inhibited
glucocorticoid metabolism, predominantly through their inhibitory effects upon 5(3-
reductase. In this Chapter, we investigated the impact of lowering hepatic bile acids
and bile acid synthesis rates via the administration of a fat-free diet.
Literature was reviewed to determine whether reducing the concentration of
cholesterol, the substrate for bile acids would suppress bile acid synthesis rates.
Cholesterol is supplied to the liver via four main routes;
1) De novo synthesis of cholesterol from acetyl-coenzyme A (CoA).
2) Reverse cholesterol transport from peripheral tissue to the liver by the
selective uptake of HDL cholesterol by SR-B1.
3) LDL receptor mediated endocytosis of serum cholesterol esters (CE).
4) Absorption of dietary cholesterol from the intestine and transportation to
the liver as chylomicrons by LDL receptor mediated mechanisms
(Chiang 2002).
Due to the complex interplay between factors controlling cholesterol
biosynthesis, utilisation and elimination, each aspect must be considered in isolation
and as part of the whole system. Rats fed a cholesterol-depleted diet compensate for
this loss by increasing the rate of de novo synthesis (Chiang et al. 2001).
Supplementation of the diet with fibrous agents such water-soluble NSP guar gum
and sodium alginate reduce circulating cholesterol levels and increase their feacal
bile acid output by as much as 2 to 3 times due to interuption of the enterohepatic
circulation (Seal & Mathers 2001). However, bile acid pool size is normal or even
increased (Moundras et al. 1997).
It is possible to inhibit the rate of cholesterol synthesis using statins, such as
simvostatin and atorvastatin. These agents inhibit 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase the rate limiting enzyme in cholesterol biosynthesis, thereby
reducing cholesterol production and consequently bile acid biosynthesis (Bilheimer
et al. 1983). Although statins are effective cholesterol lowering agent in humans,
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they are ineffective in the rat due to the high basal rate of de novo cholesterol
synthesis, with bile salt excretion being unaltered (Carella 1999). Lastly, inhibition
of cholesterol absorption was considered using agents such as ezetimibe, a potent
inhibitor of cholesterol and phytosterol uptake within the proximal jejunum of the
small intestine via the Niemann-Pick Cl-Like 1 (NPC1L1) transporter (Garcia-Calvo
et al. 2005). This agent is used for the treatment of hypercholesterolemia effectively
lowering circulating plasma cholesterol in humans by 15-20% (Bays et al. 2001;
Davis, Jr. et al. 2004). However, as with statins, ezetimibe absorption does not
influence cholesterol biosynthesis or bile acid synthesis in the rat (van Heek et al.
2003).
Finally it was determined that hepatic bile acids could be depleted using a
synthetic fat-free diet. This diet had previously been used to reduce bile acid
synthesis, suppressing it by 63% (Bertolotti et al. 1995). By removing all fat from the
diet, the functional requirement for bile acids is reduced and consequently
recirculation of bile acids along the entero-hepatic axis is much slower. Removal of
all fat from the diet necessitated the addition of other component(s), including casein
and sucrose. Sucrose has been shown to influence HPA axis independently (Opara et
al. 1996) and thus it was not possible to compare this directly to normal chow,
assuming the only difference was fat. Confounding changes in glucose and lipid
homoeostasis, which may also have occurred via administration of the fat-free diet
alone, again precluded the use of normal chow as a control diet. Control animals
were therefore regarded as animals receiving the fat-free diet supplemented with
CDCA (1% w/w; FF/CDCA) to which animals receiving the fat-free diet (FF) were
compared.
5.2 Research aims
The aims of the research in this chapter were:
1. To investigate the effect of bile acid depletion on glucocorticoid
metabolism.
2. To investigate the effect of bile acid depletion on glucocorticoid action.
3. To investigate the effect of bile acid depletion on HPA axis activation.
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5.3 Materials and methods
5.3.1 Animals and animal maintenance
Male Wistar rats (3-4 weeks; Harlan Orlac, Bicester, UK) were maintained as
described in section 2.3.1. Animals were matched for age and weight and allocated
into two groups of eight. Control group received synthetic fat-free chow
supplemented with chenodeoxycholic acid (FF/CDCA; 1% w/w section 5.3.2). The
treatment group received synthetic fat-free chow (FF; section 5.3.2). Animals were
housed singly and maintained on their respective diets for 4 weeks. Body weight,
food and fluid intake were recorded on a daily basis.
5.3.2 Preparation ofdiet
A synthetic fat-free diet (D05052506) was prepared by Research Diet
(Research Diets Inc, NJ, US). The fat was replaced with sucrose (70% w/w) and a
standard vitamin and mineral mixture (Table 5.1) in order to achieve a nutritionally
and calorifically balanced diet. Chow was prepared in which the fat-free diet was
supplemented with CDCA (1% w/w; D05052507) (Research Diets Inc, NJ, US). The
synthetic fat-free diet supplemented with bile acid was treated as a "Control" group
(Opara et al. 1996). Both diets were stored at room temperature.
5.3.3 Metabolic cages
Animals were placed into metabolic cages for 7 days as described in section
4.3.3 after 3 weeks on their respective diets. Faeces and urine were collected over the
final 72 hours and stored a -20°C for subsequent analysis. The animals were then
placed back into their original cages for at least one day prior to sacrifice.
5.3.4 Animal sacrifice and tissue collection
Animals were killed by surgical decapitation and tissue and blood samples
collected and stored as described in section 2.3.2.
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5.3.5 Analysis ofbiochemicalparameters
Enzyme activity, plasma hormone levels, liver biochemistry, urinary steroids
and bile acid levels were quantified as described in sections 4.3.5 - 4.4.0.
Bile acid depleted diet (FF) Control (FF/CDCA)
gm% kcal% gm% kcal%
Protein 20.3 22.2 20.1 22.2
Carbohydrate 71.0 77.8 70.3 77.8
Fat 0.0 0.0 0.0 0.0
Total 100.0 100.0
kcal/gm 3.65 3.61












Corn Starch 0 0 0 0
Sucrose 700 2800 700 2800
Cellulose, BW200 50 0 50 0
Mineral Mix S10001 35 0 35 0
Vitamin Mix V10001 10 40 10 40
Choline Bitartrate 2 0 2 0
Chenodeoxycholic
Acid
0 0 10.5 0
Total 1000 3652 1010.5 3652
Table 5.1 Modified AIN-76A Rodent Diet With Alcohol-Extracted Casein, 70% Sucrose (wt./wt.),
No Added Fat and with and without 1% chenodeoxycholic Acid
The sodium content of both diets was 0.3% (w/w).
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5.3.6 Abundance of transcripts
Transcript abundance of hepatic target genes were quantified as described in
section 4.3.7.
5.3.7 Statistical analyses
Individual experiments were conducted using tissues from 8 independent
animals per group (unless otherwise stated). Each assay was performed duplicate and
the mean of each duplicate taken as the final value for that individual animal. The
data represent the mean ± standard error of the mean (SEM). Results were subjected
to Students t-test. All analysis was performed using Statistica (Version 9) or




5.4.1 Effect offat-free diet on physiological parameters
5.4.1.1 Body weight
Fat-free fed (FF) animals were significantly heavier then Control (FF/CDCA)
animals gaining almost twice as much weight as those receiving the bile acid
supplemented diet (FF/CDCA; Figure 5.1 A). Weight gain was elevated in the fat
free (FF) animals over the duration of study (5.1 B). This was not attributable to a
difference in food intake as FF animals ate significantly less food than FF/CDCA
animals (Table 5.1).
Figure 5.1 A Body weight following dietary manipulation. Animals were fed a synthetic fat-free diet
(FF) or fat-free diet supplemented with CDCA (FF/CDCA; 1% w/w) for four weeks and body weight
recorded daily. Data represent (A) total weight change (B) course of weight change are mcan±SEM;
n=8; **p<0.01 vs FF/CDCA.
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Figure 5.1 B Body weight change following dietary manipulation. Animals were fed a synthetic fat-
free diet (FF), or fat-free diet supplemented with CDCA (FF/CDCA; 1% w/w) for four weeks and
body weight recorded daily. Hatched box represents time spent in metabolic cage. Data are
mean±SEM; n=8; *p<0.05 vs FF/CDCA.
5.4.1.2 Organ weight
Adrenal gland weight and plasma corticosterone levels were greater in FF
animals compared to FF/CDCA animals (Table 5.2). The difference in adrenal gland
weight however was not significant when corrected for body weight (Table 5.2).
Removal of bile acids did not influence thymus or prostate weight. Liver weights
were also comparable between groups (Table 5.2) however, liver triglyceride
(p<0.05) but not glycogen (p=0.1) levels were elevated in FF animals. Of note
adrenal and prostate weight, plasma corticosterone and hepatic triglyceride levels of
FF animals were comparable to Control animals fed standard chow for 4 weeks as
describded in detail in Chapter 4 (Table 5.2).
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Fat-Free + CDCA Fat-Free Control
(Chapter 4)
Basal weight (g) 198±4.2 235+6.4* 208+14
Weight change (g) 174.3±4.5 197.1±6.6* 161.4+7.1
Daily food intake (g/g 0.09±0.003 0.08+0.004* 0.082+0.003
body weight)
Adrenal weight (mg) 22.9±1.1 29.1±1.4* 27.4
Adrenal weight (mg/g 0.11+0.003 0.12±0.003 0.082+0.006
body weight)
Thymus weight (mg) 0.42±0.0 0.53±0.04 0.73+0.04
Prostate weight (mg/g 0.78±0.13 0.80±0.08 0.83+0.09
body weight)
Liver weight (mg/g body 33.3+3.1 38.2+3.0 45.3+0.9
weight)
Glycogen (mg/g) 6.19±0.78 4.85±0.45 3.85+0.42
Triglycerides (mg/g) 11.2+1.6 18.6±2.1* 14.7+1.8
Corticosterone 52.6+7.4 84.9+10.3* 78.1±19
Glucose (mg/ml) 5.08+0.53 6.22±0.63 8.4+0.7
Insulin (ng/ml) 1781±190 3045±482* 4740+597
Triglycerides (mM) 1.26+0.17 3.08+0.28* 1.5+0.2
Cholesterol (mM) 2.35+0.11 1.81±0.12* 1.89+0.09
HDL cholesterol (mM) 1.58±0.08 1.08±0.11* 1.33+0.08
NEFA (mM) 0.49±0.06 0.43+0.04 0.25+0.03
Bile acids
Hepatic 34.8±3.6 25.1±7.1 50.5+11.7
(pmoles/mg)
Plasma (pM) 108.0±16.34 31.9+6.2* 28.0+8.7
Fecal (pmoles/g) 114.7±15.2 53.9+12.7* 52.8+7.3
Urine (ng/ml)
5|3-THB 178±22 305+26* 377+68
5a-THB 240±27 268+49 132+32
50:5a-THB 0.96+0.18 1.44+0.39 4.15+0.9
Total 392±51 651+116 508+77
Table 5.2 Changes in physiological parameters following dietary manipulations. Animals were fed a
fat-free diet (FF), or fat-free diet supplemented with CDCA (1% w/w; FF/CDCA) for four weeks.
Urine and faeces were collected over a 72 hour period and tissues and plasma harvested at cull. Data
are expressed as mean±SEM; n=8;*p<0.05, FF vs FF/CDCA. For comparison animals fed standard
chow for 4 weeks as described in detail in Chapter 4.
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5.4.1.3 Blood and serum parameters
Plasma insulin but not glucose was elevated in FF animals and plasma
triglycerides reduced (p<0.05) (Table 5.2). Conversely, plasma total cholesterol
(p<0.05) and HDL cholesterol (p<0.05) were suppressed in fat-free animals whereas
plasma NEFA levels were not altered (Table 5.3)
When comparing the lipid profile of animals fed a diet of standard chow
(Control animals described in Chapter 4), with those fed the fat-free diet, the FF diet
had a major impact upon triglyceride storage and/or utilisation with plasma
triglyceride levels almost twice those observed in Chapter 4 Control animals (Table
5.3). NEFA levels were also elevated in FF animals although it must be noted that a
different assay was used and data are not completely comparable.
Control FF
Cholesterol (mM) 1.89±0.11 1.81±0.12
HDL (mM) 1.33±0.08 1.08±0.11
NEFA (mM) 0.25±0.03 0.43±0.04*
Triglycerides (mM) 1.5±0.02 3.1±0.3*
Table 5.3 Plasma lipid profile of animals fed standard chow (Control) compared to fat-free chow (FF)
for 4 weeks. Blood was collected at 0800h following decapitation and plasma lipid content assessed.
Data are mean±SEM; n=8 per group. *p<0.05 Control vs FF.
5.4.1.4 Bile acids
The total bile acid content of plasma and faeces were significantly suppressed
in FF animals (Table 5.2), corresponding to an increase in mRNA abundance of
CYP7A1 (Figure 5.2). Hepatic bile acid concentrations tended to decrease in FF
animals but this did not reach statistical significance. Of note, hepatic bile acid
concentrations were 2-fold lower in FF animals animals compared to Control animals
Chapter 4 (Table 5.2).
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FF FF/CDCA
Figure 5.2 Transcript abundance of CYP7A1 following dietary manipulation. mRNA abundance was
quantified by Taqman® real-time PCR and values are expressed as a ratio to the house keeping gene
cyclophilin A using the Standard Curve method. Data are expressed as mean±SEM, n=8 per
group; *p<0.05 vs FF/CDCA.
5.4.2 Impact on hepatic glucocorticoid-metabolising enzymes
5.4.2.1 Hepatic enzyme activity
Activity of hepatic 5 (3-reductase was increased in FF animals when assayed with
25nM substrate (Figure 5.3 A). This difference was abolished at higher substrate
concentration (2pM; 1.22±0.26 FF v 1.24±0.18 FF/CDCA nmol/mg/hr; p=ns). A
difference was not observed in 11(3-HSD1 dehydrogenase activity (Figure 5.3 B) or
3<xHSD activity (Figure 5.3 C) between groups.
Transcript abundance of 5f3-reductase (Figure 5.4 A), 11(3-HSD1 (Figure 5.4 B),
















Figure 5.3 Hepatic enzyme activity following dietary manipulation. (A) Activity of steroid 5|3-
reductase and (B) lip-HSDl when assayed with 25nM corticosterone and (C) 3a-HSD when assayed
with 2pM corticosterone. lip-HSDl or 3a-HSD activity were not influenced by dietary manipulation.
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Figure 5.4 Transcript abundance of glucocorticoid metabolizing genes. mRNA abundance of (A) 5P-
Reductase, (B) lip-HSDl, (C) 3a-HSD and (D) 5a-Reductase 1 was quantified by Taqman® real¬
time PCR and values are expressed as a ratio to the house keeping gene Cyclophilin A using the
Standard Curve method. Data are expressed as mean±SEM ;n=8 per group; p=ns.
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5.4.2.2 Urinary metabolites
Animals receiving FF tended to excrete more total metabolites of corticosterone
(p=0.06) in their urine, primarily due to an increase in 5p-reduced metabolites
(p<0.05; Table 5.2). A compensatory change was not observed in the excretion of
5a-reduced corticosterone metabolites (Table 5.2). Changes in 11(3-HSD1 could not
be inferred due to an inability to detect 11-dehydrocorticosterone (A) metabolites
within the urine.
5.4.2.3 Glucocorticoid sensitive genes
Abundance of mRNA for the glucocorticoid-sensitive genes angiotensinogen
(0.61±0.02 FF vs 0.61±0.03 FF/CDCA AU; p=ns), TAT (0.72±0.08 FF vs 0.83±0.13
FF/CDCA AU; p=ns) and PEPCK (0.81±0.22 FF vs 0.63±0.14 FF/CDCA AU; p=ns)
were not altered in FF animals compared to Control (FF/CDCA) treated animals.
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5.5 Discussion
The primary aim of this Chapter was to investigate the impact of bile acid
depletion on glucocorticoid metabolism and HPA axis activation. In order to achieve
this, animals were fed a synthetic fat-free diet devoid of any cholesterol or fat. This
diet reduces hepatic cholesterol synthesis by 65% and bile acid biosynthesis by 63%
(Bertolotti et al. 1995). In addition recirculation of bile acids along the entero-hepatic
axis is delayed due to reduced functional need. Supplementation of the fat-free diet
with the bile acid CDCA (1% w/w) enabled glucocorticoid metabolism to be
investigated in the presence and absence of bile acids thus providing a model in
which to investigate fully the impact of bile acids on glucocorticoid metabolism and
HPA axis activation.
The model utilised in this study achieved the required goal as shown by the
induction of CYP7A1 mRNA and rise in plasma and faecal bile acid concentration
on which were reversed when bile acids were replaced to the diet. However, when
considering the findings of this model it is important to consider the impact of the
fat-free diet alone on physiological and biochemical parameters. Table 5.2 shows a
comparison of the health of animals fed a Standard chow diet (Control animals) from
Chapter 4 and the FF animals from this study.
The major differences seen between rats receiving the FF diet and those
receiving normal chow were in triglyceride levels (elevated in both plasma and liver)
and NEFAs (elevated in plasma). In spite of an increase in triglycerides however,
glucose and insulin levels were suppressed in FF animals. This may be attributable to
the absence of fat in the diet as triglycerides are normally broken down to fatty acids
and monoglycerides by lipases within the intestine during lipolysis. In support of this
plasma free-fatty acids (NEFA) were elevated in FF animals compared to Control
animals. Replacing bile acids into the diet (FF/CDCA) reversed the changes in
plasma and hepatic triglyceride levels whilst plasma NEFA levels were reduced
again suggesting that changes in lipolysis are due to the impact of the fat-free diet.
As observed in Chapter 4 bile acids had a major impact upon glucocorticoid
metabolism. Animals receiving the FF (bile acid depeleted) diet had elevated levels
of 5(3-reduced metabolites within their urine which was reversed when CDCA was
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added to the diet. In addition, activity of hepatic 5p-reductase was suppressed in
FF/CDCA treated animals only when assayed with a low concentration of substrate
(25nM). These findings support those obtained in Chapters 3 and 4; namely that bile
acids act as competitive inhibitors of hepatic 5|3-reductase.
Although the majority of changes in glucocorticoid metabolism mirror those
obtained in Chapter 4 there are some inconsistencies which must be considered.
1) Administration of the FF diet supplemented with CDCA did not influence
activity of 11(3-HSD1. On a background of normal chow however, CDCA acted as
potent competitive inhibitor of lip-HSDl. Interestingly, stimulating bile acid
synthesis with cholestyramine also had no impact upon lip-HSDl activity. These
findings may reflect the change in absolute levels of bile acids achieved within the
hepatocytes although this would be hard to measure. lip-HSDl is located in the
endoplasmic reticulum of the cell which is not easily accessible to bile acids due to
the absence of specific bile acid transporters. In support of this hypothesis hepatic
bile acid levels were unaltered in FF/CDCA and cholestyramine treated animals. It is
possible that on a background of normal chow, supplementation of the diet with bile
acids induced hepatotoxicity damaging intracellular organelles and allowing bile
acids to gain entry to the ER. Thus only in CDCA-treated animals in Chapter 4
where bile acid levels are elevated above physiological levels is 11 (i-HSDl activity
inhibited. In it interesting to note that in the absence of changes in 11(3-HSD1 a
difference in transcription of GR sensitive genes was not observed.
2) Experimental manipulation of the HPA axis was not performed in this
protocol, however, "basal" activity was assessed by comparing urinary corticosterone
metabolites. The production of corticosterone metabolites within 24 hour urine
samples were greater in FF animals compared to both FF/CDCA and animals fed a
diet of standard chow (Control animals describded in detail in Chapter 4). This may
reflect the removal of metabolic suppression imposed upon 5p-reductase by bile
acids and suggest that bile acids produced due to ingestion of a normal chow diet
exert a moderate inhibitory effect upon enzyme activity.
3) Adrenal weight was unaltered in FF fed animals after correction for body
weight despite a rise in circulating corticosterone levels. In contrast, Chapter 4
CDCA-supplemented animals had smaller adrenal glands but maintained the level of
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corticosterone within the circulation. It is not clear why circulatory levels of
corticosterone were altered in the FF paradigm and not in the normal chow diet, but
it may reflect a resetting of the HPA axis in FF animals, as in both cases these
changes were accompanied by an increase in bile acids. It should be noted that the
increase in corticosterone concentrations observed in FF compared to FF/CDCA
animals was small and the FF animals were less accustomed to handling than those
used in Chapter 4. Therefore the small rise in circulatory corticosterone levels may
reflect a differential result of stress.
4) Although a comparison has been made between basal corticosterone levels,
to assess HPA axis response it is perhaps more appropriate to compare corticosterone
levels of FF animals at cull with those obtained from animals examined in Chapter 4
immediately post stress. The fat-free diet in itself could be viewed as a "stressor"
thus the rise in circulating corticosterone levels may reflect delayed glucocorticoid
clearance due to chronic inhibition of 5(3-reductase. Indeed, the prolonged
corticosterone peak following acute restraint stress in CDCA treated animals on a
normal chow background would support this idea. In CDCA supplemented animals
on standard chow diet, reduced clearance due to inhibition of 5|3-reductase and lower
regeneration due to inhibition of 11(3-HSD1 may suppress HPA axis responsiveness,
thus accounting for the reduction in adrenal size and maintenance of circulating
corticosterone levels in these animals.
The de novo synthesis of cholesterol accounts for approximately 50% total
body cholesterol production, with diet contributing only a small proportion (-5-
10%). Rodents have a high rate of de novo cholesterol synthesis which can be acutely
regulated in order to maintain cholesterol homeostasis. When given a cholesterol free
diet, rodents increase de novo synthesis as shown by enhanced activation of HMG-
CoA reductase to maintain cholesterol homeostasis. Although hepatic HMG-CoA
reductase levels were not assessed in this study, plasma cholesterol and HDL
cholesterol (the most prevalent form in the rat) were comparable between FF and
Control animals in Chapter 4 indicating that FF animals had achived cholesterol
homeostasis.
In summary, the work in this chapter provides further evidence supporting a
regulatory role for bile acids in glucocorticoid metabolism. Withdrawl of bile acids
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from the diet reverses the inhibiton imposed upon 5|3-reductase as demonstrated by
enhanced enzyme acitivty and a rise in the urinary excretion of 5[3-reduced
glucocorticoid metabolites. These changes are also reflected in the lipid profile of
bile acid depeleted animals where plasma cholesterol levels comparable with animals
fed a standard chow diet. Importantly, supplementing the FF diet with CDCA
induces changes in the glucocorticoid and lipid profile analogous to those observed
in CDCA supplemented animals in Chapter 4, supporting the hypothesis that bile
acids act as inhibitors of glucocorticoid metabolism.
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Chapter 6
Impact of bile acids on the renin-angiotensin-
aldosterone-system
6.1 Introduction
The experiments described in this thesis so far provide evidence of a novel
role for bile acids in the regulation of glucocorticoid metabolism. Bile acids have
been shown to act as potent competitive inhibitors of steroid metabolism catalysed
by 5(l-reductase and lip-HSDl, in vitro both in tissue homogenates and cultured
cells (Chapter 3). These findings have been recapitulated in vivo by increasing
hepatic bile acid content through supplementation of the diet with CDCA or by
stimulating bile acid synthesis with the bile acid sequesterant cholestyramine
(Chapter 4). Moreover, administration of a fat-free diet incurred the same impact
upon glucocorticoid metabolizing enzymes (Chapter 5). The impact of bile acids on
other steroidogenic tissues and steroid hormone production and metabolism however,
has not been addressed.
In addition to catalyzing the reduction of corticosterone, the A-ring
reductases (5a- and 5p-reductase and 3aHSD) are also involved in the reduction of
aldosterone. It is possible that dietary manipulation of the bile acid pool may impact
upon aldosterone synthesis and/or metabolism with consequences for the associated
renin-angiotensin-aldosterone system (RAAS). In support of this, previous work has
demonstrated that bile acids inhibit the 5(l-reduction of aldosterone (Latif et al.
1994). This in turn would lead to suppression of the RAAS and hence activation of
MR. Similarly, the licorice derivative glycerrhytinic acid (GA), acts as a potent
inhibitor of 5(3-reductase and 3a-HSD resulting in the accumulation of aldosterone
and 5a-dihydroaldosterone (5a-DHAldo) which act as potent mineralocorticoids
(Latif et al. 1990). Bile acids may also influence the RAAS through inhibition of
11(3-HSD2 (Morris et al. 2004; Gomez-Sanchez et al. 1996). Illicit activation of MR
due to 11(1-HSD2 inhibition may contribute towards the sodium retention and
potassium excretion observed in patients with biliary obstruction (Stauffer et al.
2002) and cirrhosis (Quattropani et al. 2001). Previous work using a rodent model of
chronic biliary cirrhosis, the bile-duct-ligated (BDL) rat demonstrated that disruption
of bile acid flow and the enterohepatic circulation has a major impact on blood
pressure with animals having portal hypertension and hypokalemia (Martinez-Prieto
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et al. 2000), corroborating the hypothesis that bile acids may also impact upon the
RAAS.
However, bile acids may also exert direct effects upon the adrenal gland.
Steroid hormones such as corticosterone and aldosterone are synthesized from the
common precursor cholesterol within distinct zones of the adrenal cortex.
Corticosterone is synthesized primarily within the zona fasciculata (and to a lesser
degree within the reticularis) by lip-hydroxylase (CYP11B1). Aldosterone, a potent
mineralocorticoid, is synthesized solely within the zona glomerulosa. CYP11B1 and
CYP11B2 genes encode llp-hydroxylase and aldosterone synthase that catalyse the
final steps in the biosynthesis of corticosterone and aldosterone respectively. As the
adrenal gland is the primary source of steroid hormones, defects in substrate
(cholesterol) supply and/or utilization may have a major impact upon adrenal
steroidogenesis.
The experiments presented in this chapter describe detailed analysis of cholesterol
uptake and distribution within the adrenal glands of bile acid treated rats and the
impact that bile acids have on the RAAS.
6.2 Research aims
The aims of the research in this chapter were:
1. To assess the effect of bile acids on renal function i.e. urinary electrolyte
balance and the associated indices of the renin-angiotensin-aldosterone
system (RAAS).
2. To investigate the effect of bile acids on 11 (3-HSD2 activity in the
kidney.
3. To investigate the effect of bile acids on adrenal function and
morphology.
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6.3 Materials and methods
6.3.1 Animals and animal maintenance
Animals examined in this study were those used in Chapters 4 and 5. Animals
were maintained according to the procedures described in section 2.3.1
6.3.2 Dietary manipulation
Animals received diets described fully in section 4.3.2 and section 5.3.2. The
Na+ and K+ contents of normal and fat-free chow are Control: 0.3% Na+ and 0.6% K+
Fat-free: 0.1% Na+ and 0.36% K+ respectively.
6.3.3 Metabolic cages
After 3 weeks on their respective diets, animals were placed into metabolic
cages for 7 days as described fully in section 4.3.3. Faeces and urine were collected
over the final 72 hours and stored a -20°C for subsequent analysis. The animals were
then placed back into their original cages for at least one day prior to sacrifice.
6.3.4 Animal sacrifice and tissue collection
Animals were killed by surgical decapitation and tissue and blood samples
collected and stored as described in section 2.3.2.
6.3.5 Analysis ofenzyme activity
Renal 11P-HSD2 activity was determined from whole tissue homogenates as
described in section 2.8.5. Steroid products were quantified by HPLC as described in
section 2.9.1.
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6.3.6 Analysis ofplasma hormones and intermediate metabolites
Renin activity was determined by RIA for angiotensin I as described in
section 2.4.3. Plasma aldosterone was measured by ELISA using a commercially
available kit (Coat-a-Count®, DPC, Gwynedd, UK) as described section 2.4.4.
6.3.7 Analysis ofurinary electrolytes
Urinary sodium and potassium was measured from sample specimens (1ml
from the final day of collection) by dry-slide chemistry using a Vitros® analyzer.
This analysis was performed Dr P Ashby, Department of Clinical Biochemistry,
Western General Hospital, Edinburgh.
6.3.8 Quantification of target gene abundance
Transcript abundance of adrenal SR-B1 and HMG Co-A reductase were
measured using Taqman® real-time PCR as described in section 2.13.1. Abundance
of adrenal aldosterone synthase (CYP11B1) and lip-Hydroxylase (CYP11B2) was
measured by LightCycler® real-time PCR as described section 2.13.2.
6.3.9 Adrenal glandpreparation
Adrenal glands were removed and cleaned of any residual adipose tissue. The
left adrenal gland was fixed in formalin for 24 hours and then transferred into 70%
ethanol solution for histological preparation as described in section 2.14.1. The right
gland was snap-frozen on dry ice and stored at -80°C.
6.3.10 Adrenal gland histology
To examine the morphology of the adrenal gland, sections were stained with
Hematoxylin and Eosin (H and E) as described in section 2.14.2. To examine lipid
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accumulation cryostat sections from frozen adrenals were stained with Oil red O, a
neutral lipid stain as described fully in section 2.14.3.
6.3.11 Statistical analysis
Individual experiments were conducted using tissues from 8 independent
animals per group (unless otherwise stated). Each assay was performed duplicate and
the mean of each duplicate taken as the final value for that individual animal. The
data represent the mean ± standard error of the mean (SEM). When three groups
were studied, data were analysed by one-way ANOVA followed by post hoc least
squared difference tests. When two groups were studied, data were analysed by
Students t-tests. All analysis was performed using Statistica (Version 9) or Graphpad
Prism (Version 4). The following nomenclature was used to denote significance
*p<0.05 vs Control or FF/CDCA; **p<0.01 vs Control or FF/CDCA.
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6.4 Results
6.4.1 Impact ofbile acids on fluid and electrolyte balance
The impact of bile acids on fluid and electrolyte balance are summarized in
table 6.1.
Control CDCA CT FF FF/CDCA
Fluid 0.142±0.006 0.162±0.009* 0.141±0.007 0.089±0.006* 0.145±0.017
Intake
(ml/g BW)
Food 0.108±0.002 0.105±0.002 0.114±0.003 0.085±0.002 0.095±0.004
Intake
(g/gBW)
Urine 0.041+0.002 0.051±0.006 0.057+0.002* 0.032±0.003 0.047±0.008
volume
(ml/g BW)
Faeces 0.051±0.005 0.063±0.003 0.051±0.003 0.0078±0.0005* 0.057±0.012
(wet wt g/g
BW)
Urinary 22.8±1.7 19.3±1.6 21.3+1.5 2.87±0.31* 1.39±0.51
Na+
(mmol/ml)
Urinary 34.0±2.5 42.7±2.9 29.9±2.6 5.28±0.46 4.68±1.12
K+
(mmol/ml)
Na:K 0.68±0.04 0.45±0.02** 0.71±0.04 0.54±0.02** 0.28±0.028
Table 6.1 Impact of bile acids on fluid and electrolyte balance. Data represent mean±SEM corrected
for body weight; n=8; **p<0.001 vs Control or FF/CDCA, *p<0.05 vs Control or FF/CDCA
Supplementation of the diet with CDCA (both Control and FF) increased
fluid intake. This was accompanied by a rise in the weight of faecal matter produced.
Food intake was unaltered by dietary manipulation.
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Urinary sodium (Na+) and potassium (K+) excretion was greater than 10
higher in Control animals compared to those receiving FF chow, and is likely to be
associated with different dietary electrolytes between the two diets. Sodium and
potassium content was approximately 3-fold lower in the FF diet (Standard diet:
0.3% Na and 0.6% K compared to 0.1% Na and 0.36% K for FF diet). The estimate
of sodium and potassium content of Standard diet is only an approximation as
manufacturers indicate that there are likely to be batch variations. Bile acids caused a
similar net reduction in urinary sodium excretion. However, as baseline sodium
excretion was much higher with the Standard diet the net difference was not
statistically significant. Potassium excretion tended to be increased with CDCA
treatment but again the effect was not statistically significant. The ratio of urinary
sodium to potassium (Na:K) was reduced by CDCA in both control and FF diets.
Urinary Na:K values are widely used as an indicator of mineralocorticoid activity. In
contrast, cholestyramine did not influence urinary electrolyte excretion. Fluid
turnover was increase by both CDCA and cholestyramine.
6.4.2 Impact ofbile acids on the renin-aldosterone system
The effects of CDCA and cholestyramine treatment on renin and aldosterone
are shown in Table 6.2. Overall FF fed animals had higher levels of both aldosterone
and renin than those fed a Control chow, again reflecting the electrolyte content of
the FF diet; a low sodium diet is well known to activate the renin-angiotensin system.
CDCA in rats fed a Standard control diet increased plasma aldosterone concentration
3.8 fold (Table 6.2). This increase was not caused by activation of the renin-
angiotensin system as renin activity was unaltered. Animals receiving FF diet also
demonstrated increased concentrations of aldosterone but this was commensurate
with activation of the renin-angiotensin system. Cholestyramine did not influence
plasma aldosterone or renin levels (Table 6.2).
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Control CDCA CT FF FF/CDCA
Aldosterone (pg/ml) 70.0H4.8 265.2±64.7* 92.5±30.1 220.6±12.7* 350.1±21.2
Renin (ng/ml/hr) 2.29±0.32 1.77 ±0.34 3.45±0.75 15.2±1.52* 24.1±3.93
ARR 38.3±14.9 160.9±52.1* 35.9±9.9 14.9±2.06 14.812.33
Table 6.2 Impact of bile acids on the renin-angiotensin-aldosterone system. Data are meanlSEM;
n=8,*p<0.05 vs Control or FF/CDCA. ARR = aldosterone:renin ratio
6.4.3 Transcript abundance ofadrenal target genes
Aldosterone is synthesized from cholesterol within the zona glomerulosa of
the adrenal gland culminating in a reaction catalysed by the enzyme aldosterone
synthase (CYP11B2). Transcript abundance of CYP11B2 mRNA was higher in rats
fed the FF diet compared to those receiving Standard chow. This difference was
exaggerated by CDCA treatment. In contrast, supplementation of Standard control
diet with CDCA did not affect CYP11B2 nor plasma renin activity. This reinforces
the earlier suggestion that the effects of CDCA on aldosterone are in part
independent of the RAAS. Overall, CYP11B1 expression was down-regulated by
CDCA in rats fed either Standard control or FF diet. Again CYP11B1 mRNA
abundance was not affected by cholestyramine. Lower CYP11B1 expression is
consistent with reduced adrenal weights (CDCA treated animals Chapter 4) and
urinary 5(3-THB excretion (CDCA, CT Chapter and FF/CDCA animals Chapter 5)
and probably reflects reduced HPA drive and ACTH stimulation.
Control CDCA CT FF FF/CDCA
CYP11B1 9.1310.90 7.0110.74* 8.7510.16 8.14+1.59* 4.4010.43
(xlO7 copy no./pg RNA)
CYP11B2 1.3710.14 1.4510.12 1.4110.23 8.0211.45* 15.8+2.4
(xlO6 copy no./pg RNA)
Table 6.3 Impact of bile acids on the lip-hydroxylase (CYP11B1) and aldosterone synthase
(CYP11B2) gene transcription. mRNA abundance was quantified by Light-cycler real-time PCR Data
are mean±SEM; n=8,*p<0.05 vs Control or FF vs FF/CDCA.
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6.4.4 Impact ofbile acids on 11J3-HSD2 activity
The activity of 11P-HSD2 within whole kidney homogenates was
significantly reduced in animals fed normal chow supplemented with either CDCA
or cholestyramine (Figure 6.1 A). These findings were recapitulated in FF animals
(Figure 6.1 B) with CDCA supplementation of fat-free diet inhibiting 11(3-HSD2




Figure 6.1.1 lp-HSD2 activity following dietary manipulation. Activity of 11 [1-HSD2 was reduced by
(A) CDCA and cholestyramine (CT) and (B) CDCA supplementation of a fat-free (FF) diet when
assayed with corticosterone ( I pM). Data are mean±SEM; n=8;*p<0.05 v.v Control or FF vs FF/CDCA.
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6.4.5 Impact ofbile acids on adrenal gland morphology
Having observed differences in the RAAS of bile acid treated animals in
Chapter 4, a comprehensive study of adrenal gland morphology and lipid
accumulation from FF and FF/CDCA animals was performed.
Histological examination of FF and FF/CDCA adrenal glands revealed a
difference in the size of zones of the adrenal cortex with a small but significant
increase in the size of cells within the inner zona fasiculata in FF animals (Figure
6.2).
ZG OZF IZF ZR
Figure 6.2. Size of zones within the adrenal cortex following dietary manipulation. The size of cell in
each zone of the adrenal cortex was measured under x40 magnification by counting the number of cell
nuclei in a set area. Cell size was calculated by dividing the total area measured number of nuclei
within that area. ZG=Glomerulosa; OZF=Outer zona fasiculata; IZF=Inner zona fasiculata; ZR=zona.
Data are mean±SEM; n=6; *p<0.05 vs FF/CDCA
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E Cholestyramine (x 5) F Cholestyramine (x 40)
A Vehicle (x 5)
C CDCA (x 5)
B Vehicle (x 40)
D CDCA (x 40)
Figure 4.6 Lipid accumulation within the adrenal gland following dietary manipulation. Serial
transverse sections (30pM) were cut from the left adrenal gland and stained with the neutral lipid stain
Oil red O. G=glomerulosa, ZF=zona fasiculata, ZR=zona reticularis, M=medulla, TZ=zone of
transition.
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6.4.6 Gene transcript abundance
Transcript abundance of SR-B1, which mediates the selective uptake of
cholesterol esters (CE) from HDL within the liver and adrenal glands, was enhanced
in FF adrenal glands (Figure 6.4 A), whilst HMG-CoA reductase gene abundance,




Figure 6.4 Transcript abundance of (A) SR-B1 and HMG-CoA reductase following dietary
manipulation. mRNA abundance was quantified by Taqman real-time PCR and values are expressed
as a ratio to the house keeping gene P-Actin or cyclophilin A. Data are expressed as mean±SEM, n=8
per group;*p<0.05 vs FF; **p<0.01 v.? FF/CDCA.
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6.5 Discussion
The data presented in this chapter provide evidence of an additional role for
bile acids in regulation of the renin-angiotensin system (RAAS). Supplementation of
both Standard chow and a synthetic fat-free diet (FF/CDCA) with CDCA induced
sodium retention concomitant with a reduction in potassium excretion resulting in a
fall in the overall sodium to potassium ratio. Plasma aldosterone levels were
increased in both CDCA-treated groups, albeit through different mechanisms. In
general in FF animals, the rise in plasma aldosterone was accompanied by an
increase in renin activity indicating activation of the renin angiotensin system. This
was probably due to the low sodium diet and was exaggerated following
administration of CDCA. In contrast, renin activity was unaltered in animals
receiving the standard diet supplemented with CDCA or cholestyramine. Moreover,
CYP11B2 transcript abundance within the glomerulosa was elevated in CDCA-
treated FF animals (FF/CDCA) but not in those receiving bile acids on a standard
diet. In addition, 11(1-HSD2 activity within the kidney was significantly reduced in
both bile acid and cholestyramine treated groups. Alterations in lipid accumulation
within the adrenal gland were apparent in FF/CDCA animals. These changes were
most evidennt within the zona glomerulosa, the outer most region of the adrenal
cortex with lipid droplets being smaller and more dispersed. Intruigingly, transcript
abundance of SR-B1, the predominant HDL cholesterol transporter within the
adrenal gland was down-regulated in FF/CDCA animals whilst that of HMG CoA
reductase was enhanced. These findings suggest that bile acids may also alter lipid
uptake, synthesis and/or metabolism within the adrenal gland.
The kidney represents one of the most important sites of renin production and
release in response to sympathetic stimulation (acting via pradrenoceptors), renal
artery hypotension, and decreased sodium delivery to the distal tubules.
Angiotensinogen (ANG) is a vasodilatory peptide which is synthesized
predominantly within the liver. Proteolytic cleavage of ANG by renin results in the
formation of the decapeptide angiotensin I. This in turn acts as the substrate for
angiotensin converting enzyme (ACE) which is highly abundant in vascular
endothelium, particularly within the lungs. ACE cleaves off 2 amino acids resulting
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in the formation of the octapeptide angiotensin II (All). Angiotensin II acts upon the
zona glomerulosa inducing the synthesis of aldosterone. Aldosterone is synthesized
from cholesterol within the zona glomerulosa of the adrenal gland by a series of
enzymes culimating in the conversion of corticosterone to aldosterone. This reaction
is catalysed by the enzyme aldosterone synthase (CYP11B2) in response to hormonal
stimulation in the form ofAll and ACTH and /or a drop in Na+ ions and/or rise in K+
ions within the blood (Ye et al. 2003). The elevated levels of CYP11B2 in the
adrenal glands of FF/CDCA are likely to be induced in response to the low Na+
content of the diet. The fact that both CDCA-treated groups had elevated plasma
aldosterone levels whilst only those receving the FF/CDCA diet showed alterations
in CYP11B2 expression indicate aldosterone synthesis is not the sole factor
contributing to the rise in plasma aldosterone.
The function of renal MR is clearly evident in the rare syndrome of
"Apparent Mineralocorticoid Excess" (AME) where individuals present with
hypertension, hypokalemia and sodium retention together with low plasma
aldosterone and low plasma renin activity (Shackleton & Stewart 1990). Similar
symptoms e.g. hypertension, hyperkalaemia and suppression of plasma renin activity
and aldosterone, manifest following ingestion of large amounts of liquorice.
Although these side effects were initially attributed to the direct activation of MR, it
has since been demonstrated that glycyrrhetinic acid (GA), the active component of
liquorice, acts as a potent inhibitor if 11P-HSD2 activity, thus allowing binding of
active glucocorticoids to MR. There is also evidence demonstrating bile acids as
inhibitors of 11 [1-HSD2 in tissue homogenagtes (Morris et al. 2004) and cell cultures
(Gomez-Sanchez et al. 1996). The inhibition of llfl-HSD2, resulting in illicit
activation of MR by glucocorticoids plays a role in hypertension due to enhanced
Na+ re-absorption and K+ excretion (Stewart et al. 1987; Monder et al. 1989).
The data described in this chapter corroborate these findings with bile acid
supplementation of both normal chow (normal chow/CDCA) and a fat-free diet
(FF/CDCA) causing a marked reduction in renal 11(1-HSD2 activity. In keeping with
these findings, a reduction in urinary sodium and an overall decrease in the sodium:
potassium ratio (used as an indicator of mineralocorticoid activity) was observed in
in animals fed a diet supplemented with CDCA (both standard and fat-free).
169
Although blood pressure was not measured in this study, the data described here
showing a reduction in Na+: K+ ratio would suggest that bile acid treated animals
may be mildly hypertensive. Indeed, systolic blood pressure is elevated in male
Wistar rats following treatment with cholic acid (Wu et al. 1999).
In contrast cholestyramine had no impact upon urinary electrolyte levels
which again may relate to the concentration of bile acids within the circulation,
which were elevated in CDCA-treated animals but not in those receving
cholestyramine.
In vitro, cortisol-induced nuclear translocation of MR has been demonstrated
following the treatment of HEK293 transfected with human 11|3-HSD2 and tagged
MR cells with increasing concentrations of bile acids, specifically CDCA
(Quattropani et al. 2001). This may predict elevated blood pressure and suppression
of renin (Kenyon et al. 1984). In vivo, continuous infusion of CDCA to Sprague-
Dawley rats induced hypertension which persisted over the 14 day duration of the
experiment (Morris & Souness 1996). Likewise, bile-acid-dependent inhibition of
llp-HSD2 is thought to be partly responsible for the sodium retention and potassium
excretion observed in patients with biliary obstructive disease (Stauffer et al. 2002).
In addition, the hypokalemia and hypertension induced following ligation of the
common bile duct in the rat may in part be attributable to bile acid induced inhibition
of 11(3-HSD2 (Thiesson et al, unpublished data). The fact that CDCA reduced renal
11P-HSD2 activity whilst simultaneously increasing aldosterone is paradoxical. One
may normally anticipate aldosterone levels to fall as a consequence of reduced
activation of the RAAS when 11|3-HSD2 is inhibited as demonstrated in sufferers of
AME (Phillipou et al. 1996). Interestingly, plasma concentrations of aldosterone
were 3-fold greater in FF/CDCA animals compared to those receiving standard chow
perhaps reflecting differences in electrolyte content of the diet. Indeed the sodium
and potassium content of the FF diet was approximately 3-fold lower than those of
standard control diet (control diet: 0.3% Na and 0.6% K vs 0.1% and 0.36% for FF
diet). Sodium depletion is a potent stimulant of the RAAS, indeed a low sodium diet
increased CYP11B2 abundance 57-fold within the adrenal glands of male Wistar rats
(Ye et al. 2003). Therefore, although plasma aldosterone was increased in both
CDCA-treated groups compared to controls, the mechanisms through which this was
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induced differ. Plasma renin activity was enhanced in FF/CDCA animals but not in
those receiving a normal chow suggesting that in the presence of normal dietary salt
the impact of CDCA on plasma aldosterone was independent of the renin angiotensin
system. Furthermore, transcript abundance of aldosterone synthase (CYP11B2) the
enzyme responsible for aldosterone synthesis was up-regulated in FF/CDCA animals
but unchanged in animals fed a standard chow diet supplemented with CDCA
supporting the hypothesis that changes in circulating aldosterone induced by bile
acids are in part independent of the renin angiotensin system. In summary on normal
chow, CDCA caused sodium retention through mechanism independent of the
RAAS, perhaps related to impaired inactivation and increased synthesis of
aldosterone.
Theoretically, the increase in aldosterone could have been due to reduced
clearance of aldosterone, stimulation by other factors (e.g. ACTH or plasma
potassium) or greater provision of cholesterol substrate. Reduced clearance occurs
with bile-acid-induced inhibition of aldosterone metabolism which may be
extrapolated from a reduction in urinary 5(5-reduced corticosteroid metabolites.
Furthermore, a study performed by Latif in the early 1990's demonstrated the bile
acids inhibit aldosterone metabolism catalysed by 5(5-reductase (Latif el al. 1994). It
is unlikely that ACTH is a contributory factor since adrenal weight and HPA activity
(see Chapter 4) tended to be reduced not increased in bile acid treated animals.
However, cholesterol availability could be an important factor since plasma HDL
(the main source of cholesterol for adrenal steroidogenesis in rodents) was increased.
Histological examination of the adrenal glands of FF and FF/CDCA animals revealed
that bile acid treatment may also interfere with cholesterol uptake and utilization.
When stained with Oil-red O, a neutral lipid stain which is commonly used to
identify cholesterol, lipid droplets appeared smaller and more numerous within the
zona glomerulsoa of CDCA treated animals. Furthermore, a sudanophobic region or
"zone of transition" where no lipids were present was evident between the zona
glomerulosa and reticularis in the adrenal glands of bile acid treated animals only.
This would suggest that bile acids may interfere with cholesterol uptake and/or
accumulation within the adrenal glaria. The emulsifying properties of bile acids may
171
have contributed towards the reduction in size of lipid droplets within the adrenal
glands of CDCA treated animals.
To understand the mechanisms of altered lipid accumulation within the
adrenal gland, factors influencing cholesterol uptake and de novo synthesis were
investigated. Transcript abundance of SR-B1, the principal HDL transporter in the
adrenal gland was reduced in FF/CDCA treated animals which may be anticipated as
SR-B1 is an FXR suppressible gene (Malerod et al. 2005). These findings argue
against lipid accumulation however, as this change would impede cholesterol uptake
into the adrenal. It has been demonstrated that adenovirus-mediated hepatic
overexpression of SR-B1 on both the sinusoidal and canalicular surfaces of the
hepatocyte results in a marked increase in biliary cholesterol and the virtual
disappearance of plasma HDL. In addition, SR-B1 attenuate (att) mice which carry a
mutation within the promoter of the SR-B1 gene show a reduction in the hepatic
uptake of HDL-cholesterol esters (HDL-CE) (Wang & Carey 2002). Moreover, SR-
B1 knock-out (KO) mice show impaired biliary cholesterol secretion and increased
plasma cholesterol concentrations in large apolipoprotein A-1-containing particles
and a low adrenal gland cholesterol content (Altmann et al. 2002). HDL-CE
clearance from the blood stream is markedly reduced in SR-B1 KO mice while liver
and adrenal uptake, are attenuated. The elevated levels of HDL cholesterol and
suppression of hepatic and adrenal SR-B1 in FF/CDCA (Chapter 5) treated animals
corroborate these findings. Recent studies suggest that the nuclear receptor farensoid
X receptor (FXR) may play a role in mediating these effects. FXRmice exhibit
reduced expression of hepatic genes involved in reverse cholesterol transport, most
notably, that for SR-BI (Lambert et al. 2003). Attenuation of SR-B1 gene abundance
within the liver is thought to be mediated via the induction of SHP which acts as a
negative nuclear receptor induced by FXR, thus by inducing the expression of SHP,
LXR/RXR and LRH-1 mediated transactivation of SR-BI is reduced (Malerod et al.
2005). Whether or not bile acids exert their effect on adrenal SR-BI via the same
mechanism is as yet unknown, however the adrenal gland does express both FXR
and LRH-1 (Francis et al. 2003; Zhang et al. 2006) thus a similar mechanism may be
at work. It is important to note however that there are at least 2 variants of SR-BI
expressed in the adrenal; SR-BI and a splice variant SR-BI 1 which differs from SR-
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B1 by an entirely different C-terminal cytoplasmic tail (Webb et al. 1998). Transcript
abundance of SR-B11 accounts for approximately 30% of the total SR-B1 mRNA in
the mouse adrenal (Webb et al. 1997). It is possible that the primer sequence used to
detect SR-B1 in this study is targeted towards region of the gene common to both
transcripts. It is not known whether SR-B1 and SR-BII are expressed differentially
across the zones of the adrenal gland and it is still possible that one transcript was
upregulated specifically within the zona glomerulosa. A more likely explanation of
the increase in cholesterol within the zona glomerulosa is due to the stimulation of
HMG CoA-reductase in FF/CDCA animals. This would imply increased de novo
biosynthesis of cholesterol. The rat is known to have a high rate of de novo
cholesterol synthesis which enables the animal to maintain cholesterol homeostasis
when faced with a cholesterol depleted diet. Whether or not induction of HMG Co-A
reductase is related to the fall in SR-B1 transcript abundance is as yet unknown but it
is possible that HMG Co-A reductase is enhanced in an attempt to maintain
cholesterol homeostasis within the adrenal gland, irrespective of whole body
cholesterol levels.
It is interesting to note that cholestyramine did not influence urinary
electrolytes or the RAAS, despite reducing activity of 11 (1-HSD2, again supporting a
more complex role for bile acids in regulation of the RAAS. In addition,
cholestyramine did not induce changes in adrenal morphology or CYP11B1/2
expression. These findings may relate to the overall level of bile acids achieved
within by each diet as the level bile acids within the circulation of cholestyramine
treated animals were comparable to control animals. In a similar manner, hepatic
1 ip-HSD l activity was only affected in animals where bile acids were administered
over and above those synthesised naturally.
In summary the findings of the work in this chapter provide evidence for an
additional role for bile acids in regulation of the RAAS, over and above inhibition of
lip-HSDl, perhaps causing bile acid treated animals to be hypertensive.
Furthermore, bile acids may impact upon cholesterol uptake and utilisation within
the adrenal gland. It is therefore possible that steroid hormone synthesis per se and
not just glucocorticoid synthesis and metabolism may be affected in that in
conditions of elevated bile acids such as obesity, jaundice and biliary cirrhosis.
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Moreover, inhibition of HMG Co-A reductase within the adrenal, which may be
induced by statins frequently prescribed for hypercholesterolaemia may restrict
cholesterol supply for adrenal steroidogenesis and alter blood pressure through a
mechanism influencing aldosterone biosynthesis.
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Chapter 7
Summary and future work
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7.1 Summary and Future Work
The aims of this thesis were to assess the impact of bile acids on
glucocorticoid metabolism and potential interaction between factors regulating
cholesterol and glucocorticoid homeostasis. The work described in this thesis
provides evidence that bile acids are competitive inhibitors of glucocorticoid
metabolism mediated by 5(3-reductase and 11|3-HSD1 in vitro both in tissue
homogenates and cultured cells. Inhibition occurred at a post-transcriptional level
without changes in transcript abundance or protein. These findings were pursued in
vivo in animal models of bile acid excess and bile acid depletion. In excess, bile acids
were potent competitive inhibitors of glucocorticoid metabolism, altering HPA axis
response as demonstrated by a prolonged corticosterone response following restraint
stress. Converse findings on a fat-free (bile acid) depleted diet confirming could be
reversed by bile acid supplementation confirming bile acids as the sole mediators of
this inhibition. The inhibitory impact of bile acids was corroborated in model of
chronic bile acid excess, the bile-duct-ligated rat, where enzyme activity was reduced
4 fold (McNeilly et al unpublished data). In parallel studies bile acids were
demonstrated to alter the expression of key steroidogenic enzymes within the adrenal
gland, primarily within the zona glomerulosa. These differences were associated with
altered expression of aldosterone synthase and ll|3-hydroxylase, suggesting a role
for bile acids in aldosterone action and sodium: potassium regulation within the
kidney.
Glucocorticoids regulate a myriad of metabolic and homeostatic processes
including glucose and lipid metabolism within the liver and electrolyte balance
within the kidney, the principal organs involved in glucocorticoid metabolism.
Levels within the circulation are normally tightly regulated by a combination of HPA
axis forward drive and glucocorticoid negative feedback. The importance of these
regulatory systems can be exemplified in conditions where the mechanisms
controlling glucocorticoid homeostasis are abnormal resulting in glucocorticoid
excess in the case of Cushing's syndrome or glucocorticoid deficiency as in
Addison's disease. Increasing evidence has supported a role for tissue-specific
alterations in glucocorticoid metabolism and/or synthesis in cardiovascular disease
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and in particular in the manifestation of idiopathic obesity. Obese humans and the
Zucker rat (fa/fa) a model of obesity and insulin resistance display an altered
glucocorticoid metabolic profile, with suppressed llp-HSDl activity within the liver
and enhanced expression and activity within adipose tissue, primarily the
subcutaneous tissue (Andrew et al. 1998; Livingstone et al. 2000; Rask et al. 2001).
In addition, elevated expression and activity of the A-ring reductases (5a- and 5(3-
reductase) have been observed (Andrew et al. 1998; Andrew & Walker 2005). These
changes cause an enhanced rate of glucocorticoid clearance, and compensatory
activation of the HPA-axis, and the balance of A-ring reduction often favours 5a-
reduction over that of 5|3-reduction (although in this case 5a-reductase appears to be
the predominant A-ring reductase). Insulin plays a key role in regulating 5a-
reductase activity and expression as treatment of the Zucker rat with insulin
sensitizing drugs such as metformin reverses these effects (Livingstone et al. 2005).
Likewise, insulin increases the excretion of 5a-reduced Cortisol metabolites in
individuals with polycystic ovary syndrome (PCOS) independent of obesity
(Tsilchorozidou et al. 2003). A number of key regulators of 11|3-HSD1 have been
proposed, including inflammatory cytokines (Tomlinson et al. 2001), diet (Drake et
al. 2005), steroid hormones (Ricketts et al. 1998), peroxisome proliferater-y
(PPARy) agonists (Berger et al. 2001), LXR agonists (Stulnig et al. 2002) and
pharmacological agents such as carbenoxolone (Walker et al. 1995b) and the
antidiabetic drug Arylsulfonamidothiazole (Barf et al. 2002). Factors controlling 5(3-
reductase activity and expression however remain elusive.
In addition to its involvement in glucocorticoid metabolism, 5(3-reductase
also plays a key role in bile acid biosynthesis. Indeed, mutations within 5|3-reductase
(SRD5B1) have been identified in 3 infants suffering from neonatal cholestatic liver
disease. These infants excrete elevated levels of glycine and taurine conjugates of
7a-hydroxy-3-oxo-4-cholenoic acid and 7a,12a-dihydroxy-3-oxo-4-cholenoic acid
within their urine and can be treated with CDCA or CA if liver disease is not too far
advanced (Lemonde et al. 2003). In addition, a recent study has reported improved
cholesterol absorption and cholesterol synthesis in patients with 5(3-reductase
deficiency following treatment with bile acids due to their role in the micellar
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solubilisation of cholesterol within the lumen of the gut (Woollett et al. 2006). These
studies indicate the important role that 5(Treductase plays in cholesterol and bile acid
homeostasis. This thesis provides evidence that bile acid levels may also influence
the hepatic activity of lip-HSDl and 5|3-reductase and subsequently impact upon
HPA axis activation and hepatic glucocorticoid regulated target genes.
Physiologically bile acids vary in a circadian manner. In rodents, both
cholesterol and bile acid synthesis have marked diumal rhythms that peak
synchronously at midnight (Galman et al. 2005) thus the rate of hepatic
glucocorticoid metabolism may be slower in the evening. To our knowledge the
diumal patterns of A-ring reduced metabolites have not been compared in the
literature, although one would predict a reduction in 5p-reduced metabolites when
hepatic bile acid synthesis was increased e.g. at night. Interestingly, in obesity the
diumal rhythm of circulating Cortisol is flattened with higher trough values
(Bjorntorp & Rosmond 1999). It is possible that these increased levels are associated
with exaggeration of the inhibition of steroid metabolism due to an increased drive to
synthesise bile acids and eliminate cholesterol. The diurnal rhythm of bile acids in
obesity is to our knowledge unknown but circulatory levels are elevated in humans
(Halmy et al. 1986) and the obese Zucker rat (3-fold higher; McNeilly unpublished
data). Physiologically, bile acid synthesis is stimulated following a fatty meal in
order to facilitate the absorption of fats (Costarelli & Sanders 2001). Again, this
would be predicted to occur at a time when glucocorticoid metabolism may be
impaired. Interestingly, a post-prandial rise in circulating Cortisol in observed,
although this is considered to be more pronounced following the ingestion of protein.
Pathological conditions such as liver cirrhosis and cholestasis are manifest
due to the accumulation of bile acids within the liver and bile duct. Likewise
obstmction of the bile duct leading to secondary biliary cirrhosis can result in severe
jaundice and has serious implications to health. Bile acids and their precursors are
cytotoxic when accumulated in excess. For example the genetic defects in cholesterol
catabolism can result in the accumulation of highly toxic intermediated including
oxysterols and bile acids, leading to liver disease, premature cardiovascular disease
or neurological disorders (Russell 2003b). Furthermore, bile acids have been
implicated as nephrotoxins increasing the risk of post-operative renal failure in
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individuals with obstructive jaundice (Kaler et al. 2004). There is scant research
investigating glucocorticoid metabolism in such patients although the increase in
urinary ratio of (5P-tetrahydrocortisol+5a-tetrahydrocortisol) /
tetrahydrocorticosterone has been reported in cholestatic patients which has been
attribute to alterations in ll(3-HSDl/2 and/or the A-ring reductases (Quattropani et
al. 2001). Similarly in rats following bile duct ligation, an alteration in the equivalent
ratio of corticosterone metabolites has been observed (Ackermann et al. 1999). These
studies support a role of bile acids in the regulation of glucocorticoid metabolism.
The hepatic insult of these patients may resemble that of animals receiving normal
chow supplemented with CDCA yielding a state of bile acid excess. Our data predict
that under these circumstances 5f5-reductase and 11(3-HSD1 will both be impaired
and this in turn will impact upon activation of the HPA axis and also the RAAS.
The bile-duct-ligated (BDL) rat represents an ideal model in which to assess
the progression of bile acid induced enzyme inhibition. Chronic bile duct ligation is
frequently used to model liver cirrhosis with cholestasis (Kountouras et al. 1984).
These animals also show cardiovascular and renal abnormalities. Indeed chronic
BDL induces a circulatory hyperdynamic state, with arterial hypotension and
increased cardiac output (Green & Better 1995) concomitant with renal alterations
including, portal hypertension, sodium retention, a decrease in renal angiotensinogen
and increase in renin transcript abundance (Ubeda et al. 1994), activation of intra-
renal hormones including prostaglandin E2 and thromboxane A2 (Ackerman et al.
1996) and an increase in the aldosterone : renin ratio (Thiesson et al unpublished
data). It is known that the MR protective effect of 11(3-HSD2 is diminished in
cirrhosis (Ackermann et al. 1999), however A-ring reductase activity in these
animals has not been studied. Preliminary data generated in collaboration with Dr H
Thiesson (Odense, Denmark) revealed that BDL rats exhibit changes in the same
enzyme pathways were observed in animals treated with CDCA. It must be noted
however that the tissues analysed in this thesis were taken from animals 5-7 weeks
after surgery by which stage the animals were in a state of decompensated biliary
cirrhosis with hepatic cytotoxicity. It would therefore be interesting to assess enzyme
activity and expression at earlier time points, perhaps 1-2 days following surgery and
throughout the development of biliary cirrhosis along with HPA axis tests. This
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would provide insight into the time course and degree of inhibition exerted by bile
acids and permit quantification of bile acid concentrations and a glucocorticoid
profile to be determined. It would also be interesting to measure blood pressure in
CDCA treated animals as they present with symptoms of a hypertensive phenotype
i.e. sodium retention, elevated plasma aldosterone and alterations in the urinary
electrolyte balance.
There is much evidence to support a role for glucocorticoid metabolism
regulation of the HPA axis and intermediary metabolism. Indeed, hepatic over
expression of lljl-HSDl causes dyslipidemia and hypertension in the absence of
obesity (Paterson et al. 2004), whilst transgenic mice expressing elevated levels of
11|3-HSD1 specifically within the adipose tissue exhibit the full metabolic syndrome
with visceral obesity, dyslipidemia, insulin-resistant and diabetes (Masuzaki et al.
2001b). These models demonstrate the importance of tissue specific alterations in
enzyme activity. Down regulation of hepatic lip-HSDl in obesity is thought to
protect the liver from the adverse effects of excess glucocorticoids, however, the
mechanism is as yet unknown. There are several phenotypic similarities between bile
acid treated animals and the llfJ-HSDl null mouse. For example CDCA treated
animals have elevated plasma cholesterol and HDL cholesterol, a prolonged
corticosterone peak following restraint stress and reduced plasma glucose and insulin
analogous to that seen in the 1 Ifl-HSDl knock out mouse. These mice also resist
hyperglycemia provoked by stress and obesity and have attenuated activation of the
key hepatic gluconeogenic enzymes such as PEPCK suggesting that inhibition of
llfl-HSDl may offer similar metabolic protection from the adverse impact of stress
and high fat diet (Morton et al. 2004). In support of this, the administration of
carbenoxolone, a non-specific llp-HSD inhibitor has been shown to inhibit hepatic
lip-HSDl (and enhance insulin sensitivity)(Walker et al. 1995b). This property has
been suggested as a protective mechanism to reduce the extent of insulin resistance
within the liver of diabetic obese patients (Sandeep et al. 2005). These findings
suggest that bile acids may offer potential physiological but also therapeutic benefits
in conditions of dyslipidemia such as obesity, non-alcoholic steatohepatitis (NASH)
and myotonic dystrophy. Indeed, administration of a low calorie diet and
ursodeoxycholic acid has been shown to reduce the severity of steatosis and improve
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serum lipid variable and hepatic inflammatory changes in a rodent model of NASH
(Fan et al. 2005). In addition, a recent study has shown bile acids act as general
metabolic integrators, increasing energy expenditure in brown adipose tissue, thus
preventing obesity and insulin resistance via induction of cAMP dependent thyroid
hormone activating enzyme type 2 iodothyronine deiodinase (Watanabe et al. 2006).
In support of this administration of cholic acid has been shown to reverse diet
induced obesity and improve glucose tolerance in KK-Ay mice and C57BL/6j mice
with diet induced obesity (Ikemoto et al. 1997). The findings of this thesis provide an
alternative mechanism through which bile acids may improve insulin sensitivity,
namely through inhibition of lip-HSDl within the liver. However, these beneficial
effects may be associated with altered stress and a predisposition to hypertension.
An unexpected finding of this thesis was the impact of bile acids on
cholesterol uptake and utilization within the adrenal gland. Bile acid treatment
caused a marked rise in plasma aldosterone and altered urinary electrolyte balance
suggesting that bile acid may induce a mild state of hypertension. This may be a
consequence of impaired aldosterone metabolism by 5(l-reductase and as such
monitoring blood pressure in bile acid treated animals would therefore be of interest.
Likewise a detailed study of adrenal gland morphology and the transcription of
steroidogenic genes and enzymes within the cholesterol uptake and transportation
pathway including StAR would provide insight into the mechanism through which
bile acids exert change in adrenal gland function. Again this may contribute to the
increase in blood pressure exhibited in the BDL rat and in conditions such as
cholestatic jaundice
It is difficult however to put this work into context with the changes in
glucocorticoid metabolism observed in obesity, another condition where one may
anticipate bile acid excess.
The obese Zucker rat displays an altered metabolic profile with elevated plasma and
fecal bile acids and therefore provides a model in which to investigate the impact of
chronic bile acid excess in obesity. Bile acid treated animals and the Zucker rat have
similarly elevated levels of bile acids within the circulation, which in the Zucker rat
is accompanied by raised corticosterone. However, activity of hepatic 11 fl-HSDl is
reduced and activity and expression of 5a- and 5(!-reductase are increased in the
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Zucker rat whereas hepatic enzyme activity of 5(3-reductase and lip-HSDl are both
reduced in CDCA treated animals, without changes in transcript abundance or
protein levels. The work in this thesis has demonstrated that bile acids are
competitive inhibitors of enzyme activity with bile acids and glucocorticoids
competing for the same active site of the enzyme. It is possible that the differences
observed between 5(3-reductase in the two models is an adaptation to chronic
elevation of both substrates (bile acids and glucocorticoids) over an extended period
of time which induces an increase in transcript abundance and protein level in order
to accommodate the high circulatory levels of the two competing substrates. In the
obese Zucker rat however, elevated plasma bile acids were this was associated with a
decrease in transcript abundance of llp-HSDl within the liver. It is possible that
administration of the CDCA within the diet over a longer time period of months as
opposed to weeks may have resulted in a decrease in gene transcription similarly to
the BDL rat (Thiesson et al unpublished data). It would therefore be interesting to
investigate the impact of a bile acid supplemented diet on glucocorticoid metabolism
in the obese Zucker rat. One may anticipate that in the face of elevated levels of bile
acids 5(3-reductase activity and expression may be suppressed. This may in turn
impact upon HPA axis activation and/or response. Although there was no
compensatory increase in 5a-reductase 1 activity or expression in bile acid treated
animals it is possible that this may occur in the obesity as previous studies have
demonstrated a predominating role for this enzyme in glucocorticoid clearance
(Livingstone et al. 2000). It is also possible that chronic exposure to elevated levels
of bile acids may reduce feedback sensitivity within the Zucker rat thus
overwhelming the system with additional bile acids may have no impact on enzyme
activity. One must also consider the effects of FXR mediated suppression of enzymes
involved in bile acid synthesis, detoxification and elimination as one may anticipate
enhanced induction of those involved in bile acid elimination and suppression of
those mediating bile acid biosynthesis.
It would also be of interest to examine adrenal morphology and function in
the Zucker rat as this thesis has demonstrated that bile acids also impact upon
cholesterol uptake and utilization within the adrenal gland characterized by altered
lipid accumulation within the zona glomerulosa and a decrease in expression of SR-
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Bl, the predominating cholesterol transporter in the adrenal gland. An alternative
approach would be to administer a fat-free diet to Zucker rats in an attempt to reduce
bile acid levels within the circulation and assess glucocorticoid metabolism and
cholesterol uptake and utilization within the adrenal gland.
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